

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country.

GSK Medicine: GSK2231392A (GlaxoSmithKline [GSK] Biologicals' investigational adjuvanted vaccine against Hepatitis B)
Study No.: 112115 (EARLY-CLINRES-002)
Title: Comparison of the immunogenicity and safety of Hepatitis B surface antigen (HBsAg) adjuvanted with various GSK Biologicals' Adjuvant Systems.
Rationale: This aim of this study was to compare and characterize 4 different GSK Biologicals' Adjuvant Systems and the classical Hepatitis B vaccine (<i>Engerix™-B</i>) in order to better understand their immunological characteristics using a single model antigen Hepatitis B surface antigen (HBsAg). The safety profiles, the humoral and cell-mediated immune responses of the 5 formulations – 3 investigational formulations, and 2 licensed GSK Biologicals' vaccines – were also evaluated. (HBsAg 1) GSK Biologicals' investigational adjuvanted vaccine against Hepatitis B, formulation 1. (HBsAg 2) GSK Biologicals' investigational adjuvanted vaccine against Hepatitis B, formulation 2. (HBsAg 3) GSK Biologicals' investigational adjuvanted vaccine against Hepatitis B, formulation 3. <i>Fendrix™</i> (HBsAg 4): GSK Biologicals' Hepatitis B adjuvanted vaccine <i>Engerix™-B</i> (HBsAg 5): GSK Biologicals' Hepatitis B vaccine
Phase: II
Study Period: 15 December 2008 to <ul style="list-style-type: none"> • 29 September 2010 (up to Day 60) • 14 July 2011 (up to Day 390)
Study Design: Observer-blind, randomised, multicentre study with 5 parallel groups (1:1:1:1:1)
Centres: 10 centres in Germany and 4 centres in Belgium
Indication: Immunization against Hepatitis B.
Treatment: The study groups were as follows: <ul style="list-style-type: none"> • HBsAg 1 Group: Subjects received 2 doses of HBsAg 1 vaccine • HBsAg 2 Group: Subjects received 2 doses of HBsAg 2 vaccine • HBsAg 3 Group: Subjects received 2 doses of HBsAg 3 vaccine • HBsAg 4 Group: Subjects received 2 doses of HBsAg 4 vaccine • HBsAg 5 Group: Subjects received 2 doses of HBsAg 5 vaccine <p>Subjects in all 5 groups received a vaccine dose at Day 0 & Day 30. Vaccine doses were administered intramuscularly into the deltoid muscle of the non-dominant upper arm.</p> <p>In addition, a subset of approximately 75 subjects in each group (approximately 23 subjects/group in Subset 1 and approximately 52 subjects/group in Subset 2) received a booster dose of HBsAg at Day 360. Subjects were typed for both Class I and Class II subtypes. Subjects who were identified with a pre-defined Human Leukocytes Antigen (HLA) Class I subtype were allocated to Subset 1. Subjects who were identified with a pre-defined HLA Class II subtype were allocated to Subset 2.</p>
Objectives: <ul style="list-style-type: none"> • To compare the magnitude of the cellular immune response, post Dose 2 at Day 44, induced by various GSK Adjuvant Systems in combination with HBsAg, in adult subjects aged between 18 and 45 years old, inclusive, in good general health and not previously immunised or previously infected with Hepatitis B.
Primary Outcome/Efficacy Variable: <ul style="list-style-type: none"> • Cellular immune response to components of the investigational vaccine 14 days post Dose 2 (Day 44), in all subjects. <i>Criterion for assessment:</i> Frequency of HBs-specific CD4⁺ T cells expressing at least 2 immune markers among Interleukin-2 (IL-2), Interferon-Gamma (IFN-γ), Tumour Necrosis Factor-Alpha (TNF-α), CD40 Ligand (CD40L), IL-13 and IL-17, as measured by Intracellular Cytokine Staining (ICS), using frozen Peripheral Blood Mononuclear Cells (PBMCs), 14 days post Dose 2 (Day 44), in all subjects, in all vaccine groups.
Secondary Outcome/Efficacy Variable(s): <i>Immunogenicity</i> <ul style="list-style-type: none"> • Cellular and humoral immune response to components of the investigational vaccine at protocol-defined time points. <i>Criteria for assessment:</i> <ul style="list-style-type: none"> • At Days 0, 14, 30, 44, 60, 180 (Month 6), 360 (Month 12) in all subjects and at Day 374 in subjects in the 2 subsets, in all vaccine groups: <ul style="list-style-type: none"> • Frequency of HBs-specific CD4⁺/CD8⁺ T cells expressing at least 2 immune markers among IL-2, IFN-γ, TNF-α, CD40L, IL-13 and IL-17, as measured by ICS, using frozen PBMCs.

- At Days 0, 14, 30, 44, 60 and 180 (Month 6), in all subjects, in all vaccine groups:
 - Frequency of HBs-specific CD4⁺/CD8⁺ T* cells expressing T helper cell type 1 response/T helper cell type 2 response (Th1/Th2) cytokine profile, as measured by ICS, using frozen PBMCs.
- At Days 0, 14, 30, 33, 37, 44 and 60, in all subjects recruited at the Centre for Vaccinology (CEVAC) in Ghent, Belgium.
 - Frequency of HBs-specific CD4⁺/CD8⁺ T cells expressing at least 2 immune markers among IL-2, IFN- γ , TNF- α , CD40L, as measured by ICS, using whole blood.
- At Days 0, 30, 44, 60, 180 (Month 6), 360 (Month 12), 374 and 390 (Month 13), in subjects in the 2 subsets, in all vaccine groups:
 - Anti-HBs antibody concentrations in serum, as measured by Enzyme-Linked Immunosorbent Assay (ELISA).
- At Days 0, 30, 37, 44, 60, 180 (Month 6) and 360 (Month 12), in subjects in the 2 subsets, in all vaccine groups:
 - Frequency of HBs-specific memory B Cells, as measured by B-cell ELISPOT.
- At Days 0, 0⁺ (+ 3-6hrs), 1, 30, 30⁺ (+ 3-6hrs), 31, 33 and 37 in subjects in the 2 subsets, in all vaccine groups:
 - Levels of Th1 and regulatory cytokine (e.g. IFN- γ , IL10) in serum, as measured by Cytokine bead assay (CBA) or by an equivalent assay.
 - Levels of Th2 cytokine (e.g. IL-4, IL-5, IL-13) in serum, as measured by CBA or by an equivalent assay.
 - Levels of pro-inflammatory cytokines (e.g. TNF- α , IL-6, IFN- γ) in serum, as measured by CBA or by an equivalent assay.
 - Levels of white blood cells with differential count, C-reactive protein (CRP) and creatine phosphokinases (CPK).
- At Days 0, 0⁺ (3-6hrs), 1, 14, 30, 30⁺ (3-6hrs), 31, 33 and 37 in up to the first 140 subjects in the 2 subsets recruited at the Immune Health (IH) centre in La Louvière, Belgium:
 - Gene expression signature related to the immune response as measured by microarray/ Polymerase Chain Reaction (PCR) array/ quantitative PCR, using whole blood.

Safety

In all subjects, in all vaccine groups:

- Occurrence, intensity and relationship% to vaccination of any solicited local and general signs and symptoms during a 14-day follow up period (i.e. day of vaccination and 13 subsequent days) after each vaccine dose.
- Occurrence, intensity and relationship to vaccination of unsolicited local and general signs and symptoms during a 31-day follow up period (i.e. day of vaccination and 30 subsequent days) after each vaccine dose.
- Occurrence and relationship to vaccination of all serious adverse events (SAEs) occurring throughout the study period.
- Occurrence of any adverse event of specific interest (AESI), including Autoimmune Disease (AID), throughout the entire study period. Adverse event of specific interest for safety monitoring include neurological/demyelinating events, rheumatic and connective diseases, autoimmune endocrine diseases, inflammatory bowel diseases, autoimmune blood disorders, inflammatory skin disorders, and other autoimmune/inflammatory events.

In subjects in the subsets 1 and 2 (a total of approximately 75 subjects/group), in all vaccine groups:

- Occurrence, intensity and relationship% to booster vaccination of any solicited local and general signs and symptoms during a 7-day follow up period (i.e. day of vaccination and 6 subsequent days).
- Occurrence, intensity and relationship to booster vaccination of unsolicited local and general signs and symptoms during a 31-day follow up period (i.e. day of vaccination and 30 subsequent days).

At Days 0, 30, 37, 60 (Month 2), 180 (Month 6), 360 (Month 12) in all subjects and at Day 390 (Month 13) in the subjects in the 2 subsets in all vaccine groups:

- Haematological and biochemical levels.

**Only CD4⁺ T cells results are presented.*

%All solicited local symptoms were considered causally related to vaccination

Statistical Methods:

The analyses were performed on the Total Vaccinated cohort, the Booster Total Vaccinated cohort, the According-To-Protocol (ATP) cohort for adaptive immunogenicity up to Day 60, the ATP cohort for innate immunogenicity up to Day 60, the ATP cohort for persistence, and the Booster ATP cohort for immunogenicity:

- The Total Vaccinated cohort included all vaccinated subjects.
- The Booster Total Vaccinated cohort included all vaccinated subjects from subsets 1 and 2 who received a booster vaccination at Day 360.
- The ATP cohort for adaptive immunogenicity up to Day 60 included all evaluable subjects (i.e. those meeting all eligibility criteria, complying with the procedures defined in the protocol, with no elimination criteria during the study), who complied with the vaccination schedule, and for whom adaptive immunogenicity data^s were available for at least one post-vaccination time point.

- The ATP cohort for innate immunogenicity up to Day 60 included all evaluable subjects (i.e. those meeting all eligibility criteria, complying with the procedures defined in the protocol, with no elimination criteria during the study), who complied with the vaccination schedule, for whom data concerning immunogenicity outcome measures were available and for whom innate immunogenicity data[§] were available for at least one post-vaccination time point.
- The ATP cohort for persistence included all subjects from the ATP cohort for adaptive immunogenicity up to Day 60 for whom adaptive immunogenicity data were available for at least one post-vaccination time point (Day 180 or Day 360).
- The Booster ATP cohort for immunogenicity included all subjects from subsets 1 and 2 who received a booster vaccination at Day 360 for whom adaptive immunogenicity data were available for at least one post-booster time point.

[§] Note: The adaptive response refers to the T cell response, the antibody response and the memory B cell response, whereas the innate response refers to the early immune response (i.e. cytokines in serum, gene expression signature, white blood cells counts).

Analysis of Immunogenicity

The analysis was based on the ATP cohort for adaptive immunogenicity up to Day 60, the ATP cohort for innate immunogenicity up to Day 60, the ATP cohort for persistence and the Booster ATP cohort for immunogenicity.

The 5 different study vaccine groups were compared in terms of HBs-specific CD4⁺ frequencies at Day 44 (CD4⁺ T-cells expressing at least 2 immune markers among CD40L, IL-2, TNF- α , IFN- γ , IL-13, IL-17) using Dunnett's method via a one-way ANOVA model. The main comparisons were performed between HBsAg 1 (reference group) and any of other four groups. Geometric mean ratios and associated Dunnett's 95% CIs of the ratios were tabulated.

In addition, for each treatment group, at each blood sampling time point for which results were available, descriptive statistics of the following parameters were tabulated:

- Frequencies of HBs-specific CD4⁺/CD8⁺ T cells (per million cells) expressing at least 2 immune markers among IL-2, INF- γ , TNF- α , CD40L, IL-13 and IL-17 as measured by ICS, using frozen PBMCs in all subjects,
- Frequency of HBs-specific CD4⁺ T cells (per million cells) expressing Th1 (i.e. expressing at least IFN- γ but not IL-13) /Th2 (i.e. expressing at least IL-13 but not IFN- γ) cytokine profile, using frozen PBMCs in all subjects
- Frequency of HBs-specific CD4⁺/CD8⁺ T cells (per million cells) expressing at least 2 immune markers among IL-2, INF- γ , TNF- α , CD40L, using whole blood, in all subjects recruited at the CEVAC in Ghent
- Frequency of HBs-specific memory B cells (per million cells), as measured by B-cell ELISPOT, in subjects of subsets 1 and 2.
- Concentration of each cytokine (pg/mL) in serum, in subjects of subsets 1 and 2: levels of Th1 and regulatory cytokine in serum, levels of Th2 cytokine in serum, levels of pro-inflammatory cytokines in serum,
- Normalized levels of white blood cells with differential count, C-reactive protein (CRP) and creatine phosphokinases (CPK).
- Messenger (m)RNA levels [presented as $\Delta\Delta C_t$ values] of 14 target genes as measured by qPCR

Additionally, similarly for each treatment group, for subjects in subsets 1 and 2, and at each blood sampling time point for which results were available, the percentage of subjects with seropositive and seroprotective levels of anti-HBs (proportions of subjects with anti-HBs antibody concentrations ≥ 6.2 and 10 mIU/mL, respectively)* with 95% confidence interval (CI) were determined. Antibody concentrations were summarized by geometric mean concentrations (GMCs) with 95% CI at the same time points.

**Note: A decrease in the specificity of the anti-HBs ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL). Following these laboratory quality issues, GSK Biologicals decided to stop testing with the HBs in-house ELISA and to have the anti-HB analysis performed using the new validated Chemi Luminescence Immuno Assay (CLIA). The results table shows updated results following complete retesting/reanalysis.*

Analysis of Safety

The analysis was based on the Total Vaccinated Cohort and on the Booster Total Vaccinated cohort.

The percentages of subjects reporting each solicited local and general symptom, during the 14-day (i.e. day of vaccination and 13 subsequent days) follow-up period after each primary vaccination and during the 7-day (i.e. day of vaccination and 6 subsequent days) follow-up period after the booster dose, were tabulated for each group with exact 95% CI. The same calculation was performed for any grade 3 symptoms and for general symptoms assessed by the investigator as causally related to vaccination.

The percentage of subjects with at least one report of unsolicited adverse event (AE) classified by Medical Dictionary for Regulatory Activities (MedDRA) Preferred Terms and reported during a 31-day follow up period after each primary vaccine dose and after the booster one was tabulated for each group. The same tabulation was performed for grade 3 AEs, and for AEs assessed by the investigator as causally related to vaccination.

SAEs and AESIs, including AID, were collected through the entire study period (Day 0 to Day 390) and tabulated according to the MedDRA preferred terms.

The frequency distribution of all clinical laboratory parameters with respect to normal ranges was tabulated per treatment group.

Normalized levels of these parameters were also tabulated per treatment group, at each scheduled time point.

Study Population: Healthy male or female subjects between, and including, 18 and 45 years at the time of the first vaccination were

enrolled in the study. Female subjects were to be of non-childbearing potential or if of childbearing potential, had to practice adequate contraception for 30 days prior to vaccination, to have a negative pregnancy test and were to continue such precautions for 2 months after completion of the vaccination series. Subjects should not have any previous administration of vaccine components nor received any previous vaccination against Hepatitis B. Written informed consent was obtained from the subjects prior to any study procedure.

Number of subjects	HBsAg 1 Group	HBsAg 2 Group	HBsAg 3 Group	HBsAg 4 Group	HBsAg 5 Group
Planned, N	142	142	142	142	142
Randomised, N (Total Vaccinated cohort)	143	142	141	145	142
Completed to Day 60, n (%)	141 (98.6)	141 (99.3)	133 (94.3)	137 (94.5)	138 (97.2)
Completed to Day 360/390	136 (95.1)	137 (96.5)	129 (91.5)	128 (88.3)	129 (90.8)
Total Number Subjects Withdrawn, n (%)	7 (4.9)	5 (3.5)	12 (8.5)	17 (11.7)	13 (9.2)
Withdrawn due to Adverse Events, n (%)	0 (0.0)	0 (0.0)	1 (0.7)	2 (1.4)	0 (0.0)
Withdrawn due to Lack of Efficacy, n (%)	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable
Withdrawn for other reasons, n (%)	7 (4.9)	5 (3.5)	11 (7.8)	15 (10.3)	13 (9.2)
Demographics	HBsAg 1 Group	HBsAg 2 Group	HBsAg 3 Group	HBsAg 4 Group	HBsAg 5 Group
N (Total Vaccinated Cohort)	143	142	141	145	142
Females:Males	66:77	66:76	64:77	66:79	65:77
Mean Age, years (SD)	34.7 (6.94)	33.7 (7.28)	32.9 (7.58)	33.5 (7.41)	32.9 (7.50)
White - Caucasian / European heritage, n (%)	135 (94.4)	138 (97.2)	138 (97.9)	142 (97.9)	136 (95.8)

Primary Efficacy Results: Comparison between groups (each group vs. the reference group [HBsAg 1]) in terms of frequency of HBs-specific CD4⁺ T cells expressing at least 2 markers among CD40L, IL-2, IFN- γ , TNF- α , IL-13 and IL-17 at Day 44 (by ICS, using PBMC) (ATP cohort for adaptive immunogenicity up to Day 60)

Reference group	N	GM	95% CI		Other groups	N	GM	95% CI		Ratio (Reference group/other groups)			
			LL	UL				LL	UL	GMR	Dunnett's 95% CI		Dunnett's p-value
HBsAg 1	112	1281	1061	1546	HBsAg 2	109	1098	915	1318	1.17	0.84	1.61	0.5608
					HBsAg 3	103	725	627	838	1.77	1.32	2.37	<.0001
					HBsAg 4	108	390	341	445	3.29	2.48	4.37	<.0001
					HBsAg 5	101	333	290	383	3.84	2.88	5.13	<.0001

N = Number of subjects with available results

GM = geometric mean

GMR = geometric mean ratio

95% CI = 95% confidence interval; LL = lower limit; UL = upper limit

Dunnett's 95% CI = 95% confidence interval based on Dunnett's adjustment

Primary Efficacy Results: Descriptive statistics of the frequency of HBs-specific CD4⁺ T cells expressing at least 2 markers among CD40L, IL-2, IFN- γ , TNF- α , IL-13 and IL-17 (by ICS, using PBMC) (ATP cohort for adaptive immunogenicity up to Day 60)

Group	Timing	N	GM	Median
HBsAg 1	PRE	111	241	228
	PI(D14)	114	417	408
	PI(D30)	108	297	277
	PII(D44)*	112	1281	1345
	PII(D60)	108	957	965
HBsAg 2	PRE	110	239	230
	PI(D14)	110	452	447
	PI(D30)	107	334	333
	PII(D44)*	109	1098	1257
	PII(D60)	112	904	958
HBsAg 3	PRE	107	246	234
	PI(D14)	106	481	460
	PI(D30)	109	338	314
	PII(D44)*	103	725	647
	PII(D60)	108	617	587
HBsAg 4	PRE	109	247	234
	PI(D14)	112	304	289

HBsAg 5	PI(D30)	109	266	255
	PII(D44)*	108	390	391
	PII(D60)	112	415	393
	PRE	106	247	235
	PI(D14)	107	264	245
	PI(D30)	101	263	249
	PII(D44)*	101	333	299
	PII(D60)	104	345	308

N = number of subjects with available results

GM = geometric mean

PRE = Pre-vaccination at Day 0

PI(D14) = Post-vaccination 1 at Day 14

PI(D30) = Post-vaccination 1 at Day 30

PII(D44) = Post-vaccination 2 at Day 44

PII(D60) = Post-vaccination 2 at Day 60

* Primary Outcome variable

Secondary Outcome Variable(s): Descriptive statistics of the frequency of HBs-specific CD8⁺ T cells expressing at least 2 markers among CD40L, IL-2, IFN- γ , TNF- α , IL-13 and IL-17 (by ICS, using PBMC) (ATP cohort for adaptive immunogenicity up to Day 60)

Group	Timing	N	GM	Median
HBsAg 1	PRE	107	179	176
	PI(D14)	112	184	174
	PI(D30)	105	179	185
	PII(D44)	107	206	212
	PII(D60)	108	201	209
HBsAg 2	PRE	108	182	174
	PI(D14)	110	169	160
	PI(D30)	103	175	173
	PII(D44)	106	228	213
	PII(D60)	112	218	228
HBsAg 3	PRE	105	177	172
	PI(D14)	104	179	174
	PI(D30)	107	167	160
	PII(D44)	102	180	177
	PII(D60)	107	188	171
HBsAg 4	PRE	104	192	201
	PI(D14)	108	198	193
	PI(D30)	107	183	191
	PII(D44)	105	179	157
	PII(D60)	109	192	184
HBsAg 5	PRE	104	173	184
	PI(D14)	105	186	177
	PI(D30)	100	181	173
	PII(D44)	98	166	169
	PII(D60)	104	181	166

N = number of subjects with available results

GM = geometric mean

PRE = Pre-vaccination at Day 0

PI(D14) = Post-vaccination 1 at Day 14

PI(D30) = Post-vaccination 1 at Day 30

PII(D44) = Post-vaccination 2 at Day 44

PII(D60) = Post-vaccination 2 at Day 60

Secondary Outcome Variable(s): Descriptive statistics of the frequency of HBs-specific CD4⁺ T cells expressing at least 2 markers among CD40L, IL-2, IFN- γ , TNF- α , IL-13 and IL-17 (by ICS, using PBMC) (ATP cohort for persistence)

Group	Timing	N	GM	Median
HBsAg 1	PRE	106	244	230
	PI(D14)	109	418	411

	PI(D30)	103	293	272
	PII(D44)	105	1286	1359
	PII(D60)	101	944	957
	PII(D180)	104	1051	1090
	PII(D360)	108	935	960
HBsAg 2	PRE	102	239	231
	PI(D14)	102	451	442
	PI(D30)	100	334	333
	PII(D44)	103	1054	1182
	PII(D60)	105	866	936
	PII(D180)	107	891	954
	PII(D360)	105	833	829
HBsAg 3	PRE	98	254	248
	PI(D14)	95	477	448
	PI(D30)	99	335	314
	PII(D44)	96	713	642
	PII(D60)	100	606	579
	PII(D180)	97	563	546
	PII(D360)	101	542	564
HBsAg 4	PRE	99	242	223
	PI(D14)	102	304	285
	PI(D30)	102	266	252
	PII(D44)	102	393	394
	PII(D60)	104	416	393
	PII(D180)	106	416	360
	PII(D360)	100	388	388
HBsAg 5	PRE	97	245	240
	PI(D14)	98	263	246
	PI(D30)	95	262	249
	PII(D44)	97	339	306
	PII(D60)	98	338	302
	PII(D180)	101	351	334
	PII(D360)	95	363	350

N = number of subjects with available results

GM = geometric mean

PRE = Pre-vaccination at Day 0

PI(D14) = Post-vaccination 1 at Day 14

PI(D30) = Post-vaccination 1 at Day 30

PII(D44) = Post-vaccination 2 at Day 44

PII(D60) = Post-vaccination 2 at Day 60

PII(D180) = Post-vaccination 2 at Day 180

PII(D360) = Post-vaccination 2 at Day 360

Secondary Outcome Variable(s): Descriptive statistics of the frequency of HBs-specific CD8⁺ T cells expressing at least 2 markers among CD40L, IL-2, IFN- γ , TNF- α , IL-13 and IL-17 (by ICS, using PBMC) (ATP cohort for persistence)

Group	Timing	N	GM	Median
HBsAg 1	PRE	102	175	175
	PI(D14)	107	185	175
	PI(D30)	102	175	183
	PII(D44)	100	202	214
	PII(D60)	101	202	208
	PII(D180)	104	126	120
	PII(D360)	108	115	114
HBsAg 2	PRE	100	179	169
	PI(D14)	102	169	162
	PI(D30)	96	178	175

	PII(D44)	100	231	213
	PII(D60)	105	221	219
	PII(D180)	107	125	124
	PII(D360)	104	109	115
HBsAg 3	PRE	96	185	176
	PI(D14)	93	180	172
	PI(D30)	97	166	156
	PII(D44)	95	182	177
	PII(D60)	99	189	171
	PII(D180)	96	100	92
	PII(D360)	99	118	112
HBsAg 4	PRE	96	182	191
	PI(D14)	99	200	189
	PI(D30)	100	183	192
	PII(D44)	99	176	156
	PII(D60)	101	188	182
	PII(D180)	105	106	102
	PII(D360)	98	110	104
HBsAg 5	PRE	95	172	184
	PI(D14)	96	181	174
	PI(D30)	94	181	173
	PII(D44)	94	164	166
	PII(D60)	98	178	165
	PII(D180)	101	115	110
	PII(D360)	94	105	90

N = number of subjects with available results

GM = geometric mean

PRE = Pre-vaccination at Day 0

PI(D14) = Post-vaccination 1 at Day 14

PI(D30) = Post-vaccination 1 at Day 30

PII(D44) = Post-vaccination 2 at Day 44

PII(D60) = Post-vaccination 2 at Day 60

PII(D180) = Post-vaccination 2 at Day 180

PII(D360) = Post-vaccination 2 at Day 360

Secondary Outcome Variable(s): Descriptive statistics of the frequency of HBs-specific CD4⁺ T cells expressing at least 2 markers among CD40L, IL-2, IFN- γ , TNF- α , IL-13 and IL-17 (by ICS, using PBMC) (Booster ATP cohort for immunogenicity; Subjects in subsets 1 and 2)

Group	Timing	N	GM	Median
HBsAg 1	PRE	53	252	228
	PI(D14)	53	440	464
	PI(D30)	52	298	284
	PII(D44)	51	1400	1653
	PII(D60)	49	1012	1042
	PII(D180)	51	1176	1267
	PII(D360)	54	1015	1029
	PIII(D374)	50	1097	1006
HBsAg 2	PRE	47	235	233
	PI(D14)	48	465	497
	PI(D30)	47	364	343
	PII(D44)	49	1126	1182
	PII(D60)	48	857	880
	PII(D180)	51	836	907
	PII(D360)	51	818	770
	PIII(D374)	48	1006	1037
HBsAg 3	PRE	50	257	254

	PI(D14)	48	600	611
	PI(D30)	53	366	344
	PII(D44)	49	787	844
	PII(D60)	50	689	629
	PII(D180)	50	563	525
	PII(D360)	53	539	538
	PIII(D374)	49	677	688
HBsAg 4	PRE	49	243	234
	PI(D14)	49	320	322
	PI(D30)	48	250	220
	PII(D44)	49	377	418
	PII(D60)	51	391	369
	PII(D180)	50	343	316
	PII(D360)	52	336	300
HBsAg 5	PIII(D374)	52	443	401
	PRE	44	264	266
	PI(D14)	46	309	270
	PI(D30)	48	290	288
	PII(D44)	45	387	335
	PII(D60)	46	375	349
	PII(D180)	48	357	340
	PII(D360)	48	357	360
	PIII(D374)	48	403	353

N = number of subjects with available results

GM = geometric mean

PRE = Pre-vaccination at Day 0

PI(D14) = Post-vaccination 1 at Day 14

PI(D30) = Post-vaccination 1 at Day 30

PII(D44) = Post-vaccination 2 at Day 44

PII(D60) = Post-vaccination 2 at Day 60

PII(D180) = Post-vaccination 2 at Day 180

PII(D360) = Pre-booster at Day 360

PIII(D374) = Post-booster at Day 374

Secondary Outcome Variable(s): Descriptive statistics of the frequency of HBs-specific CD8+ T cells expressing at least 2 markers among CD40L, IL-2, IFN- γ , TNF- α , IL-13 and IL-17 (by ICS, using PBMC) (Booster ATP cohort for immunogenicity; Subjects in subsets 1 and 2)

Group	Timing	N	GM	Median
HBsAg 1	PRE	51	187	187
	PI(D14)	52	193	203
	PI(D30)	52	175	186
	PII(D44)	49	214	232
	PII(D60)	49	204	203
	PII(D180)	51	129	121
	PII(D360)	54	109	109
	PIII(D374)	50	102	107
HBsAg 2	PRE	45	164	161
	PI(D14)	48	159	150
	PI(D30)	46	189	180
	PII(D44)	49	224	217
	PII(D60)	48	224	228
	PII(D180)	51	122	120
	PII(D360)	51	109	118
	PIII(D374)	48	112	111
HBsAg 3	PRE	49	196	196
	PI(D14)	47	192	194

	PI(D30)	52	168	169
	PII(D44)	49	185	177
	PII(D60)	50	192	172
	PII(D180)	49	106	94
	PII(D360)	51	124	121
	PIII(D374)	49	123	122
HBsAg 4	PRE	46	217	244
	PI(D14)	47	229	236
	PI(D30)	47	187	193
	PII(D44)	48	181	165
	PII(D60)	49	203	195
	PII(D180)	50	107	101
	PII(D360)	50	100	99
	PIII(D374)	52	122	121
HBsAg 5	PRE	42	168	168
	PI(D14)	45	205	187
	PI(D30)	48	192	187
	PII(D44)	45	168	167
	PII(D60)	46	179	162
	PII(D180)	48	112	100
	PII(D360)	47	106	90
	PIII(D374)	48	129	111

N = number of subjects with available results

GM = geometric mean

PRE = Pre-vaccination at Day 0

PI(D14) = Post-vaccination 1 at Day 14

PI(D30) = Post-vaccination 1 at Day 30

PII(D44) = Post-vaccination 2 at Day 44

PII(D60) = Post-vaccination 2 at Day 60

PII(D180) = Post-vaccination 2 at Day 180

PII(D360) = Pre-booster at Day 360

PIII(D374) = Post-booster at Day 374

Secondary Outcome Variable(s): Descriptive statistics of the frequency of HBs-specific CD4⁺ T cells expressing Th1 cytokine profile, i.e. at least IFN- γ and not IL-13 (by ICS, using PBMC) (ATP cohort for adaptive immunogenicity up to Day 60)

Group	Timing	N	GM	Median
HBsAg 1	PRE	111	64	65
	PI(D14)	114	65	64
	PI(D30)	108	59	61
	PII(D44)	112	170	155
	PII(D60)	108	123	119
HBsAg 2	PRE	110	69	62
	PI(D14)	110	78	75
	PI(D30)	107	69	66
	PII(D44)	109	163	174
	PII(D60)	112	147	141
HBsAg 3	PRE	107	59	53
	PI(D14)	106	69	68
	PI(D30)	109	73	75
	PII(D44)	103	93	95
	PII(D60)	108	91	90
HBsAg 4	PRE	109	76	70
	PI(D14)	112	82	81
	PI(D30)	109	66	64
	PII(D44)	108	86	74
	PII(D60)	112	87	94

HBsAg 5	PRE	106	69	67
	PI(D14)	107	68	66
	PI(D30)	101	75	72
	PII(D44)	101	68	64
	PII(D60)	104	72	61

N = number of subjects with available results

GM = geometric mean

PRE = Pre-vaccination at Day 0

PI(D14) = Post-vaccination 1 at Day 14

PI(D30) = Post-vaccination 1 at Day 30

PII(D44) = Post-vaccination 2 at Day 44

PII(D60) = Post-vaccination 2 at Day 60

Secondary Outcome Variable(s): Descriptive statistics of the frequency of HBs-specific CD4⁺ T cells expressing Th2 cytokine profile, i.e. at least IL-13 and not INF- γ (by ICS, using PBMC) (ATP cohort for adaptive immunogenicity up to Day 60)

Group	Timing	N	GM	Median
HBsAg 1	PRE	111	50	50
	PI(D14)	114	52	52
	PI(D30)	108	44	39
	PII(D44)	112	71	85
	PII(D60)	108	69	78
HBsAg 2	PRE	110	61	63
	PI(D14)	110	60	58
	PI(D30)	107	51	52
	PII(D44)	109	77	77
	PII(D60)	112	62	58
HBsAg 3	PRE	107	52	55
	PI(D14)	106	59	60
	PI(D30)	109	54	56
	PII(D44)	103	76	87
	PII(D60)	108	70	71
HBsAg 4	PRE	109	56	53
	PI(D14)	112	50	42
	PI(D30)	109	49	45
	PII(D44)	108	59	55
	PII(D60)	112	63	53
HBsAg 5	PRE	106	55	52
	PI(D14)	107	59	57
	PI(D30)	101	56	47
	PII(D44)	101	69	74
	PII(D60)	104	67	59

N = number of subjects with available results

GM = geometric mean

PRE = Pre-vaccination at Day 0

PI(D14) = Post-vaccination 1 at Day 14

PI(D30) = Post-vaccination 1 at Day 30

PII(D44) = Post-vaccination 2 at Day 44

PII(D60) = Post-vaccination 2 at Day 60

Secondary Outcome Variable(s): Descriptive statistics of the frequency of HBs-specific CD4⁺ T cells expressing Th1 cytokine profile, i.e. at least INF- γ and not IL-13 (by ICS, using PBMC) (ATP cohort for persistence)

Group	Timing	N	GM	Median
HBsAg 1	PRE	106	63	66
	PI(D14)	109	65	64
	PI(D30)	103	60	63
	PII(D44)	105	167	144
	PII(D60)	101	121	119

	PII(D180)	104	130	129
HBsAg 2	PRE	102	71	63
	PI(D14)	102	77	72
	PI(D30)	100	69	65
	PII(D44)	103	158	163
	PII(D60)	105	145	139
	PII(D180)	107	128	137
HBsAg 3	PRE	98	57	53
	PI(D14)	95	66	67
	PI(D30)	99	73	75
	PII(D44)	96	93	96
	PII(D60)	100	89	86
	PII(D180)	97	80	76
HBsAg 4	PRE	99	73	65
	PI(D14)	102	81	80
	PI(D30)	102	67	64
	PII(D44)	102	86	74
	PII(D60)	104	85	94
	PII(D180)	106	69	68
HBsAg 5	PRE	97	65	64
	PI(D14)	98	64	65
	PI(D30)	95	75	72
	PII(D44)	97	67	64
	PII(D60)	98	68	57
	PII(D180)	101	65	70

N = number of subjects with available results

GM = geometric mean

PRE = Pre-vaccination at Day 0

PI(D14) = Post-vaccination 1 at Day 14

PI(D30) = Post-vaccination 1 at Day 30

PII(D44) = Post-vaccination 2 at Day 44

PII(D60) = Post-vaccination 2 at Day 60

PII(D180) = Post-vaccination 2 at Day 180

Secondary Outcome Variable(s): Descriptive statistics of the frequency of HBs-specific CD4⁺ T cells expressing Th2 cytokine profile, i.e. at least IL-13 and not INF- γ (by ICS, using PBMC) (ATP cohort for persistence)

Group	Timing	N	GM	Median
HBsAg 1	PRE	106	50	51
	PI(D14)	109	51	51
	PI(D30)	103	44	39
	PII(D44)	105	72	85
	PII(D60)	101	69	77
	PII(D180)	104	54	54
HBsAg 2	PRE	102	62	64
	PI(D14)	102	60	58
	PI(D30)	100	51	52
	PII(D44)	103	77	77
	PII(D60)	105	62	60
	PII(D180)	107	57	63
HBsAg 3	PRE	98	55	57
	PI(D14)	95	60	60
	PI(D30)	99	52	52
	PII(D44)	96	75	90
	PII(D60)	100	67	70
	PII(D180)	97	45	46
HBsAg 4	PRE	99	52	50

	PI(D14)	102	50	41
	PI(D30)	102	50	47
	PII(D44)	102	59	55
	PII(D60)	104	63	52
	PII(D180)	106	57	54
HBsAg 5	PRE	97	55	48
	PI(D14)	98	61	63
	PI(D30)	95	57	48
	PII(D44)	97	70	76
	PII(D60)	98	67	60
	PII(D180)	101	49	49

N = number of subjects with available results

GM = geometric mean

PRE = Pre-vaccination at Day 0

PI(D14) = Post-vaccination 1 at Day 14

PI(D30) = Post-vaccination 1 at Day 30

PII(D44) = Post-vaccination 2 at Day 44

PII(D60) = Post-vaccination 2 at Day 60

PII(D180) = Post-vaccination 2 at Day 180

Secondary Outcome Variable(s): Descriptive statistics of the frequency of HBs-specific CD4⁺ T cells expressing at least 2 markers among CD40L, IL-2, IFN- γ and TNF- α (by ICS, using whole blood) (ATP cohort for adaptive immunogenicity up to Day 60; Subjects from CEVAC)

Group	Timing	N	GM	Median
HBsAg 1	PRE	13	47	68
	PI(D14)	16	362	425
	PI(D30)	15	227	313
	PII(D33)	16	131	114
	PII(D37)	17	886	844
	PII(D44)	14	1792	2021
	PII(D60)	11	1063	1291
HBsAg 2	PRE	11	71	98
	PI(D14)	14	435	498
	PI(D30)	14	262	314
	PII(D33)	12	253	270
	PII(D37)	13	1070	869
	PII(D44)	13	2461	2890
	PII(D60)	12	1650	1477
HBsAg 3	PRE	13	40	25
	PI(D14)	10	189	149
	PI(D30)	13	158	243
	PII(D33)	13	88	110
	PII(D37)	14	543	486
	PII(D44)	14	1104	1253
	PII(D60)	15	721	768
HBsAg 4	PRE	16	40	48
	PI(D14)	19	58	75
	PI(D30)	17	48	67
	PII(D33)	15	54	63
	PII(D37)	19	88	67
	PII(D44)	17	245	271
	PII(D60)	16	232	200
HBsAg 5	PRE	12	39	31
	PI(D14)	11	73	85
	PI(D30)	14	74	110
	PII(D33)	13	72	126

	PII(D37)	14	122	174
	PII(D44)	12	204	265
	PII(D60)	14	206	247

N = number of subjects with available results

GM = geometric mean

PRE = Pre-vaccination at Day 0

PI(D14) = Post-vaccination 1 at Day 14

PI(D30) = Post-vaccination 1 at Day 30

PII(D33) = Post-vaccination 2 at Day 33

PII(D37) = Post-vaccination 2 at Day 37

PII(D44) = Post-vaccination 2 at Day 44

PII(D60) = Post-vaccination 2 at Day 60

Secondary Outcome Variable(s): Descriptive statistics of the frequency of HBs-specific CD8⁺ T cells expressing at least 2 markers among CD40L, IL-2, IFN- γ and TNF- α (by ICS, using whole blood) (ATP cohort for adaptive immunogenicity up to Day 60; Subjects from CEVAC)

Group	Timing	N	GM	Median
HBsAg 1	PRE	13	16	11
	PI(D14)	13	30	12
	PI(D30)	14	44	64
	PII(D33)	16	28	11
	PII(D37)	16	33	11
	PII(D44)	13	38	11
	PII(D60)	11	35	37
HBsAg 2	PRE	10	21	11
	PI(D14)	10	29	11
	PI(D30)	12	13	11
	PII(D33)	12	24	11
	PII(D37)	13	57	103
	PII(D44)	13	73	99
	PII(D60)	9	68	102
HBsAg 3	PRE	13	16	11
	PI(D14)	10	20	11
	PI(D30)	13	20	11
	PII(D33)	10	31	41
	PII(D37)	14	30	11
	PII(D44)	13	32	11
	PII(D60)	16	24	11
HBsAg 4	PRE	14	19	11
	PI(D14)	15	30	11
	PI(D30)	15	20	11
	PII(D33)	12	18	11
	PII(D37)	15	18	11
	PII(D44)	14	28	11
	PII(D60)	13	23	11
HBsAg 5	PRE	11	15	11
	PI(D14)	11	36	11
	PI(D30)	14	29	11
	PII(D33)	13	28	11
	PII(D37)	14	37	42
	PII(D44)	11	37	11
	PII(D60)	13	25	11

N = number of subjects with available results

GM = geometric mean

PRE = Pre-vaccination at Day 0

PI(D14) = Post-vaccination 1 at Day 14

PI(D30) = Post-vaccination 1 at Day 30

PII(D33) = Post-vaccination 2 at Day 33
PII(D37) = Post-vaccination 2 at Day 37
PII(D44) = Post-vaccination 2 at Day 44
PII(D60) = Post-vaccination 2 at Day 60

Secondary Outcome Variable(s): Seropositivity rates, seroprotection rates and GMCs for Anti-HBs antibodies (by CLIA)[£] (ATP cohort for adaptive immunogenicity up to Day 60, subjects in subsets 1 and 2)

				≥ 6.2 mIU/mL				≥ 10 mIU/mL				GMC (mIU/mL)		
				95% CI				95% CI				95% CI		
Antibody	Group	Timing	N	n	%	LL	UL	n	%	LL	UL	value	LL	UL
HBs	HBsAg 1	PRE	59	1	1.7	0.0	9.1	0	0.0	0.0	6.1	3.1	3.1	3.2
		PI(D30)	59	54	91.5	81.3	97.2	51	86.4	75.0	94.0	108.0	65.0	179.6
		PII(D44)	59	59	100	93.9	100	59	100	93.9	100	11986.2	8676.4	16558.7
		PII(D60)	59	59	100	93.9	100	59	100	93.9	100	7454.3	5603.6	9916.2
	HBsAg 2	PRE	57	0	0.0	0.0	6.3	0	0.0	0.0	6.3	3.1	3.1	3.1
		PI(D30)	57	47	82.5	70.1	91.3	42	73.7	60.3	84.5	59.6	31.9	111.5
		PII(D44)	56	56	100	93.6	100	56	100	93.6	100	7942.6	5288.7	11928.2
		PII(D60)	57	57	100	93.7	100	57	100	93.7	100	5030.9	3396.4	7452.1
	HBsAg 3	PRE	58	3	5.2	1.1	14.4	1	1.7	0.0	9.2	3.3	3.1	3.6
		PI(D30)	58	51	87.9	76.7	95.0	45	77.6	64.7	87.5	66.3	35.7	123.0
		PII(D44)	57	57	100	93.7	100	57	100	93.7	100	5525.4	3639.3	8389.2
		PII(D60)	58	58	100	93.8	100	58	100	93.8	100	4194.3	2805.4	6270.8
	HBsAg 4	PRE	62	0	0.0	0.0	5.8	0	0.0	0.0	5.8	3.1	3.1	3.1
		PI(D30)	60	19	31.7	20.3	45.0	12	20.0	10.8	32.3	6.1	4.2	9.1
		PII(D44)	60	54	90.0	79.5	96.2	51	85.0	73.4	92.9	220.2	126.5	383.3
		PII(D60)	59	56	94.9	85.9	98.9	55	93.2	83.5	98.1	251.9	150.6	421.5
	HBsAg 5	PRE	57	0	0.0	0.0	6.3	0	0.0	0.0	6.3	3.1	3.1	3.1
		PI(D30)	55	3	5.5	1.1	15.1	2	3.6	0.4	12.5	3.5	2.9	4.2
		PII(D44)	53	30	56.6	42.3	70.2	28	52.8	38.6	66.7	19.2	11.1	33.2
		PII(D60)	55	33	60.0	45.9	73.0	32	58.2	44.1	71.3	21.5	12.7	36.4

[£]Note: A decrease in the specificity of the anti-HBs ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL). Following these laboratory quality issues, GSK Biologicals decided to stop testing with the HBs in-house ELISA and to have the anti-HB analysis performed using the CLIA assay. The results table shows results following analysis with this latter assay.

Seropositivity was defined as anti-HBs antibody concentration ≥ 6.2 mIU/mL

Seroprotection was defined as anti-HBs antibody concentration ≥ 10 mIU/mL

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE = Pre-vaccination at Day 0

PI(D30) = Post-vaccination 1 at Day 30

PII(D44) = Post-vaccination 2 at Day 44

PII(D60) = Post-vaccination 2 at Day 60

Secondary Outcome Variable(s): Seropositivity rates, seroprotection rates and GMCs for Anti-HBs antibodies (by CLIA)[£] (ATP cohort for persistence, subjects in subsets 1 and 2)

				≥ 6.2 mIU/mL				≥ 10 mIU/mL				GMC (mIU/mL)		
				95% CI				95% CI				95% CI		
Antibody	Group	Timing	N	n	%	LL	UL	n	%	LL	UL	value	LL	UL
Anti-HBs	HBsAg 1	PRE	58	1	1.7	0.0	9.2	0	0.0	0.0	6.2	3.1	3.1	3.2
		PI(D30)	58	53	91.4	81.0	97.1	50	86.2	74.6	93.9	108.8	64.9	182.5
		PII(D44)	58	58	100	93.8	100	58	100	93.8	100	12201.9	8799.6	16919.7
		PII(D60)	58	58	100	93.8	100	58	100	93.8	100	7523.0	5630.0	10052.4
		PII(D180)	57	57	100	93.7	100	57	100	93.7	100	3840.7	2953.4	4994.6
		PII(D360)	58	58	100	93.8	100	58	100	93.8	100	2150.7	1602.7	2885.9
	HBsAg 2	PRE	54	0	0.0	0.0	6.6	0	0.0	0.0	6.6	3.1	3.1	3.1
		PI(D30)	54	44	81.5	68.6	90.7	40	74.1	60.3	85.0	59.8	31.2	115.0
		PII(D44)	54	54	100	93.4	100	54	100	93.4	100	7579.9	5002.9	11484.3

		PII(D60)	54	54	100	93.4	100	54	100	93.4	100	4895.3	3267.3	7334.6
		PII(D180)	54	54	100	93.4	100	54	100	93.4	100	2657.5	1972.1	3581.0
		PII(D360)	53	53	100	93.3	100	53	100	93.3	100	1650.6	1159.7	2349.4
	HBsAg 3	PRE	55	3	5.5	1.1	15.1	1	1.8	0.0	9.7	3.3	3.1	3.6
		PI(D30)	55	49	89.1	77.8	95.9	43	78.2	65.0	88.2	71.1	37.4	135.2
		PII(D44)	55	55	100	93.5	100	55	100	93.5	100	5534.7	3589.3	8534.7
		PII(D60)	55	55	100	93.5	100	55	100	93.5	100	4558.2	3095.4	6712.4
		PII(D180)	55	55	100	93.5	100	55	100	93.5	100	3330.2	2502.2	4432.1
		PII(D360)	54	54	100	93.4	100	54	100	93.4	100	2122.5	1542.3	2921.1
	HBsAg 4	PRE	56	0	0.0	0.0	6.4	0	0.0	0.0	6.4	3.1	3.1	3.1
		PI(D30)	56	19	33.9	21.8	47.8	12	21.4	11.6	34.4	6.5	4.3	9.8
		PII(D44)	56	50	89.3	78.1	96.0	48	85.7	73.8	93.6	218.3	122.6	388.7
		PII(D60)	56	53	94.6	85.1	98.9	52	92.9	82.7	98.0	240.9	140.4	413.4
		PII(D180)	55	55	100	93.5	100	55	100	93.5	100	254.5	169.9	381.2
		PII(D360)	54	50	92.6	82.1	97.9	49	90.7	79.7	96.9	94.5	59.6	149.8
	HBsAg 5	PRE	54	0	0.0	0.0	6.6	0	0.0	0.0	6.6	3.1	3.1	3.1
		PI(D30)	54	2	3.7	0.5	12.7	2	3.7	0.5	12.7	3.5	2.9	4.2
		PII(D44)	52	29	55.8	41.3	69.5	27	51.9	37.6	66.0	17.7	10.4	30.3
		PII(D60)	54	32	59.3	45.0	72.4	31	57.4	43.2	70.8	20.1	12.0	33.8
		PII(D180)	53	41	77.4	63.8	87.7	40	75.5	61.7	86.2	39.0	23.3	65.2
		PII(D360)	51	35	68.6	54.1	80.9	30	58.8	44.2	72.4	19.8	12.5	31.3

[‡]Note: A decrease in the specificity of the anti-HBs ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL). Following these laboratory quality issues, GSK Biologicals decided to stop testing with the HBs in-house ELISA and to have the anti-HB analysis performed using the CLIA assay. The results table shows results following analysis with this latter assay.

Seropositivity was defined as anti-HBs antibody concentration ≥ 6.2 mIU/mL

Seroprotection was defined as anti-HBs antibody concentration ≥ 10 mIU/mL

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE = Pre-vaccination at Day 0

PI(D30) = Post-vaccination 1 at Day 30

PII(D44) = Post-vaccination 2 at Day 44

PII(D60) = Post-vaccination 2 at Day 60

PII(D180) = Post-vaccination 2 at Day 180

PII(D360) = Post-vaccination 2 at Day 360

Secondary Outcome Variable(s): Seropositivity rates, seroprotection rates and GMCs for Anti-HBs antibodies (by CLIA)[‡] (Booster ATP cohort for immunogenicity, subjects in subsets 1 and 2)

				≥ 6.2 mIU/mL				≥ 10 mIU/mL				GMC (mIU/mL)		
				95% CI				95% CI				95% CI		
Antibody	Group	Timing	N	n	%	LL	UL	n	%	LL	UL	value	LL	UL
Anti-HBs	HBsAg 1	PRE	55	1	1.8	0.0	9.7	0	0.0	0.0	6.5	3.1	3.1	3.2
		PI(D30)	55	50	90.9	80.0	97.0	47	85.5	73.3	93.5	109.8	63.7	189.3
		PII(D44)	55	55	100	93.5	100	55	100	93.5	100	12781.9	9102.9	17947.9
		PII(D60)	55	55	100	93.5	100	55	100	93.5	100	7859.2	5827.2	10599.6
		PII(D180)	54	54	100	93.4	100	54	100	93.4	100	3854.9	2921.8	5086.0
		PII(D360)	55	55	100	93.5	100	55	100	93.5	100	2157.6	1585.4	2936.2
		PIII(D374)	52	52	100	93.2	100	52	100	93.2	100	51509.0	35731.5	74253.1
		PIII(D390)	52	52	100	93.2	100	52	100	93.2	100	43674.6	29975.7	63633.8
	HBsAg 2	PRE	52	0	0.0	0.0	6.8	0	0.0	0.0	6.8	3.1	3.1	3.1
		PI(D30)	52	42	80.8	67.5	90.4	38	73.1	59.0	84.4	59.0	30.2	115.4
		PII(D44)	52	52	100	93.2	100	52	100	93.2	100	7752.4	5048.2	11905.2
		PII(D60)	52	52	100	93.2	100	52	100	93.2	100	5017.8	3325.2	7571.9
		PII(D180)	52	52	100	93.2	100	52	100	93.2	100	2702.9	1994.8	3662.2
		PII(D360)	52	52	100	93.2	100	52	100	93.2	100	1703.6	1195.5	2427.6
		PIII(D374)	50	50	100	92.9	100	50	100	92.9	100	31985.9	22628.6	45212.7
		PIII(D390)	48	48	100	92.6	100	48	100	92.6	100	27035.7	18737.0	39009.7

	HBsAg 3	PRE	54	3	5.6	1.2	15.4	1	1.9	0.0	9.9	3.3	3.1	3.6
		PI(D30)	54	48	88.9	77.4	95.8	42	77.8	64.4	88.0	67.7	35.4	129.5
		PII(D44)	54	54	100	93.4	100	54	100	93.4	100	5604.5	3607.2	8707.7
		PII(D60)	54	54	100	93.4	100	54	100	93.4	100	4584.1	3090.5	6799.5
		PII(D180)	54	54	100	93.4	100	54	100	93.4	100	3378.3	2528.2	4514.1
		PII(D360)	54	54	100	93.4	100	54	100	93.4	100	2122.5	1542.3	2921.1
		PIII(D374)	53	53	100	93.3	100	53	100	93.3	100	27135.3	19376.8	38000.5
		PIII(D390)	53	53	100	93.3	100	53	100	93.3	100	25105.7	17730.1	35549.4
	HBsAg 4	PRE	54	0	0.0	0.0	6.6	0	0.0	0.0	6.6	3.1	3.1	3.1
		PI(D30)	54	18	33.3	21.1	47.5	12	22.2	12.0	35.6	6.5	4.2	10.1
		PII(D44)	54	48	88.9	77.4	95.8	46	85.2	72.9	93.4	209.1	115.3	379.3
		PII(D60)	54	51	94.4	84.6	98.8	50	92.6	82.1	97.9	233.8	133.8	408.5
		PII(D180)	53	53	100	93.3	100	53	100	93.3	100	251.8	165.8	382.5
		PII(D360)	54	50	92.6	82.1	97.9	49	90.7	79.7	96.9	94.5	59.6	149.8
		PIII(D374)	54	54	100	93.4	100	54	100	93.4	100	3788.4	2047.8	7008.6
		PIII(D390)	51	51	100	93.0	100	51	100	93.0	100	3352.2	1756.0	6399.1
	HBsAg 5	PRE	50	0	0.0	0.0	7.1	0	0.0	0.0	7.1	3.1	3.1	3.1
		PI(D30)	50	2	4.0	0.5	13.7	2	4.0	0.5	13.7	3.5	2.9	4.3
		PII(D44)	48	27	56.3	41.2	70.5	25	52.1	37.2	66.7	17.6	10.1	30.7
		PII(D60)	50	30	60.0	45.2	73.6	29	58.0	43.2	71.8	20.2	11.8	34.6
		PII(D180)	49	38	77.6	63.4	88.2	37	75.5	61.1	86.7	39.2	23.1	66.5
		PII(D360)	50	34	68.0	53.3	80.5	29	58.0	43.2	71.8	19.1	12.0	30.2
		PIII(D374)	50	44	88.0	75.7	95.5	44	88.0	75.7	95.5	341.3	143.7	810.4
		PIII(D390)	50	44	88.0	75.7	95.5	42	84.0	70.9	92.8	351.1	147.0	838.5

[£]Note: A decrease in the specificity of the anti-HBs ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL). Following these laboratory quality issues, GSK Biologicals decided to stop testing with the HBs in-house ELISA and to have the anti-HB analysis performed using the CLIA assay. The results table shows results following analysis with this latter assay.

Seropositivity was defined as anti-HBs antibody concentration ≥ 6.2 mIU/mL

Seroprotection was defined as anti-HBs antibody concentration ≥ 10 mIU/mL

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE = Pre-vaccination at Day 0

PI(D30) = Post-vaccination 1 at Day 30

PII(D44) = Post-vaccination 2 at Day 44

PII(D60) = Post-vaccination 2 at Day 60

PII(D180) = Post-vaccination 2 at Day 180

PII(D360) = Post-vaccination 2 at Day 360

PII(D374) = Post-vaccination 3 at Day 374

PII(D390) = Post-vaccination 3 at Day 390

Secondary Outcome Variable(s): Descriptive statistics of the frequency of HBs-specific memory B cells (by ELISPOT, using PBMC) (ATP cohort for adaptive immunogenicity up to Day 60; Subjects in subsets 1 and 2)

Group	Timing	N	GM	Median
HBsAg 1	PRE	50	9	14
	PI(D30)	54	128	296
	PII(D37)	52	3246	3817
	PII(D44)	54	3729	4656
	PII(D60)	52	2238	3742
HBsAg 2	PRE	51	5	1
	PI(D30)	51	109	186
	PII(D37)	53	3043	3577
	PII(D44)	52	4042	4808
	PII(D60)	51	2666	3383
HBsAg 3	PRE	53	6	1
	PI(D30)	55	155	265

	PII(D37)	48	1879	2597
	PII(D44)	50	1436	2498
	PII(D60)	54	1258	1806
HBsAg 4	PRE	53	6	1
	PI(D30)	53	13	28
	PII(D37)	53	32	71
	PII(D44)	51	28	51
	PII(D60)	53	20	47
HBsAg 5	PRE	51	5	1
	PI(D30)	52	6	1
	PII(D37)	52	11	19
	PII(D44)	48	14	28
	PII(D60)	47	17	44

N = number of subjects with available results

GM = geometric mean

PRE = Pre-vaccination at Day 0

PI(D30) = Post-vaccination 1 at Day 30

PII(D37) = Post-vaccination 2 at Day 37

PII(D44) = Post-vaccination 2 at Day 44

PII(D60) = Post-vaccination 2 at Day 60

Secondary Outcome Variable(s): Descriptive statistics of the frequency of HBs-specific memory B cells (by ELISPOT, using PBMC) (ATP cohort for persistence; Subjects in subsets 1 and 2)

Group	Timing	N	GM	Median
HBsAg 1	PRE	49	8	10
	PI(D30)	53	121	277
	PII(D37)	51	3048	3449
	PII(D44)	53	3583	4396
	PII(D60)	51	2137	3300
	PII(D180)	49	896	1454
	PII(D360)	52	1226	1070
HBsAg 2	PRE	48	5	1
	PI(D30)	49	104	166
	PII(D37)	51	3079	3577
	PII(D44)	51	4042	5105
	PII(D60)	48	2641	3383
	PII(D180)	48	456	1013
	PII(D360)	46	590	1437
HBsAg 3	PRE	50	6	1
	PI(D30)	52	156	266
	PII(D37)	45	1920	2685
	PII(D44)	48	1464	2498
	PII(D60)	51	1330	2011
	PII(D180)	49	1014	1410
	PII(D360)	50	1162	1473
HBsAg 4	PRE	49	6	1
	PI(D30)	50	12	26
	PII(D37)	50	32	70
	PII(D44)	48	26	45
	PII(D60)	50	18	46
	PII(D180)	45	15	24
	PII(D360)	49	32	66
HBsAg 5	PRE	48	5	1
	PI(D30)	51	7	1
	PII(D37)	51	11	20
	PII(D44)	47	14	27

	PII(D60)	46	16	36
	PII(D180)	50	6	1
	PII(D360)	49	11	21

N = number of subjects with available results

GM = geometric mean

PRE = Pre-vaccination at Day 0

PI(D30) = Post-vaccination 1 at Day 30

PII(D37) = Post-vaccination 2 at Day 37

PII(D44) = Post-vaccination 2 at Day 44

PII(D60) = Post-vaccination 2 at Day 60

PII(D180) = Post-vaccination 2 at Day 180

PII(D360) = Post-vaccination 2 at Day 360

Secondary Outcome Variable(s): Descriptive statistics of the cytokine concentrations in serum (by CBA) (ATP cohort for innate immunogenicity up to Day 60; Subjects in Subsets 1 and 2)

Parameter	Group	Timing	N	Min	Median	Max
IFN- γ PROTEIN	HBsAg 1	PRE	59	3.704	3.704	3.704
		PI(D0)	59	3.704	3.704	856.207
		PI(D1)	58	3.704	3.704	154.362
		PI(D30)	59	3.704	3.704	3.704
		PII(D30)	59	3.704	3.704	10.628
		PII(D31)	58	3.704	5.568	1145.122
		PII(D33)	59	3.704	3.704	218.924
		PII(D37)	59	3.704	3.704	12.483
	HBsAg 2	PRE	57	3.704	3.704	3.704
		PI(D0)	57	3.704	3.704	3.704
		PI(D1)	57	3.704	3.704	19.042
		PI(D30)	57	3.704	3.704	3.704
		PII(D30)	57	3.704	3.704	3.704
		PII(D31)	57	3.704	3.704	203.291
		PII(D33)	57	3.704	3.704	12.755
		PII(D37)	56	3.704	3.704	13.408
	HBsAg 3	PRE	59	3.704	3.704	3.704
		PI(D0)	59	3.704	3.704	38.581
		PI(D1)	58	3.704	3.704	3.704
		PI(D30)	57	3.704	3.704	15.971
		PII(D30)	57	3.704	3.704	8.133
		PII(D31)	56	3.704	3.704	197.853
		PII(D33)	57	3.704	3.704	12.114
		PII(D37)	57	3.704	3.704	8.135
	HBsAg 4	PRE	60	3.704	3.704	3.704
		PI(D0)	61	3.704	3.704	30.231
		PI(D1)	61	3.704	3.704	3.704
		PI(D30)	59	3.704	3.704	13.464
		PII(D30)	59	3.704	3.704	3.704
		PII(D31)	57	3.704	3.704	8.82
		PII(D33)	59	3.704	3.704	10.872
		PII(D37)	58	3.704	3.704	37.275
	HBsAg 5	PRE	55	3.704	3.704	31.94
		PI(D0)	55	3.704	3.704	37.165
		PI(D1)	55	3.704	3.704	3.704
		PI(D30)	55	3.704	3.704	10.628
		PII(D30)	54	3.704	3.704	15.615
		PII(D31)	55	3.704	3.704	15.336
		PII(D33)	55	3.704	3.704	3.704
		PII(D37)	55	3.704	3.704	30.859

IL1 B PROTEIN	HBsAg 1	PRE	59	0.411	0.411	8.198
		PI(D0)	59	0.411	1.636	11.933
		PI(D1)	58	0.411	2.024	7.388
		PI(D30)	59	0.411	1.232	13.468
		PII(D30)	59	0.411	1.292	8.832
		PII(D31)	58	0.411	0.991	13.211
		PII(D33)	59	0.411	0.411	12.951
		PII(D37)	59	0.411	0.411	6.004
	HBsAg 2	PRE	57	0.411	1.379	10.913
		PI(D0)	57	0.411	1.873	13.185
		PI(D1)	57	0.411	2.237	13.988
		PI(D30)	57	0.411	0.879	10.034
		PII(D30)	57	0.411	1.099	14.235
		PII(D31)	57	0.411	1.263	12.741
		PII(D33)	57	0.411	0.411	12.691
		PII(D37)	56	0.411	0.411	10.545
	HBsAg 3	PRE	59	0.411	0.411	12.046
		PI(D0)	59	0.411	0.856	10.46
		PI(D1)	58	0.411	1.912	13.643
		PI(D30)	57	0.411	1.017	27.104
		PII(D30)	57	0.411	0.856	26.269
		PII(D31)	56	0.411	1.117	8.702
		PII(D33)	57	0.411	0.411	4.83
		PII(D37)	57	0.411	0.411	7.205
	HBsAg 4	PRE	60	0.411	0.411	11.479
		PI(D0)	61	0.411	0.947	10.008
		PI(D1)	61	0.411	1.628	10.122
		PI(D30)	59	0.411	0.925	9.416
		PII(D30)	59	0.411	1.214	5.202
		PII(D31)	57	0.411	1.159	9.702
		PII(D33)	59	0.411	0.411	4.078
		PII(D37)	58	0.411	0.411	6.968
	HBsAg 5	PRE	55	0.411	0.411	9.33
		PI(D0)	55	0.411	1.146	15.259
		PI(D1)	55	0.411	1.885	15.958
		PI(D30)	55	0.411	0.411	9.56
		PII(D30)	54	0.411	1.349	18.084
		PII(D31)	55	0.411	1.135	10.545
		PII(D33)	55	0.411	0.86	13.725
		PII(D37)	55	0.411	0.411	6.732
IL10 PROTEIN	HBsAg 1	PRE	59	0.411	0.411	1.68
		PI(D0)	59	0.411	0.411	3.244
		PI(D1)	58	0.411	0.977	8.267
		PI(D30)	59	0.411	0.411	4.953
		PII(D30)	59	0.411	0.411	4.179
		PII(D31)	58	0.411	0.705	8.402
		PII(D33)	59	0.411	0.411	3.074
		PII(D37)	59	0.411	0.411	4.108
	HBsAg 2	PRE	57	0.411	0.411	2.772
		PI(D0)	57	0.411	0.411	5.622
		PI(D1)	57	0.411	1.08	8.132
		PI(D30)	57	0.411	0.411	7.242
		PII(D30)	57	0.411	0.411	3.292
		PII(D31)	57	0.411	0.411	9.092
		PII(D33)	57	0.411	0.411	3.968

	HBsAg 3	PII(D37)	56	0.411	0.411	4.458
		PRE	59	0.411	0.411	21.037
		PI(D0)	59	0.411	0.411	24.625
		PI(D1)	58	0.411	1.055	8.828
		PI(D30)	57	0.411	0.411	6.775
		PII(D30)	57	0.411	0.411	4.813
		PII(D31)	56	0.411	0.411	8.538
		PII(D33)	57	0.411	0.411	6.073
		PII(D37)	57	0.411	0.411	6.181
	HBsAg 4	PRE	60	0.411	0.411	2.805
		PI(D0)	61	0.411	0.411	6.05
		PI(D1)	61	0.411	0.893	7.603
		PI(D30)	59	0.411	0.411	3.638
		PII(D30)	59	0.411	0.411	3.603
		PII(D31)	57	0.411	0.411	9.659
		PII(D33)	59	0.411	0.411	4.249
		PII(D37)	58	0.411	0.411	4.249
	HBsAg 5	PRE	55	0.411	0.411	3.43
		PI(D0)	55	0.411	0.411	7.04
		PI(D1)	55	0.411	0.916	6.959
		PI(D30)	55	0.411	0.411	10.33
		PII(D30)	54	0.411	0.411	3.314
		PII(D31)	55	0.411	0.411	9.803
		PII(D33)	55	0.411	0.411	16.184
		PII(D37)	55	0.411	0.411	4.847
IL5 PROTEIN	HBsAg 1	PRE	59	0.411	0.411	3.821
		PI(D0)	59	0.411	1.161	3.339
		PI(D1)	58	0.411	2.004	7.058
		PI(D30)	59	0.411	1.202	4.516
		PII(D30)	59	0.411	0.884	8.692
		PII(D31)	58	0.411	1.119	8.38
		PII(D33)	59	0.411	0.411	5.445
		PII(D37)	59	0.411	0.411	4.307
	HBsAg 2	PRE	57	0.411	0.411	4.475
		PI(D0)	57	0.411	1.37	3.925
		PI(D1)	57	0.411	2.089	6.297
		PI(D30)	57	0.411	0.411	5.231
		PII(D30)	57	0.411	0.916	3.582
		PII(D31)	57	0.411	0.951	7.003
		PII(D33)	57	0.411	0.411	4.938
		PII(D37)	56	0.411	0.411	4.852
	HBsAg 3	PRE	59	0.411	0.905	5.203
		PI(D0)	59	0.411	0.905	4.434
		PI(D1)	58	0.411	1.83	7.281
		PI(D30)	57	0.411	1.011	11.14
		PII(D30)	57	0.411	0.411	8.999
		PII(D31)	56	0.411	1.289	7.058
		PII(D33)	57	0.411	1.192	5.731
		PII(D37)	57	0.411	0.411	4.56
	HBsAg 4	PRE	60	0.411	0.867	3.56
		PI(D0)	61	0.411	0.411	4.473
		PI(D1)	61	0.411	1.77	6.404
		PI(D30)	59	0.411	0.89	5.891
		PII(D30)	59	0.411	0.992	3.804
		PII(D31)	57	0.411	1.113	7.968

	HBsAg 5	PII(D33)	59	0.411	0.411	4.343
		PII(D37)	58	0.411	0.411	4.927
		PRE	55	0.411	0.411	3.85
		PI(D0)	55	0.411	1.092	4.464
		PI(D1)	55	0.411	1.942	6.723
		PI(D30)	55	0.411	0.411	7.606
		PII(D30)	54	0.411	0.411	7.047
		PII(D31)	55	0.411	0.99	8.32
		PII(D33)	55	0.411	0.411	5.255
		PII(D37)	55	0.411	0.411	7.083
IL6 PROTEIN	HBsAg 1	PRE	59	0.411	1.291	8.571
		PI(D0)	59	0.411	2.882	12.962
		PI(D1)	58	0.411	4.07	21.787
		PI(D30)	59	0.411	1.641	7.795
		PII(D30)	59	0.411	3.195	15.801
		PII(D31)	58	1.18	7.459	38.824
		PII(D33)	59	0.411	1.644	17.972
		PII(D37)	59	0.411	1.003	4.588
	HBsAg 2	PRE	57	0.411	1.19	22.999
		PI(D0)	57	0.411	2.523	35.4
		PI(D1)	57	0.411	2.578	42.655
		PI(D30)	57	0.411	1.377	24.442
		PII(D30)	57	0.411	2.53	15.119
		PII(D31)	57	0.411	4.174	28.727
		PII(D33)	57	0.411	1.253	16.538
		PII(D37)	56	0.411	0.976	44.36
	HBsAg 3	PRE	59	0.411	1.291	15.47
		PI(D0)	59	0.411	1.605	32.033
		PI(D1)	58	0.411	2.223	6.824
		PI(D30)	57	0.411	1.79	10.688
		PII(D30)	57	0.411	1.664	11.889
		PII(D31)	56	0.411	3.457	10.529
		PII(D33)	57	0.411	1.435	6.828
		PII(D37)	57	0.411	0.95	8.539
	HBsAg 4	PRE	60	0.411	1.26	3.977
		PI(D0)	61	0.411	1.579	7.354
		PI(D1)	61	0.411	2.147	7.182
		PI(D30)	59	0.411	1.653	7.874
		PII(D30)	59	0.411	1.753	5.674
		PII(D31)	57	0.411	2.538	8.46
		PII(D33)	59	0.411	1.676	6.212
		PII(D37)	58	0.411	1.321	4.498
	HBsAg 5	PRE	55	0.411	1.055	66.667
		PI(D0)	55	0.411	1.418	66.667
		PI(D1)	55	0.411	1.739	66.667
		PI(D30)	55	0.411	1.218	27.914
		PII(D30)	54	0.411	1.394	28.006
		PII(D31)	55	0.411	1.567	26.586
		PII(D33)	55	0.411	1.389	18.577
		PII(D37)	55	0.411	1.158	32.716
IP-10 PROTEIN	HBsAg 1	PRE	59	41	94	276
		PI(D0)	57	20	80	296
		PI(D1)	58	41	147	608
		PI(D30)	59	45	103	463
		PII(D30)	59	20	75	336

		PII(D31)	58	49	295	2500
		PII(D33)	59	53	232	1282
		PII(D37)	59	44	119	289
	HBsAg 2	PRE	57	20	92	550
		PI(D0)	57	20	81	424
		PI(D1)	57	20	111	768
		PI(D30)	57	20	109	796
		PII(D30)	57	20	63	352
		PII(D31)	57	20	211	891
		PII(D33)	57	20	170	644
		PII(D37)	56	20	100.5	256
	HBsAg 3	PRE	58	20	101.5	634
		PI(D0)	59	20	78	420
		PI(D1)	58	20	92.5	434
		PI(D30)	57	43	106	418
		PII(D30)	56	20	70.5	277
		PII(D31)	56	20	176.5	864
		PII(D33)	57	20	156	709
		PII(D37)	57	20	90	355
	HBsAg 4	PRE	60	20	102	506
		PI(D0)	61	20	80	349
		PI(D1)	60	20	85.5	381
		PI(D30)	59	49	104	1010
		PII(D30)	59	20	68	441
		PII(D31)	57	20	63	399
		PII(D33)	59	20	86	425
		PII(D37)	58	20	83.5	495
	HBsAg 5	PRE	55	20	91	476
		PI(D0)	54	20	75.5	407
		PI(D1)	55	20	85	848
		PI(D30)	55	20	107	437
		PII(D30)	54	20	70	370
		PII(D31)	55	20	76	475
		PII(D33)	55	20	84	275
		PII(D37)	55	20	85	432
MCP-1 PROTEIN	HBsAg 1	PRE	59	20	130	482
		PI(D0)	57	20	112	350
		PI(D1)	58	20	144	527
		PI(D30)	59	20	151	620
		PII(D30)	59	20	140	391
		PII(D31)	58	20	171	684
		PII(D33)	59	20	83	748
		PII(D37)	59	20	129	446
	HBsAg 2	PRE	57	20	168	516
		PI(D0)	57	20	141	353
		PI(D1)	57	20	139	412
		PI(D30)	57	20	179	385
		PII(D30)	57	20	114	828
		PII(D31)	57	20	155	641
		PII(D33)	57	20	92	499
		PII(D37)	56	20	138.5	603
	HBsAg 3	PRE	58	20	148.5	476
		PI(D0)	59	20	114	564
		PI(D1)	58	20	111.5	523
		PI(D30)	57	20	164	423

		PII(D30)	56	20	121.5	328
		PII(D31)	56	20	114.5	751
		PII(D33)	57	20	79	463
		PII(D37)	57	20	150	315
	HBsAg 4	PRE	60	20	143	1073
		PI(D0)	61	20	131	409
		PI(D1)	60	20	133.5	540
		PI(D30)	59	20	165	766
		PII(D30)	59	20	121	448
		PII(D31)	57	20	120	630
		PII(D33)	59	20	122	446
		PII(D37)	58	20	140.5	475
	HBsAg 5	PRE	55	20	120	453
		PI(D0)	54	20	95	276
		PI(D1)	55	20	133	404
		PI(D30)	55	20	161	452
		PII(D30)	54	20	114.5	313
		PII(D31)	55	20	105	368
		PII(D33)	55	20	88	233
		PII(D37)	55	20	133	387
TNF- α PROTEIN	HBsAg 1	PRE	59	0.411	0.411	3.638
		PI(D0)	59	0.411	1.482	4.922
		PI(D1)	58	0.411	1.902	9.871
		PI(D30)	59	0.411	0.969	17.656
		PII(D30)	59	0.411	1.069	8.825
		PII(D31)	58	0.411	0.881	9.737
		PII(D33)	59	0.411	0.411	5.513
		PII(D37)	59	0.411	0.411	6.063
	HBsAg 2	PRE	57	0.411	1.262	4.409
		PI(D0)	57	0.411	1.641	4.054
		PI(D1)	57	0.411	1.909	10.21
		PI(D30)	57	0.411	1.023	7.838
		PII(D30)	57	0.411	1.08	8.579
		PII(D31)	57	0.411	1.151	9.584
		PII(D33)	57	0.411	0.981	6.983
		PII(D37)	56	0.411	0.934	8.496
	HBsAg 3	PRE	59	0.411	0.411	9.913
		PI(D0)	59	0.411	0.411	6.023
		PI(D1)	58	0.411	1.727	12.252
		PI(D30)	57	0.411	1.203	14.253
		PII(D30)	57	0.411	1.321	14.013
		PII(D31)	56	0.411	1.081	11.189
		PII(D33)	57	0.411	1.129	9.68
		PII(D37)	57	0.411	0.411	16.696
	HBsAg 4	PRE	60	0.411	0.651	3.51
		PI(D0)	61	0.411	0.411	5.122
		PI(D1)	61	0.411	1.579	10.691
		PI(D30)	59	0.411	0.411	4.817
		PII(D30)	59	0.411	1.243	3.828
		PII(D31)	57	0.411	1.091	10.415
		PII(D33)	59	0.411	0.411	5.573
		PII(D37)	58	0.411	0.411	4.617
	HBsAg 5	PRE	55	0.411	0.411	3.231
		PI(D0)	55	0.411	0.911	4.546
		PI(D1)	55	0.411	1.701	8.755

		PI(D30)	55	0.411	0.411	7.948
		PII(D30)	54	0.411	1.323	4.253
		PII(D31)	55	0.411	1.375	10.415
		PII(D33)	55	0.411	0.891	5.484
		PII(D37)	55	0.411	0.841	7.141

N = number of subjects with available results

Min/Max = Minimum/Maximum

PRE = Pre-vaccination at Day 0

PI(D0) = Post-vaccination 1 at Day 0+3-6h

PI(D1) = Post-vaccination 1 at Day 1

PI(D30) = Post-vaccination 1 at Day 30

PII(D30) = Post-vaccination 2 at Day 30+3-6h

PII(D31) = Post-vaccination 2 at Day 31

PII(D33) = Post-vaccination 2 at Day 33

PII(D37) = Post-vaccination 2 at Day 37

Secondary Outcome Variable(s): Descriptive statistics of normalized white blood cells, normalized levels of CRP, and CPK, with reference ranges in Immune Health (IH) centre (ATP cohort for innate immunogenicity up to Day 60; Subjects in subsets 1 and 2)

Parameter	Group	Timing	N	Min	Median	Max
WHITE BLOOD CELLS	HBsAg 1	PRE	59	3580.952	6840	13800
		PI(D0)	59	4910	7729.231	15650
		PI(D1)	58	4330	8265	12970
		PI(D30)	59	3238.095	5960	13730
		PII(D30)	59	4560	7570	15080
		PII(D31)	59	4850	8160	16140
		PII(D33)	59	3610	6450	13810
		PII(D37)	59	3840	6219.048	13810
		PII(D60)	59	3157.895	6400	12710
	HBsAg 2	PRE	57	3960	6090	14100
		PI(D0)	57	4160	7670	16000
		PI(D1)	57	3789.474	7850	14530
		PI(D30)	57	3750	6090	12222.222
		PII(D30)	57	4180	7350	12888.889
		PII(D31)	57	4720	7533.333	12670
		PII(D33)	57	3360	6080	13320
		PII(D37)	56	4100	6464.341	13740
		PII(D60)	57	3690	6320	10942.857
	HBsAg 3	PRE	59	2971.429	6650	16000
		PI(D0)	59	3933.333	7520	15111.111
		PI(D1)	58	4400	7610	13820
		PI(D30)	57	3190.476	6290	12030
		PII(D30)	57	4409.524	7120	15010
		PII(D31)	56	4200	7422.222	14020
		PII(D33)	57	3285.714	6290	12800
		PII(D37)	57	3276.19	6760	12240
		PII(D60)	57	3352.381	6090	16840
	HBsAg 4	PRE	61	3920	6523.81	11280
		PI(D0)	61	4660	7620	11921.971
		PI(D1)	61	5000	8400	11650
		PI(D30)	59	4019.048	6421.053	14880
		PII(D30)	59	4111.111	7371.429	13680
		PII(D31)	59	4555.556	7980	12150
		PII(D33)	59	4046.154	7150	12780
		PII(D37)	58	4444.444	6740	10850
		PII(D60)	58	3970	6540	15110
	HBsAg 5	PRE	55	4080	6480	10910

		PI(D0)	55	4630	7210	14910
		PI(D1)	55	4000	7130	14171.429
		PI(D30)	55	4240	6076.923	10280
		PII(D30)	54	4690	7625	15038.095
		PII(D31)	55	4390	6550	12315.789
		PII(D33)	55	3820	6170	12100
		PII(D37)	55	4580	6870	12315.789
		PII(D60)	55	3560	5970	14526.316
CRP	HBsAg 1	PRE	59	0.01	0.248	3.701
		PI(D0)	59	0.01	0.248	3.094
		PI(D1)	58	0.32	1.97	11.934
		PI(D30)	58	0.01	0.248	2.17
		PII(D30)	59	0.02	0.248	1.92
		PII(D31)	58	0.3	1.521	15.837
		PII(D33)	58	0.32	2.6	23.62
		PII(D37)	59	0.05	0.319	4.27
	HBsAg 2	PRE	57	0.02	0.248	21.906
		PI(D0)	57	0.01	0.248	19.05
		PI(D1)	57	0.07	0.962	13.814
		PI(D30)	57	0.01	0.248	3.58
		PII(D30)	57	0.03	0.248	3.342
		PII(D31)	56	0.06	1.047	8.102
		PII(D33)	56	0.05	1.2	8.34
		PII(D37)	55	0.02	0.248	4.31
	HBsAg 3	PRE	59	0.02	0.248	7.077
		PI(D0)	59	0.01	0.248	7.174
		PI(D1)	58	0.03	0.486	9.069
		PI(D30)	57	0.02	0.248	2.88
		PII(D30)	57	0.02	0.248	2.75
		PII(D31)	55	0.04	0.61	4.746
		PII(D33)	56	0.04	0.707	14.504
		PII(D37)	55	0.02	0.248	1.533
	HBsAg 4	PRE	61	0.02	0.248	2.914
		PI(D0)	61	0.01	0.248	2.699
		PI(D1)	61	0.02	0.462	2.676
		PI(D30)	57	0.01	0.248	2.502
		PII(D30)	59	0.01	0.248	2.519
		PII(D31)	59	0.01	0.486	3.654
		PII(D33)	59	0.04	0.486	4.294
		PII(D37)	56	0.01	0.248	1.608
	HBsAg 5	PRE	54	0.01	0.248	2.39
		PI(D0)	54	0.02	0.248	2.866
		PI(D1)	55	0.01	0.248	2.795
		PI(D30)	53	0.01	0.248	13.338
		PII(D30)	54	0.02	0.248	13.814
		PII(D31)	55	0.02	0.248	5.96
		PII(D33)	55	0.03	0.248	3.104
		PII(D37)	53	0.03	0.248	6.198
CPK	HBsAg 1	PRE	59	54	113	1006.235
		PI(D0)	59	56	117	942.235
		PI(D1)	58	55	109	1191.622
		PI(D30)	59	55	123.263	1375.895
		PII(D30)	59	57	120	1478
		PII(D31)	59	-21.147	109	1263.263
		PII(D33)	59	46	107	1439.053

		PII(D37)	59	36	112.118	568.526
		PII(D60)	59	57	120	1786.471
	HBsAg 2	PRE	57	24.6	93	478
		PI(D0)	57	41	99.297	412.737
		PI(D1)	57	35	89.784	193.789
		PI(D30)	57	40	90	265
		PII(D30)	57	38	91.772	269
		PII(D31)	57	36	90	189
		PII(D33)	57	39	87	221
		PII(D37)	56	40	93.986	274.842
		PII(D60)	57	39.647	85	307
	HBsAg 3	PRE	59	35	110	1677.789
		PI(D0)	59	37.162	112	1431.053
		PI(D1)	57	37.162	104	763.263
		PI(D30)	57	34.287	115.73	399.405
		PII(D30)	57	38	115.73	408.054
		PII(D31)	56	34	106.973	239.053
		PII(D33)	57	36	104	885.368
		PII(D37)	57	33	118	425
		PII(D60)	57	34.287	114	393
	HBsAg 4	PRE	61	40	114	2594.432
		PI(D0)	61	38	114.842	2313.351
		PI(D1)	61	40	102	1434.649
		PI(D30)	59	29.243	99	372.824
		PII(D30)	59	39	106	581.892
		PII(D31)	59	36.824	103.614	646
		PII(D33)	59	45	101	812.921
		PII(D37)	58	42	106.311	409.111
		PII(D60)	58	39	110.647	553.026
	HBsAg 5	PRE	55	30	84.108	427.474
		PI(D0)	55	31	94	442.211
		PI(D1)	55	33	86	380.105
		PI(D30)	55	33.664	93	1112
		PII(D30)	54	36	93	1022
		PII(D31)	55	32	98	561
		PII(D33)	55	35	91.772	324.162
		PII(D37)	55	38	93.689	586.421
		PII(D60)	55	24	96	304.27

N = number of subjects with available results

Min/Max = Minimum/Maximum

PRE = Pre-vaccination at Day 0

PI(D0) = Post-vaccination 1 at Day 0+ 3-6h

PI(D1) = Post-vaccination 1 at Day 1

PI(D30) = Post-vaccination 1 at Day 30

PII(D30) = Post-vaccination 2 at Day 30+ 3-6h

PII(D31) = Post-vaccination 2 at Day 31

PII(D33) = Post-vaccination 2 at Day 33

PII(D37) = Post-vaccination 2 at Day 37

PII(D60) = Post-vaccination 2 at Day 60

Secondary Outcome Variable(s): Descriptive statistics of normalized white blood cells and differential counts, with reference ranges in IH centre (ATP cohort for innate immunogenicity up to Day 60; Subjects in subsets 1 and 2 and in selected centres (raw data in absolute counts))

Parameter	Group	Timing	N	Min	Median	Max
WHITE BLOOD CELLS	HBsAg 1	PRE	38	3610	6785	13800
		PI(D0)	38	4910	7605	15650
		PI(D1)	38	4330	8230	12970

		PI(D30)	38	3360	5920	13730
		PII(D30)	38	4560	7275	15080
		PII(D31)	38	4850	8095	16140
		PII(D33)	38	3610	6310	13810
		PII(D37)	38	3840	6205	13810
		PII(D60)	38	3960	6270	12710
	HBsAg 2	PRE	40	3960	5945	14100
		PI(D0)	40	4160	7175	14530
		PI(D1)	40	4520	7805	14530
		PI(D30)	40	3750	5985	10790
		PII(D30)	40	4180	6855	10850
		PII(D31)	40	4720	7490	12670
		PII(D33)	40	3360	6080	13320
		PII(D37)	39	4100	6150	13740
		PII(D60)	40	3690	6215	10930
	HBsAg 3	PRE	45	3900	6650	11740
		PI(D0)	45	4890	7520	13530
		PI(D1)	44	4400	7620	13820
		PI(D30)	44	3830	6360	12030
		PII(D30)	44	4510	7045	15010
		PII(D31)	44	4320	7205	14020
		PII(D33)	44	4080	6230	12800
		PII(D37)	44	4240	6625	12240
		PII(D60)	44	4010	6120	16840
	HBsAg 4	PRE	39	3920	6410	11280
		PI(D0)	39	4660	7280	11730
		PI(D1)	39	5000	8460	11650
		PI(D30)	37	5090	6760	14880
		PII(D30)	37	4710	7560	13680
		PII(D31)	37	5120	8400	12150
		PII(D33)	37	4550	7330	12780
		PII(D37)	36	4760	6770	10850
		PII(D60)	36	3970	6540	15110
	HBsAg 5	PRE	41	4080	6160	10910
		PI(D0)	41	4630	6900	14910
		PI(D1)	41	4000	6890	11430
		PI(D30)	41	4240	5810	10280
		PII(D30)	40	4690	7300	12010
		PII(D31)	41	4390	6270	11540
		PII(D33)	41	3820	6120	12100
		PII(D37)	41	4580	6340	11840
		PII(D60)	41	3560	5840	11530
NEUTROPHILS	HBsAg 1	PRE	38	1622.7	3835	8980
		PI(D0)	38	2465.6	4669.7	10390
		PI(D1)	38	2465.6	5652.6	9660
		PI(D30)	38	1522.9	3280.8	8521.3
		PII(D30)	38	1888.9	4499.9	12114.7
		PII(D31)	38	3430.5	6473.6	70807.8
		PII(D33)	38	1456.4	3796.5	9464
		PII(D37)	38	1990	3355.4	8020
		PII(D60)	38	2050	3790.4	8390
	HBsAg 2	PRE	40	1933.3	3535	10660
		PI(D0)	40	2144	4500.8	10910
		PI(D1)	40	3010	5149.8	8600
		PI(D30)	40	1500.7	3526.3	8070

		PII(D30)	40	1822.4	4088.6	9800
		PII(D31)	40	3110	5612.2	10770
		PII(D33)	40	1680	3515	11105.5
		PII(D37)	39	1844.5	3760	8220
		PII(D60)	40	1672.6	3685	6650
	HBsAg 3	PRE	45	2100	4070	7120
		PI(D0)	45	2864.9	4672.7	9170
		PI(D1)	44	2953.6	4927.8	9830
		PI(D30)	44	1800	3730	9010
		PII(D30)	44	2510	4333.9	11270
		PII(D31)	44	3000	4995	11310
		PII(D33)	44	1870	3649	8200
		PII(D37)	44	1922.2	3781.6	7710
		PII(D60)	44	2022	3425.3	10320
	HBsAg 4	PRE	39	2132.9	3740	7656.2
		PI(D0)	39	2498.9	4390	8354.9
		PI(D1)	39	2831.6	5360.4	8488
		PI(D30)	37	2443.5	4151.5	11449.3
		PII(D30)	37	2643.1	4683.8	10939.1
		PII(D31)	37	2870	5271.6	8430
		PII(D33)	37	2583.2	4306.7	9680
		PII(D37)	36	2321.5	4045	7123.8
		PII(D60)	36	2266	3820	12040
	HBsAg 5	PRE	41	2033.1	3520	7920
		PI(D0)	41	2742.9	4107.1	10380
		PI(D1)	41	2155.1	3920	7960
		PI(D30)	41	2388	3685.6	7430
		PII(D30)	40	2587.6	4405	9275.5
		PII(D31)	41	2180	3820	7400
		PII(D33)	41	2140	3580	11005.6
		PII(D37)	41	2177.3	3786.5	7970
		PII(D60)	41	1977.6	3490	8300
LYMPHOCYTES	HBsAg 1	PRE	38	-153.5	1985	4361.5
		PI(D0)	38	61.5	2325	4834.5
		PI(D1)	38	-820	1811.5	3824
		PI(D30)	38	-153.5	2020	5660
		PII(D30)	38	-325.5	2290	5520
		PII(D31)	38	-1207	1003.8	3308
		PII(D33)	38	-153.5	1685	5920
		PII(D37)	38	-175	2086.3	4870
		PII(D60)	38	-153.5	1870	4877.5
	HBsAg 2	PRE	40	-583.5	1810	3480
		PI(D0)	40	341	2020	4770
		PI(D1)	40	-46	1652.5	6290
		PI(D30)	40	-497.5	1495	3845.5
		PII(D30)	40	-347	1989	4146.5
		PII(D31)	40	-153.5	1082.8	3170
		PII(D33)	40	61.5	1695	3437
		PII(D37)	39	-519	2070	4705.5
		PII(D60)	40	-390	2066.3	5268.8
	HBsAg 3	PRE	45	-368.5	1950	5845
		PI(D0)	45	83	2400	4190
		PI(D1)	44	491.5	2024.8	5479.5
		PI(D30)	44	126	1845	3738
		PII(D30)	44	448.5	2075	3830

		PII(D31)	44	-282.5	1545	3670
		PII(D33)	44	-20.2	1840	3867
		PII(D37)	44	104.5	2065	4834.5
		PII(D60)	44	319.5	2115	4750
	HBsAg 4	PRE	39	298	2082.5	5350.5
		PI(D0)	39	728	2297.5	6081.5
		PI(D1)	39	1029	2310	5608.5
		PI(D30)	37	319.5	1970	4125
		PII(D30)	37	900	2290	5329
		PII(D31)	37	341	2090	6038.5
		PII(D33)	37	-691	2018	4684
		PII(D37)	36	255	2215	4619.5
		PII(D60)	36	233.5	1950	3308
	HBsAg 5	PRE	41	-175	2000	3580
		PI(D0)	41	255	2090	4220
		PI(D1)	41	40	2080	4180
		PI(D30)	41	-476	1781.5	3620
		PII(D30)	40	341	2205.1	4360
		PII(D31)	41	61.5	1820	4010
		PII(D33)	41	-218	1800	3260
		PII(D37)	41	-347	1840	3920
		PII(D60)	41	-906	1870	3590
MONOCYTES	HBsAg 1	PRE	38	188	462	944
		PI(D0)	38	230	445	1014
		PI(D1)	38	300	621	1476
		PI(D30)	38	150	358	1126
		PII(D30)	38	140	415	1210
		PII(D31)	38	240	498	1616
		PII(D33)	38	170	565	1462
		PII(D37)	38	120	435	1014
		PII(D60)	38	180	384	1364
	HBsAg 2	PRE	40	130	435	1308
		PI(D0)	40	170	422	1546
		PI(D1)	40	240	648	1574
		PI(D30)	40	160	390	888
		PII(D30)	40	160	435	958
		PII(D31)	40	220	580	1224
		PII(D33)	40	190	525	1462
		PII(D37)	39	140	410	972
		PII(D60)	40	150	423	902
	HBsAg 3	PRE	45	150	440	1250
		PI(D0)	45	180	470	1252
		PI(D1)	44	190	550	1546
		PI(D30)	44	160	445	1040
		PII(D30)	44	170	450	1000
		PII(D31)	44	180	521	1238
		PII(D33)	44	180	510	1960.4
		PII(D37)	44	150	412	972
		PII(D60)	44	170	457	1260
	HBsAg 4	PRE	39	190	380	1252
		PI(D0)	39	210	420	1070
		PI(D1)	39	180	470	1364
		PI(D30)	37	160	370	1518
		PII(D30)	37	190	380	1322
		PII(D31)	37	230	490	1210

	HBsAg 5	PII(D33)	37	147.4	390	1476
		PII(D37)	36	180	365	1336
		PII(D60)	36	190	390	1000
		PRE	41	210	384	748
		PI(D0)	41	210	410	692
		PI(D1)	41	210	410	832
		PI(D30)	41	81.6	360	790
		PII(D30)	40	210	390	874
		PII(D31)	41	180	400	1028
		PII(D33)	41	220	380	1084
		PII(D37)	41	210	370	832
		PII(D60)	41	170	370	664
EOSINOPHILS	HBsAg 1	PRE	38	60	168.9	1222.2
		PI(D0)	38	-44.4	145	1066.7
		PI(D1)	38	-44.4	152.8	1088.9
		PI(D30)	38	40	216.1	1355.6
		PII(D30)	38	0	190	1088.9
		PII(D31)	38	-88.9	75	733.3
		PII(D33)	38	-22.2	255	1044.4
		PII(D37)	38	40	231.1	1088.9
		PII(D60)	38	60	220	1088.9
	HBsAg 2	PRE	40	-44.4	226.1	1000
		PI(D0)	40	-44.4	140	1066.7
		PI(D1)	40	-44.4	200	1000
		PI(D30)	40	-66.7	242.2	1777.8
		PII(D30)	40	-66.7	160	1640
		PII(D31)	40	-44.4	115.6	1335.6
		PII(D33)	40	10	268.3	1244.4
		PII(D37)	39	-22.2	200	822.2
		PII(D60)	40	22.2	195	1111.1
	HBsAg 3	PRE	45	30	155.6	844.4
		PI(D0)	45	0	111.1	933.3
		PI(D1)	44	20	145	800
		PI(D30)	44	0	165	2066.7
		PII(D30)	44	20	150	2133.3
		PII(D31)	44	20	133.3	1422.2
		PII(D33)	44	60	205	1688.9
		PII(D37)	44	0	150	1488.9
		PII(D60)	44	0	150	844.4
	HBsAg 4	PRE	39	-88.9	170	1133.3
		PI(D0)	39	-22.2	160	822.2
		PI(D1)	39	70	200	1088.9
		PI(D30)	37	30	180	755.6
		PII(D30)	37	30	140	844.4
		PII(D31)	37	20	200	977.8
		PII(D33)	37	20	190	666.7
		PII(D37)	36	40	220	800
		PII(D60)	36	0	160	800
	HBsAg 5	PRE	41	-46.2	200	1822.2
		PI(D0)	41	22.2	133.3	1755.6
		PI(D1)	41	-46.2	190	2200
		PI(D30)	41	-15.4	200	711.1
		PII(D30)	40	-15.4	173.9	810
		PII(D31)	41	-15.4	200	810
		PII(D33)	41	0	200	790

BASOPHILS		PII(D37)	41	30.8	260	1177.8
		PII(D60)	41	-66.7	200	1088.9
	HBsAg 1	PRE	38	-11.8	35.3	247.1
		PI(D0)	38	-11.8	32.6	270.6
		PI(D1)	38	-11.8	30	152.9
		PI(D30)	38	-11.8	35.3	180
		PII(D30)	38	-11.8	35.3	176.5
		PII(D31)	38	-11.8	25	130
		PII(D33)	38	-11.8	20	152.9
		PII(D37)	38	11.8	40	129.4
		PII(D60)	38	-35.3	30	129.4
	HBsAg 2	PRE	40	-11.8	32.6	152.9
		PI(D0)	40	-35.3	30	129.4
		PI(D1)	40	-11.8	30	129.4
		PI(D30)	40	-11.8	30	152.9
		PII(D30)	40	-35.3	37.6	105.9
		PII(D31)	40	-35.3	25	110
		PII(D33)	40	10	32.6	152.9
		PII(D37)	39	-35.3	35.3	200
		PII(D60)	40	-35.3	35.3	176.5
	HBsAg 3	PRE	45	-11.8	30	180
		PI(D0)	45	-11.8	20	110
		PI(D1)	44	-11.8	30	120
		PI(D30)	44	-11.8	30	129.4
		PII(D30)	44	-11.8	30	152.9
		PII(D31)	44	-11.8	30	100
		PII(D33)	44	-11.8	30	209.4
		PII(D37)	44	-11.8	40	129.4
		PII(D60)	44	-11.8	32.6	129.4
	HBsAg 4	PRE	39	-35.3	30	317.6
		PI(D0)	39	-11.8	30	317.6
		PI(D1)	39	0	35.3	341.2
		PI(D30)	37	0	35.3	364.7
		PII(D30)	37	0	35.3	317.6
		PII(D31)	37	0	30	294.1
		PII(D33)	37	-11.8	35.3	82.4
		PII(D37)	36	-11.8	40	317.6
		PII(D60)	36	0	35.3	364.7
	HBsAg 5	PRE	41	-11.8	30	129.4
		PI(D0)	41	-11.8	30	129.4
		PI(D1)	41	-11.8	35.3	100
		PI(D30)	41	-35.3	35.3	110
		PII(D30)	40	-35.3	30	105.9
		PII(D31)	41	-35.3	35.3	90
		PII(D33)	41	-11.8	30	82.4
		PII(D37)	41	-11.8	35.3	140
		PII(D60)	41	-11.8	30	185.9

N = number of subjects with available results

Min/Max = Minimum/Maximum

PRE = Pre-vaccination at Day 0

PI(D0) = Post-vaccination 1 at Day 0+ 3-6h

PI(D1) = Post-vaccination 1 at Day 1

PI(D30) = Post-vaccination 1 at Day 30

PII(D30) = Post-vaccination 2 at Day 30+ 3-6h

PII(D31) = Post-vaccination 2 at Day 31

PII(D33) = Post-vaccination 2 at Day 33 PII(D37) = Post-vaccination 2 at Day 37 PII(D60) = Post-vaccination 2 at Day 60						
Secondary Outcome Variable(s): Descriptive statistics of normalized white blood cells and differential counts (ATP cohort for innate immunogenicity up to Day 60, subjects in subsets 1 and 2 and in selected centres (raw data in %))						
Parameter	Group	Timing	N	Min	Median	Max
WHITE BLOOD CELLS	HBsAg 1	PRE	21	-0.07	0.498	0.895
		PI(D0)	21	0.257	0.702	1.772
		PI(D1)	20	0.333	0.76	1.491
		PI(D30)	21	-0.127	0.456	1.088
		PII(D30)	21	0.29	0.69	1.613
		PII(D31)	21	0.346	0.79	1.448
		PII(D33)	21	0.127	0.441	1.246
		PII(D37)	21	0.029	0.379	1.105
		PII(D60)	21	-0.14	0.41	1.105
	HBsAg 2	PRE	17	0.048	0.509	1.169
		PI(D0)	17	0.173	1.123	2
		PI(D1)	17	-0.035	0.756	1.222
		PI(D30)	17	-0.018	0.596	1.37
		PII(D30)	17	0.119	0.789	1.481
		PII(D31)	17	0.185	0.737	1.143
		PII(D33)	17	-0.07	0.491	1.158
		PII(D37)	17	0.018	0.525	0.941
		PII(D60)	17	0.159	0.557	1.157
	HBsAg 3	PRE	14	-0.171	0.341	2
		PI(D0)	14	-0.011	0.578	1.852
		PI(D1)	14	0.075	0.54	1.526
		PI(D30)	13	-0.135	0.263	1.016
		PII(D30)	13	0.068	0.574	1.105
		PII(D31)	12	0.033	0.629	1.098
		PII(D33)	13	-0.119	0.404	0.914
		PII(D37)	13	-0.121	0.468	1.322
		PII(D60)	13	-0.108	0.271	0.825
	HBsAg 4	PRE	22	0.118	0.43	0.792
		PI(D0)	22	0.335	0.647	1.32
		PI(D1)	22	0.295	0.698	1.246
		PI(D30)	22	0.003	0.385	1.116
		PII(D30)	22	0.019	0.556	1.316
		PII(D31)	22	0.093	0.633	1.163
		PII(D33)	22	0.008	0.441	0.951
		PII(D37)	22	0.074	0.354	0.889
		PII(D60)	22	0.103	0.42	1.086
	HBsAg 5	PRE	14	0.105	0.479	1.035
		PI(D0)	14	0.175	0.662	1.333
		PI(D1)	14	0.211	0.607	1.695
		PI(D30)	14	0.152	0.517	1.018
		PII(D30)	14	0.246	0.76	1.84
		PII(D31)	14	0.07	0.536	1.386
		PII(D33)	14	0.068	0.537	1.198
		PII(D37)	14	0.163	0.49	1.386
		PII(D60)	14	0.152	0.446	1.754
NEUTROPHILS	HBsAg 1	PRE	21	0.016	0.648	1.07
		PI(D0)	21	0.309	0.84	1.36
		PI(D1)	20	-0.026	0.93	1.443
		PI(D30)	21	-0.01	0.604	1.057
		PII(D30)	21	0.287	0.9	1.32

			PII(D31)	21	0.681	1.161	1.552
			PII(D33)	21	-0.25	0.591	1.177
			PII(D37)	21	-0.259	0.63	1.08
			PII(D60)	21	-0.926	0.656	1.25
		HBsAg 2	PRE	17	0.084	0.53	1.103
			PI(D0)	17	0.097	0.752	1.239
			PI(D1)	17	0.484	0.817	1.077
			PI(D30)	17	0.278	0.6	1.127
			PII(D30)	17	0.252	0.717	1.13
			PII(D31)	17	0.37	0.959	1.443
			PII(D33)	17	-0.009	0.509	1.041
			PII(D37)	17	-0.028	0.652	1.071
			PII(D60)	17	0.122	0.543	1.191
		HBsAg 3	PRE	14	0.009	0.58	1.3
			PI(D0)	14	0.022	0.693	1.361
			PI(D1)	14	0.288	0.727	1.243
			PI(D30)	13	0.074	0.387	1.117
			PII(D30)	13	-0.003	0.609	1.107
			PII(D31)	12	0.24	0.921	1.487
			PII(D33)	13	0.091	0.539	1.093
			PII(D37)	13	0.133	0.443	0.947
			PII(D60)	13	-0.091	0.54	0.84
		HBsAg 4	PRE	22	-0.027	0.663	1.063
			PI(D0)	22	0.339	0.767	1.33
			PI(D1)	22	0.178	0.769	1.45
			PI(D30)	22	-0.243	0.578	1.197
			PII(D30)	22	0.25	0.663	1.104
			PII(D31)	22	0.129	0.78	1.263
			PII(D33)	22	-0.162	0.587	1.007
			PII(D37)	22	0	0.569	1.033
			PII(D60)	22	0.003	0.61	1.153
		HBsAg 5	PRE	14	0.322	0.445	0.757
			PI(D0)	14	0.33	0.654	0.843
			PI(D1)	14	0.27	0.654	1.043
			PI(D30)	14	0.243	0.581	0.887
			PII(D30)	14	0.25	0.642	1.163
			PII(D31)	14	0.203	0.589	0.93
			PII(D33)	14	0.263	0.567	0.957
			PII(D37)	14	0.293	0.542	1.274
			PII(D60)	14	0.173	0.561	1.073
	LYMPHOCYTES	HBsAg 1	PRE	21	-0.1	0.474	0.986
			PI(D0)	21	-0.165	0.328	0.734
			PI(D1)	20	-0.487	0.178	0.528
			PI(D30)	21	-0.161	0.452	1.134
			PII(D30)	21	-0.196	0.3	0.824
			PII(D31)	21	-0.509	-0.086	0.221
			PII(D33)	21	-0.126	0.309	1.172
			PII(D37)	21	-0.122	0.503	1.169
			PII(D60)	21	-0.317	0.452	1.222
		HBsAg 2	PRE	17	-0.107	0.366	0.972
			PI(D0)	17	-0.209	0.407	0.848
			PI(D1)	17	-0.158	0.272	0.603
			PI(D30)	17	-0.297	0.51	0.872
			PII(D30)	17	-0.2	0.386	0.669
			PII(D31)	17	-0.313	-0.003	0.513
			PII(D33)	17	-0.128	0.407	0.8

	HBsAg 3	PII(D37)	17	-0.117	0.357	0.948	
		PII(D60)	17	-0.255	0.376	0.807	
		PRE	14	-0.491	0.531	1.179	
		PI(D0)	14	-0.448	0.543	0.903	
		PI(D1)	14	-0.457	0.412	0.741	
		PI(D30)	13	0.17	0.528	1.021	
		PII(D30)	13	-0.026	0.497	1.224	
		PII(D31)	12	-0.426	0.15	0.786	
		PII(D33)	13	0.161	0.445	0.897	
		PII(D37)	13	0.366	0.555	1.117	
		PII(D60)	13	0.065	0.534	1.069	
	HBsAg 4	PRE	22	-0.103	0.403	1.071	
		PI(D0)	22	-0.297	0.361	0.769	
		PI(D1)	22	-0.145	0.283	0.821	
		PI(D30)	22	0.025	0.433	1.164	
		PII(D30)	22	-0.291	0.413	0.928	
		PII(D31)	22	-0.225	0.302	0.79	
		PII(D33)	22	0.009	0.405	1.225	
		PII(D37)	22	-0.034	0.423	1.055	
		PII(D60)	22	-0.138	0.402	0.904	
		HBsAg 5	PRE	14	0.287	0.68	0.886
	PI(D0)		14	0.157	0.609	0.852	
	PI(D1)		14	-0.048	0.478	0.921	
	PI(D30)		14	0.091	0.536	0.99	
	PII(D30)		14	0.122	0.54	0.924	
	PII(D31)		14	0.087	0.54	0.972	
	PII(D33)		14	-0.087	0.622	0.924	
	PII(D37)		14	-0.226	0.572	0.952	
	PII(D60)		14	0.104	0.538	1.024	
	MONOCYTES	HBsAg 1	PRE	21	0.256	0.5	0.822
			PI(D0)	21	0.209	0.422	0.74
			PI(D1)	20	0.244	0.594	1.12
			PI(D30)	21	0.023	0.533	0.94
			PII(D30)	21	0.156	0.456	0.7
			PII(D31)	21	0.221	0.533	1.12
			PII(D33)	21	0.367	0.767	1.4
PII(D37)			21	0.04	0.478	1.011	
PII(D60)			21	0.151	0.5	2.022	
HBsAg 2		PRE	17	0.058	0.311	0.756	
		PI(D0)	17	0.012	0.367	0.638	
		PI(D1)	17	0.116	0.522	0.826	
		PI(D30)	17	0.14	0.411	0.656	
		PII(D30)	17	0.116	0.422	0.656	
		PII(D31)	17	0.256	0.544	1.151	
		PII(D33)	17	-0.2	0.578	1.511	
		PII(D37)	17	0.151	0.433	0.76	
		PII(D60)	17	0.128	0.467	0.678	
HBsAg 3		PRE	14	0.116	0.439	1.156	
		PI(D0)	14	0.128	0.367	0.844	
		PI(D1)	14	0.356	0.522	0.911	
		PI(D30)	13	0.077	0.5	0.7	
		PII(D30)	13	0.128	0.433	0.622	
		PII(D31)	12	0.133	0.632	1.256	
	PII(D33)	13	0.141	0.656	0.944		
	PII(D37)	13	-0.013	0.433	0.656		
	PII(D60)	13	0.013	0.456	0.633		

EOSINOPHILS	HBsAg 4	PRE	22	-0.346	0.51	0.911
		PI(D0)	22	0.14	0.439	1.2
		PI(D1)	22	0	0.477	0.8
		PI(D30)	22	0.038	0.472	0.967
		PII(D30)	22	0.12	0.443	0.911
		PII(D31)	22	0.2	0.427	0.933
		PII(D33)	22	-0.09	0.549	1.256
		PII(D37)	22	-0.346	0.472	0.789
		PII(D60)	22	0.218	0.461	0.778
	HBsAg 5	PRE	14	0.144	0.489	0.84
		PI(D0)	14	0.133	0.389	0.64
		PI(D1)	14	0.167	0.45	0.82
		PI(D30)	14	0.167	0.422	0.64
		PII(D30)	14	0.178	0.363	0.6
		PII(D31)	14	0.144	0.478	1.5
		PII(D33)	14	0.087	0.472	1.02
		PII(D37)	14	0.178	0.394	0.6
		PII(D60)	14	0.178	0.344	0.76
	HBsAg 1	PRE	21	0.159	0.5	1.02
		PI(D0)	21	0.145	0.3	0.7
		PI(D1)	20	0.1	0.291	2.65
		PI(D30)	21	0.16	0.45	1.1
		PII(D30)	21	0.06	0.32	1.025
		PII(D31)	21	0.025	0.145	0.525
		PII(D33)	21	0.02	0.6	1.35
		PII(D37)	21	0.175	0.46	1.92
		PII(D60)	21	0.116	0.45	0.76
	HBsAg 2	PRE	17	0.2	0.594	1.22
		PI(D0)	17	0.113	0.429	0.75
		PI(D1)	17	0.161	0.48	1.082
		PI(D30)	17	0.177	0.673	1.225
		PII(D30)	17	0.097	0.475	1.05
		PII(D31)	17	0.065	0.38	0.9
		PII(D33)	17	0.32	0.667	1.74
		PII(D37)	17	0.224	0.64	1.25
		PII(D60)	17	0.1	0.652	1.46
	HBsAg 3	PRE	14	0.118	0.37	1.072
		PI(D0)	14	0.059	0.25	0.975
		PI(D1)	14	0.118	0.313	0.8
		PI(D30)	13	0.14	0.42	1.159
		PII(D30)	13	0.1	0.34	0.925
		PII(D31)	12	0.078	0.25	0.986
		PII(D33)	13	0.14	0.58	1.625
		PII(D37)	13	0.12	0.44	1.45
		PII(D60)	13	0.116	0.38	1.15
	HBsAg 4	PRE	22	0.059	0.596	2.925
		PI(D0)	22	-0.059	0.423	2.1
		PI(D1)	22	-0.039	0.464	1.8
		PI(D30)	22	0.098	0.693	2.3
		PII(D30)	22	0	0.496	1.42
		PII(D31)	22	0.118	0.505	2.15
		PII(D33)	22	0.194	0.645	2.1
		PII(D37)	22	0.2	0.69	2.375
		PII(D60)	22	0	0.709	2.55
	HBsAg 5	PRE	14	0.21	0.495	1.04
		PI(D0)	14	0.097	0.42	0.74

BASOPHILS		PI(D1)	14	0.161	0.41	0.82
		PI(D30)	14	0.226	0.53	0.96
		PII(D30)	14	0.2	0.38	0.82
		PII(D31)	14	0.145	0.43	0.6
		PII(D33)	14	0.177	0.443	0.9
		PII(D37)	14	0.2	0.52	1.06
		PII(D60)	14	0.226	0.465	0.78
	HBsAg 1	PRE	21	0.05	0.25	0.6
		PI(D0)	21	0.1	0.25	0.5
		PI(D1)	20	0.1	0.232	0.65
		PI(D30)	21	0.05	0.4	0.7
		PII(D30)	21	0.05	0.25	0.7
		PII(D31)	21	0.053	0.2	1.9
		PII(D33)	21	0.15	0.35	1.95
		PII(D37)	21	0.15	0.316	1.1
		PII(D60)	21	0.1	0.3	0.6
	HBsAg 2	PRE	17	0	0.35	0.6
		PI(D0)	17	0.071	0.3	0.5
		PI(D1)	17	0	0.25	2.4
		PI(D30)	17	0.1	0.35	1.357
		PII(D30)	17	0.1	0.25	0.714
		PII(D31)	17	-0.071	0.3	0.7
		PII(D33)	17	0.1	0.4	1.5
		PII(D37)	17	0.143	0.421	2.1
		PII(D60)	17	0.143	0.4	1.5
	HBsAg 3	PRE	14	0.05	0.325	0.5
		PI(D0)	14	0.091	0.232	0.474
		PI(D1)	14	0.05	0.286	0.6
		PI(D30)	13	0.105	0.35	0.8
		PII(D30)	13	0.05	0.25	0.9
		PII(D31)	12	0.091	0.3	1.2
		PII(D33)	13	0.15	0.35	0.9
		PII(D37)	13	0.15	0.286	1.2
		PII(D60)	13	0.1	0.4	2.2
	HBsAg 4	PRE	22	0	0.25	2.636
		PI(D0)	22	0	0.25	1.1
		PI(D1)	22	0	0.179	0.7
		PI(D30)	22	0.05	0.333	1.727
		PII(D30)	22	0	0.211	0.8
		PII(D31)	22	0.1	0.25	1.053
		PII(D33)	22	0.05	0.3	1.4
		PII(D37)	22	-0.091	0.286	1
		PII(D60)	22	0	0.25	0.8
	HBsAg 5	PRE	14	0.15	0.375	0.8
		PI(D0)	14	0.1	0.225	0.7
		PI(D1)	14	0.1	0.25	0.8
		PI(D30)	14	0.2	0.3	0.8
		PII(D30)	14	0.15	0.333	1
		PII(D31)	14	-0.1	0.325	0.9
		PII(D33)	14	0.2	0.3	1
		PII(D37)	14	0.2	0.3	0.9
		PII(D60)	14	0.2	0.308	0.9

N = number of subjects with available results

Min/Max = Minimum/Maximum

PRE = Pre-vaccination at Day 0

PI(D0) = Post-vaccination 1 at Day 0 + 3-6h

PI(D1) = Post-vaccination 1 at Day 1
PI(D30) = Post-vaccination 1 at Day 30
PII(D30) = Post-vaccination 2 at Day 30 + 3-6h
PII(D31) = Post-vaccination 2 at Day 31
PII(D33) = Post-vaccination 2 at Day 33
PII(D37) = Post-vaccination 2 at Day 37
PII(D60) = Post-vaccination 2 at Day 60

Secondary Outcome Variable(s): Descriptive statistics of normalized white blood cells, normalized levels of CRP and CPK, with reference ranges in IH centre (Total Vaccinated cohort; Subjects not in subsets)

Parameter	Group	Timing	N	Min	Median	Max
WHITE BLOOD CELLS	HBsAg 1	PRE	68	4030	6627.764	12888.889
		PI(D30)	68	4290	6870.05	10883.333
		PII(D37)	65	4910	6736.842	12444.444
		PII(D60)	68	3590	6738.636	14000
	HBsAg 2	PRE	68	3803.279	6748.689	12780
		PI(D30)	65	4050	6454.545	12100
		PII(D37)	66	3894.737	7196.579	15263.158
		PII(D60)	66	3760	6330	14220
	HBsAg 3	PRE	66	3780	6782.414	16430
		PI(D30)	65	3901.639	6600	12870
		PII(D37)	61	4080	6550	11157.895
		PII(D60)	60	4098.361	6625.789	12610
	HBsAg 4	PRE	71	3700	7590	13836.066
		PI(D30)	69	3157.895	6950.82	11868.852
		PII(D37)	66	4000	6673.182	14444.444
		PII(D60)	68	3280	7175.909	15114.754
	HBsAg 5	PRE	67	3320	6810	13700
		PI(D30)	66	3600	6590	15890
		PII(D37)	63	4393.443	6440	13104.723
		PII(D60)	65	3311.475	6740	12610
CRP	HBsAg 1	PRE	65	0.01	0.33	5.353
		PI(D30)	66	0.01	0.248	3.507
		PII(D37)	64	0.01	0.486	10.21
	HBsAg 2	PRE	65	0.034	0.486	3.92
		PI(D30)	66	0.034	0.371	4.066
		PII(D37)	65	0.034	0.523	18.336
	HBsAg 3	PRE	64	0.01	0.253	7.388
		PI(D30)	64	0.034	0.38	8.461
		PII(D37)	59	0.034	0.486	3.866
	HBsAg 4	PRE	69	0.01	0.296	3.747
		PI(D30)	69	0.01	0.277	2.628
		PII(D37)	66	0.01	0.363	3.937
	HBsAg 5	PRE	64	0.034	0.365	2.754
		PI(D30)	66	0.01	0.319	5.722
		PII(D37)	59	0.01	0.248	6.349
CPK	HBsAg 1	PRE	68	21.459	105.529	1078
		PI(D30)	68	42.471	108.617	2380.105
		PII(D37)	65	30.235	105.351	834
		PII(D60)	68	24.588	112.842	24213.765
	HBsAg 2	PRE	68	21.357	102.696	581.529
		PI(D30)	65	45.294	103.647	350.308
		PII(D37)	66	18.211	99.399	259.176
		PII(D60)	66	25	104	227.474
	HBsAg 3	PRE	66	41	109.756	613.368
		PI(D30)	65	40.592	114	537.161

		PII(D37)	61	37	109.294	432.737
		PII(D60)	61	48	107.6	2516.526
	HBsAg 4	PRE	71	48	114	3710.308
		PI(D30)	68	45	102.1	922.649
		PII(D37)	66	57	122.66	758
		PII(D60)	68	35	102.4	839
	HBsAg 5	PRE	67	36.824	120.857	3329.158
		PI(D30)	66	32.545	113.079	689.765
		PII(D37)	63	37.765	124.667	972.105
		PII(D60)	65	18.08	120.989	1196.851

N = number of subjects with available results

Min/Max = Minimum/Maximum

PRE = Pre-vaccination at Day 0

PI(D30) = Post-vaccination 1 at Day 30

PII(D37) = Post-vaccination 2 at Day 37

PII(D60) = Post-vaccination 2 at Day 60

Secondary Outcome Variable(s): Descriptive statistics of normalized white blood cells and differential counts, with reference ranges in IH centre (Total Vaccinated cohort; Subjects not in subsets and in selected centres (raw data in absolute counts))

Parameter	Group	Timing	N	Min	Median	Max
WHITE BLOOD CELLS	HBsAg 1	PRE	21	4030	6909.1	9750
		PI(D30)	21	4290	6300	9800
		PII(D37)	21	5040	7290	10900
		PII(D60)	21	3610	6780	10600
	HBsAg 2	PRE	21	4480	7200	10770
		PI(D30)	18	4050	6360	10420
		PII(D37)	19	5310	6750	9760
		PII(D60)	20	3760	6025	11600
	HBsAg 3	PRE	24	4500	6410	16430
		PI(D30)	24	4700	6615	12680
		PII(D37)	23	4500	7000	9818.2
		PII(D60)	23	4380	6620	11454.5
	HBsAg 4	PRE	28	3700	7095	11630
		PI(D30)	28	3454.5	6542.7	10100
		PII(D37)	26	4090.9	6440	10840
		PII(D60)	27	3280	6000	10030
	HBsAg 5	PRE	20	4600	6919.1	13700
		PI(D30)	20	4270	6505	9730
		PII(D37)	20	5000	6340	10130
		PII(D60)	20	4340	5970	9040
NEUTROPHILS	HBsAg 1	PRE	21	2520	4428.7	7480
		PI(D30)	21	2444.6	4353.3	7156
		PII(D37)	21	2110.7	4530	8706.5
		PII(D60)	21	2100	4116	7520
	HBsAg 2	PRE	21	2088.5	4050	7650
		PI(D30)	18	1434.2	3695.7	7780
		PII(D37)	19	2521.1	4100	7530
		PII(D60)	19	1966.5	3400	9080
	HBsAg 3	PRE	24	2840	3915	13700
		PI(D30)	24	2630	4289.5	9508.4
		PII(D37)	23	2589.9	4470	7168.2
		PII(D60)	23	2332.5	3918.5	8491.9
	HBsAg 4	PRE	28	2096.8	4377.7	8870
		PI(D30)	28	2195.2	3950	8483.6
		PII(D37)	26	2490.3	3472.4	6900
		PII(D60)	27	1711.5	3671	6520

LYMPHOCYTES	HBsAg 5	PRE	20	2636.4	4395	10072.9
		PI(D30)	20	2630	3655	7110
		PII(D37)	20	2580	4009	6646.9
		PII(D60)	20	2300	3659.2	5903.8
	HBsAg 1	PRE	21	448.5	2061	5372
		PI(D30)	21	642	1878.6	5109.5
		PII(D37)	21	964.5	2220	4376.2
		PII(D60)	21	362.5	2382.8	5018.9
	HBsAg 2	PRE	21	749.5	2018	6087.2
		PI(D30)	18	448.5	2020	3837.6
		PII(D37)	19	1545	2812.8	5155.5
		PII(D60)	19	448.5	1930	4172.5
	HBsAg 3	PRE	24	642	1868.4	5204.5
		PI(D30)	24	728	2060.7	5894.8
		PII(D37)	23	878.5	2230	6834
		PII(D60)	23	835.5	2290	5935.5
	HBsAg 4	PRE	28	-175	2160	4591.2
		PI(D30)	28	104.5	2281.3	4113.7
		PII(D37)	26	276.5	2390.3	4966.9
		PII(D60)	27	-239.5	2430	4973.7
	HBsAg 5	PRE	20	820.8	2033.3	6573.7
		PI(D30)	20	276.5	2060	4063.9
		PII(D37)	20	255	2236.5	5716
		PII(D60)	20	814	2136.3	5679.8
MONOCYTES	HBsAg 1	PRE	21	160	454	903.4
		PI(D30)	21	190	412	809.6
		PII(D37)	21	160	393.8	948.2
		PII(D60)	21	130	440	836.2
	HBsAg 2	PRE	21	244	496	1070
		PI(D30)	18	146	429.5	958
		PII(D37)	19	220	496	790
		PII(D60)	19	160	468	939.8
	HBsAg 3	PRE	24	252.4	425	972
		PI(D30)	24	240	416	930
		PII(D37)	23	220	454	1084
		PII(D60)	23	240	461	1406
	HBsAg 4	PRE	28	270	501.3	1084
		PI(D30)	28	230	500.2	1014
		PII(D37)	26	290	477.8	1126
		PII(D60)	27	260	496	1126
	HBsAg 5	PRE	20	230	482.8	1088.2
		PI(D30)	20	240	428.1	890.8
		PII(D37)	20	254.5	475	790
		PII(D60)	20	212.5	450	678
EOSINOPHILS	HBsAg 1	PRE	21	44.4	130.5	926.3
		PI(D30)	21	-22.2	140	1962.1
		PII(D37)	21	25.3	180	3473.7
		PII(D60)	21	16.8	170	840
	HBsAg 2	PRE	21	40	190	800
		PI(D30)	18	88.9	286.1	694.7
		PII(D37)	19	22.2	222.2	555.6
		PII(D60)	19	44.4	183.3	1066.7
	HBsAg 3	PRE	24	-16.8	160	1266.7
		PI(D30)	24	-6.3	168.3	955.6
		PII(D37)	23	29.5	260	1488.9

	HBsAg 4	PII(D60)	23	16.8	230	1577.8
		PRE	28	-123.1	177.9	762.1
		PI(D30)	28	-123.1	191.7	1555.6
		PII(D37)	26	-123.1	233.2	2222.2
	HBsAg 5	PII(D60)	27	-61.5	183.3	2600
		PRE	20	15.4	199.7	1109.5
		PI(D30)	20	0	183.9	955.6
		PII(D37)	20	22.2	215	750
		PII(D60)	20	22.2	146.1	1040
BASOPHILS	HBsAg 1	PRE	21	-11.8	35.3	100
		PI(D30)	21	11.8	43.3	100
		PII(D37)	21	-11.8	40	180
		PII(D60)	21	-11.8	40	123.3
	HBsAg 2	PRE	21	-11.8	60	233.3
		PI(D30)	18	-11.8	41	140
		PII(D37)	19	11.8	40	180
		PII(D60)	19	11.8	58.8	226.7
	HBsAg 3	PRE	24	11.8	55	206.7
		PI(D30)	24	10	35.3	230
		PII(D37)	23	10	40	180
		PII(D60)	23	10	36.7	266.7
	HBsAg 4	PRE	28	-11.8	37.6	200
		PI(D30)	28	-11.8	43.3	243.3
		PII(D37)	26	-11.8	54.4	236.7
		PII(D60)	27	-11.8	50	260
	HBsAg 5	PRE	20	10	37.6	240
		PI(D30)	20	10	37.6	341.2
		PII(D37)	20	-11.8	60	176.5
		PII(D60)	20	11.8	40	129.4

N = number of subjects with available results

Min/Max = Minimum/Maximum

PRE = Pre-vaccination at Day 0

PI(D30) = Post-vaccination 1 at Day 30

PII(D37) = Post-vaccination 2 at Day 37

PII(D60) = Post-vaccination 2 at Day 60

Secondary Outcome Variable(s): Descriptive statistics of normalized white blood cells and differential counts (Total vaccinated cohort, subjects not in subsets and in selected centres (raw data in %))

Parameter	Group	Timing	N	Min	Median	Max
WHITE BLOOD CELLS	HBsAg 1	PRE	47	0.008	0.426	1.481
		PI(D30)	47	0.066	0.492	1.147
		PII(D37)	44	0.152	0.455	1.407
		PII(D60)	47	-0.068	0.44	1.667
	HBsAg 2	PRE	47	-0.033	0.413	1.463
		PI(D30)	47	0.015	0.426	1.35
		PII(D37)	47	-0.018	0.574	1.877
		PII(D60)	46	-0.015	0.44	1.703
	HBsAg 3	PRE	42	-0.037	0.497	1.478
		PI(D30)	41	-0.016	0.428	1.478
		PII(D37)	38	0.013	0.405	1.193
		PII(D60)	37	0.016	0.439	1.435
	HBsAg 4	PRE	43	0.005	0.672	1.639
		PI(D30)	41	-0.14	0.573	1.311
		PII(D37)	40	0	0.523	1.741
		PII(D60)	41	-0.053	0.607	1.852
	HBsAg 5	PRE	47	-0.113	0.465	1.375
		PI(D30)	46	-0.067	0.455	1.982

NEUTROPHILS		PII(D37)	43	0.066	0.426	1.517
		PII(D60)	45	-0.115	0.478	1.435
	HBsAg 1	PRE	47	-0.175	0.534	1.167
		PI(D30)	47	-0.365	0.457	1.275
		PII(D37)	44	-0.625	0.417	1.086
		PII(D60)	47	-0.417	0.47	1.265
	HBsAg 2	PRE	46	-0.405	0.559	1.205
		PI(D30)	47	-0.365	0.524	1.333
		PII(D37)	47	-0.391	0.5	1.104
		PII(D60)	46	-0.33	0.496	1.167
	HBsAg 3	PRE	42	-0.417	0.426	1.15
		PI(D30)	41	-0.222	0.491	1.18
		PII(D37)	38	-0.13	0.436	1.208
		PII(D60)	37	-0.583	0.389	1.235
	HBsAg 4	PRE	43	-0.083	0.503	1.587
		PI(D30)	41	-0.5	0.5	1.209
		PII(D37)	40	-0.417	0.458	1.165
		PII(D60)	41	-1.167	0.471	1.23
	HBsAg 5	PRE	47	-0.125	0.458	1.343
		PI(D30)	46	-0.81	0.532	1.286
		PII(D37)	43	-0.84	0.491	1.027
		PII(D60)	45	-0.555	0.474	1.131
LYMPHOCYTES	HBsAg 1	PRE	47	-0.25	0.408	0.943
		PI(D30)	47	-0.74	0.45	1.147
		PII(D37)	44	-0.147	0.514	1.25
		PII(D60)	47	-0.393	0.45	1.05
	HBsAg 2	PRE	46	-0.487	0.388	1.009
		PI(D30)	47	-0.4	0.404	1.253
		PII(D37)	47	-0.28	0.433	1
		PII(D60)	46	-0.72	0.388	1.02
	HBsAg 3	PRE	42	-0.233	0.552	1.396
		PI(D30)	41	-0.28	0.55	1.16
		PII(D37)	38	-0.5	0.605	1.047
		PII(D60)	37	-0.54	0.578	1.75
	HBsAg 4	PRE	43	-0.88	0.37	1.05
		PI(D30)	41	-0.453	0.373	1.12
		PII(D37)	40	-0.453	0.492	1.267
		PII(D60)	41	-0.8	0.426	1.95
	HBsAg 5	PRE	47	-0.287	0.45	1.247
		PI(D30)	46	-0.333	0.43	2.107
		PII(D37)	43	-0.55	0.43	1.673
		PII(D60)	45	-0.207	0.417	1.807
MONOCYTES	HBsAg 1	PRE	47	-0.014	0.52	1.263
		PI(D30)	47	0.07	0.556	1.333
		PII(D37)	44	-0.111	0.471	1.333
		PII(D60)	47	0	0.463	1.16
	HBsAg 2	PRE	46	0.056	0.473	1.8
		PI(D30)	47	-0.167	0.471	1.58
		PII(D37)	47	-0.012	0.456	1.333
		PII(D60)	46	0	0.41	1.68
	HBsAg 3	PRE	42	0	0.5	1.667
		PI(D30)	41	0.078	0.538	1.833
		PII(D37)	38	-0.167	0.465	0.875
		PII(D60)	37	-0.333	0.444	1.507
	HBsAg 4	PRE	43	-0.011	0.438	1.667
		PI(D30)	41	0.078	0.431	1.5

	HBsAg 5	PII(D37)	40	0.035	0.465	1.167
		PII(D60)	41	0.044	0.456	1.667
		PRE	47	0	0.55	1.449
		PI(D30)	46	-0.167	0.506	1.34
		PII(D37)	43	0.154	0.5	1.438
		PII(D60)	45	0.078	0.5	1.333
EOSINOPHILS	HBsAg 1	PRE	47	-0.333	0.304	3.333
		PI(D30)	47	-0.032	0.4	2.333
		PII(D37)	44	-0.065	0.409	2.667
		PII(D60)	47	-0.097	0.429	2.667
	HBsAg 2	PRE	46	-0.075	0.29	2
		PI(D30)	47	-0.333	0.4	2.125
		PII(D37)	47	0	0.35	2.5
		PII(D60)	46	-0.333	0.324	4.667
	HBsAg 3	PRE	42	-0.333	0.275	1
		PI(D30)	41	-0.333	0.35	1.12
		PII(D37)	38	-0.333	0.329	1.325
		PII(D60)	37	-0.333	0.299	0.984
	HBsAg 4	PRE	43	-0.175	0.299	5
		PI(D30)	41	-0.333	0.375	4.84
		PII(D37)	40	0.05	0.496	7.42
		PII(D60)	41	-0.333	0.347	3.58
	HBsAg 5	PRE	47	-0.081	0.319	3.667
		PI(D30)	46	-0.08	0.333	4.667
		PII(D37)	43	0.02	0.522	3.667
		PII(D60)	45	-0.15	0.388	5
BASOPHILS	HBsAg 1	PRE	47	-0.1	0.263	1.3
		PI(D30)	47	0	0.3	1.818
		PII(D37)	44	0.091	0.351	3
		PII(D60)	47	0	0.3	3
	HBsAg 2	PRE	46	0	0.286	3
		PI(D30)	47	-0.1	0.294	3
		PII(D37)	47	0	0.294	1.5
		PII(D60)	46	-0.1	0.2	2
	HBsAg 3	PRE	42	-0.1	0.3	1
		PI(D30)	41	0	0.316	1.2
		PII(D37)	38	0	0.377	1
		PII(D60)	37	0	0.4	1.3
	HBsAg 4	PRE	43	0	0.353	2
		PI(D30)	41	0	0.294	3
		PII(D37)	40	0	0.353	2
		PII(D60)	41	0	0.343	2
	HBsAg 5	PRE	47	-0.1	0.353	3
		PI(D30)	46	0	0.316	2
		PII(D37)	43	0	0.3	2
		PII(D60)	45	0	0.286	1

N = number of subjects with available results

Min/Max = Minimum/Maximum

PRE = Pre-vaccination at Day 0

PI(D30) = Post-vaccination 1 at Day 30

PII(D37) = Post-vaccination 2 at Day 37

PII(D60) = Post-vaccination 2 at Day 60

Secondary Outcome Variable(s): Descriptive statistics of normalized red blood cells and platelets counts, haemoglobin, ALT, AST, Serum creatinine, Urea and LDH, with reference ranges in IH centre (Total Vaccinated cohort, all subjects)

Parameter	Group	Activity	N	Min	Median	Max
RED BLOOD CELLS	HBsAg 1	PRE	143	3.8	4.45	5.171

		PI(D30)	141	3.77	4.461	5.1
		PII(D37)	128	3.61	4.372	5.229
		PII(D60)	141	3.676	4.421	5.193
	HBsAg 2	PRE	142	3.71	4.433	5.979
		PI(D30)	139	3.8	4.382	5.929
		PII(D37)	124	3.69	4.346	5.479
		PII(D60)	140	3.56	4.393	6.086
	HBsAg 3	PRE	141	3.905	4.464	5.2
		PI(D30)	138	3.831	4.423	5.31
		PII(D37)	120	3.75	4.395	4.9
		PII(D60)	133	3.694	4.364	5.279
	HBsAg 4	PRE	145	3.713	4.38	5.38
		PI(D30)	140	3.806	4.388	5.57
		PII(D37)	126	3.759	4.37	7.143
		PII(D60)	137	3.769	4.371	5.107
	HBsAg 5	PRE	142	3.613	4.456	5.59
		PI(D30)	139	3.729	4.486	5.74
		PII(D37)	121	3.688	4.388	5.17
		PII(D60)	138	3.75	4.4	5.12
PLATELETS	HBsAg 1	PRE	143	126666.67	269318.18	532142.86
		PI(D30)	141	140000	261363.64	592000
		PII(D37)	128	159166.67	295000	541000
		PII(D60)	141	140833.33	263333.33	689000
	HBsAg 2	PRE	142	118390.81	270833.33	526190.48
		PI(D30)	139	131321.84	262000	513095.24
		PII(D37)	124	155747.13	274431.82	597619.05
		PII(D60)	140	135632.18	267045.46	510714.29
	HBsAg 3	PRE	141	148239.44	270000	506818.18
		PI(D30)	138	137500	260470.78	460000
		PII(D37)	120	152640.85	269000	488000
		PII(D60)	133	146478.87	259000	453000
	HBsAg 4	PRE	145	114788.73	267187.5	514772.73
		PI(D30)	140	126232.39	274431.82	561363.64
		PII(D37)	126	132394.37	282477.27	607954.55
		PII(D60)	137	105985.92	273239.44	532954.55
	HBsAg 5	PRE	142	99712.644	259000	571428.57
		PI(D30)	139	89655.172	258333.33	536904.76
		PII(D37)	121	105459.77	268622.45	597619.05
		PII(D60)	138	88218.391	262588.03	483333.33
HAEMOGLOBIN	HBsAg 1	PRE	143	10.835	13.4	15.75
		PI(D30)	141	11.047	13.35	15.1
		PII(D37)	128	10.729	13.05	15.525
		PII(D60)	141	10.835	13.275	15.6
	HBsAg 2	PRE	142	10.306	13.35	15.6
		PI(D30)	139	10.059	13.186	35.118
		PII(D37)	124	10.271	12.957	14.55
		PII(D60)	140	10.341	13.136	15
	HBsAg 3	PRE	141	10.659	13.4	15.5
		PI(D30)	138	10.694	13.275	15.6
		PII(D37)	120	10.694	13.025	37.297
		PII(D60)	133	10.694	13.1	15.3
	HBsAg 4	PRE	145	10.125	13.275	15.5
		PI(D30)	140	10.518	13.121	36.794
		PII(D37)	126	9.9	13.05	15.079
		PII(D60)	137	10.1	12.975	15.474

	HBsAg 5	PRE	142	10.906	13.35	15.975
		PI(D30)	139	10.853	13.35	38.1
		PII(D37)	121	11.012	13.05	14.8
		PII(D60)	138	10.8	13.163	37.946
ALT	HBsAg 1	PRE	143	3.28	21.086	117.875
		PI(D30)	141	1.708	21.32	104.55
		PII(D37)	128	5.125	21.221	86.686
		PII(D60)	141	1.708	21.161	287.854
	HBsAg 2	PRE	142	3.417	18.792	91.939
		PI(D30)	139	0	18.743	94.424
		PII(D37)	124	1.025	18.767	86.97
		PII(D60)	140	0	17.447	371.485
	HBsAg 3	PRE	141	0	18.636	82
		PI(D30)	138	0	19.897	60.839
		PII(D37)	120	-1.64	18.596	73.458
		PII(D60)	134	1.64	18.07	136.667
	HBsAg 4	PRE	145	1.708	21.8	80
		PI(D30)	140	-3.347	20.5	127.271
		PII(D37)	126	3.417	20.7	78.583
		PII(D60)	137	0	20.541	78.3
	HBsAg 5	PRE	142	1.673	21.32	182.04
		PI(D30)	139	3.417	18.743	76.875
		PII(D37)	121	2.485	19.8	93.714
		PII(D60)	138	1.64	18.518	119.583
AST	HBsAg 1	PRE	143	1.48	21	66.1
		PI(D30)	141	0	20.72	61.332
		PII(D37)	128	2.775	20.881	49.58
		PII(D60)	141	1.48	20.72	966.933
	HBsAg 2	PRE	142	2.96	20	47
		PI(D30)	139	2.775	19.24	45.633
		PII(D37)	124	2.96	19.097	51.1
		PII(D60)	140	4.625	17.986	240
	HBsAg 3	PRE	141	-1.48	20	72
		PI(D30)	138	-2.96	20.188	41.4
		PII(D37)	120	-1.48	20.043	45.355
		PII(D60)	134	-1.48	20.76	86.9
	HBsAg 4	PRE	145	0.925	21	101
		PI(D30)	140	3.7	20	118.4
		PII(D37)	126	2.96	20	34.613
		PII(D60)	137	1.85	21	57.6
	HBsAg 5	PRE	142	0	20.478	123.58
		PI(D30)	139	0	19.097	40.5
		PII(D37)	121	-1.48	20	52.9
		PII(D60)	138	4.625	19.339	59.2
SERUM CREATININE	HBsAg 1	PRE	143	0.53	0.893	1.522
		PI(D30)	141	0.5	0.9	53.175
		PII(D37)	128	0.517	0.906	1.69
		PII(D60)	141	0.517	0.92	1.578
	HBsAg 2	PRE	142	0.36	0.841	1.452
		PI(D30)	140	0.512	0.84	1.41
		PII(D37)	124	0.262	0.83	1.375
		PII(D60)	140	0.514	0.84	30.425
	HBsAg 3	PRE	141	0.43	0.889	1.422
		PI(D30)	138	0.5	0.874	1.405
		PII(D37)	120	0.5	0.883	1.41

	HBsAg 4	PII(D60)	134	0.51	0.873	1.41
		PRE	145	0.402	0.86	1.62
		PI(D30)	140	0.422	0.888	1.48
		PII(D37)	126	0.36	0.92	1.34
	HBsAg 5	PII(D60)	137	0.325	0.934	1.418
		PRE	142	0.378	0.85	1.511
		PI(D30)	139	0.29	0.87	1.62
		PII(D37)	120	0.304	0.909	1.452
UREA	HBsAg 1	PII(D60)	138	0.39	0.915	1.466
		PRE	143	13.7	29.5	45.9
		PI(D30)	141	14.241	30.127	50.333
		PII(D37)	128	10.06	29.5	45.846
	HBsAg 2	PII(D60)	141	12.2	29.8	49.5
		PRE	142	12.569	28.667	43.5
		PI(D30)	140	14.9	28.667	47.3
		PII(D37)	124	16.3	27.833	42.833
	HBsAg 3	PII(D60)	140	16.749	28.905	47.3
		PRE	141	15.6	30.095	56.6
		PI(D30)	138	14.3	30.462	59.5
		PII(D37)	120	15.5	30.333	52.4
	HBsAg 4	PII(D60)	134	12.569	29.5	50.8
		PRE	145	16.286	30	64.5
		PI(D30)	140	16	30.048	61.118
		PII(D37)	126	15.913	31	54.5
	HBsAg 5	PII(D60)	137	15.077	30.095	53.667
		PRE	142	15	29.202	59.5
		PI(D30)	139	16	30.095	55.125
		PII(D37)	121	17	28.667	53.25
		PII(D60)	138	17.3	29.65	54.5
LDH	HBsAg 1	PRE	143	155.2	336.364	504
		PI(D30)	141	134.2	343.75	615
		PII(D37)	128	160.6	348.894	569
		PII(D60)	141	118.5	341.975	1066.255
	HBsAg 2	PRE	141	132.018	335.281	515
		PI(D30)	139	101.316	329.6	613
		PII(D37)	123	90.351	342.857	553
		PII(D60)	140	99.123	335.141	922.944
	HBsAg 3	PRE	141	144.7	328.3	505
		PI(D30)	138	155.8	330.32	505
		PII(D37)	120	152.3	331.967	486.008
		PII(D60)	134	143.6	324.675	484
	HBsAg 4	PRE	145	67.347	336.054	586.054
		PI(D30)	140	162.121	337.428	751.948
		PII(D37)	126	175.877	340.606	463
		PII(D60)	137	208.772	348.438	533.333
	HBsAg 5	PRE	142	175.877	325.85	678
		PI(D30)	138	168.1	320.671	725
		PII(D37)	121	159.4	319.048	669
		PII(D60)	138	173.9	320.927	730

N = number of subjects with available results

Min/Max = Minimum/Maximum

PRE = Pre-vaccination at Day 0

PI(D30) = Post-vaccination 1 at Day 30

PII(D37) = Post-vaccination 2 at Day 37

PII(D60) = Post-vaccination 2 at Day 60

ALT = Alanine aminotransferase
AST= Aspartate aminotransferase
LDH = Lactate dehydrogenase

Secondary Outcome Variable(s): Frequency distribution of white blood cells and differential counts, CRP and CPK with respect to normal ranges at baseline (Day 0) versus post vaccination up to Day 60 (Total Vaccinated cohort, Subjects in subsets 1 and 2)

		Post vaccination up to Day 60														
		HBsAg1 Group					HBsAg2 Group					HBsAg3 Group				
		N	n	%	n	%	N	n	%	n	%	N	n	%	n	%
Laboratory parameter	Baseline Assessment (Day 0)															
WHITE BLOOD CELLS	Normal	69	39	56.5	30	43.5	68	42	61.8	26	38.2	65	46	70.8	19	29.2
	Abnormal	6	0	0.0	6	100	6	1	16.7	5	83.3	10	1	10.0	9	90.0
NEUTROPHILS	Normal	68	36	52.9	32	47.1	71	44	62.0	27	38.0	72	53	73.6	19	26.4
	Abnormal	7	0	0.0	7	100	3	1	33.3	2	66.7	3	0	0.0	3	100
LYMPHOCYTES	Normal	65	35	53.8	30	46.2	68	39	57.4	29	42.6	67	51	76.1	16	23.9
	Abnormal	10	0	0.0	10	100	6	0	0.0	6	100	8	1	12.5	7	87.5
MONOCYTES	Normal	74	45	60.8	29	39.2	69	54	78.3	15	21.7	68	56	82.4	12	17.6
	Abnormal	1	0	0.0	1	100	5	2	40.0	3	60.0	7	3	42.9	4	57.1
EOSINOPHILS	Normal	71	58	81.7	13	18.3	68	59	86.8	9	13.2	71	65	91.5	6	8.5
	Abnormal	4	1	25.0	3	75.0	6	0	0.0	6	100	4	1	25.0	3	75.0
BASOPHILS	Normal	72	61	84.7	11	15.3	72	62	86.1	10	13.9	71	62	87.3	9	12.7
	Abnormal	3	0	0.0	3	100	2	0	0.0	2	100	4	2	50.0	2	50.0
CRP	Normal	72	16	22.2	56	77.8	66	33	50.0	33	50.0	70	48	68.6	22	31.4
	Abnormal	3	0	0.0	3	100	8	0	0.0	8	100	5	0	0.0	5	100
CPK	Normal	63	42	66.7	21	33.3	63	54	85.7	9	14.3	62	44	71.0	18	29.0
	Abnormal	12	0	0.0	12	100	11	0	0.0	11	100	13	0	0.0	13	100

		Post vaccination up to Day 60									
		HBsAg4 Group					HBsAg5 Group				
		N	n	%	n	%	N	n	%	n	%
Laboratory parameter	Baseline Assessment (Day 0)										
WHITE BLOOD CELLS	Normal	71	52	73.2	19	26.8	68	54	79.4	14	20.6
	Abnormal	3	1	33.3	2	66.7	7	1	14.3	6	85.7
NEUTROPHILS	Normal	70	57	81.4	13	18.6	75	67	89.3	8	10.7
	Abnormal	4	1	25.0	3	75.0	0	-	-	-	-
LYMPHOCYTES	Normal	67	56	83.6	11	16.4	69	59	85.5	10	14.5
	Abnormal	7	1	14.3	6	85.7	6	1	16.7	5	83.3
MONOCYTES	Normal	70	62	88.6	8	11.4	75	69	92.0	6	8.0
	Abnormal	4	0	0.0	4	100	0	-	-	-	-
EOSINOPHILS	Normal	66	60	90.9	6	9.1	71	65	91.5	6	8.5
	Abnormal	8	1	12.5	7	87.5	4	1	25.0	3	75.0
BASOPHILS	Normal	69	64	92.8	5	7.2	71	64	90.1	7	9.9
	Abnormal	5	2	40.0	3	60.0	4	0	0.0	4	100
CRP	Normal	70	56	80.0	14	20.0	70	62	88.6	8	11.4
	Abnormal	4	0	0.0	4	100	4	1	25.0	3	75.0
CPK	Normal	60	40	66.7	20	33.3	65	51	78.5	14	21.5
	Abnormal	14	2	14.3	12	85.7	10	2	20.0	8	80.0

% = Percentage of subjects based on N

N = Number of subjects with the administered dose for whom data is available

n = Number of subjects in the appropriate category

Secondary Outcome Variable(s): Frequency distribution of white blood cells and differential counts, CRP and CPK with respect to normal ranges at baseline (Day 0) versus post vaccination up to Day 60 (Total Vaccinated cohort, Subjects not in subsets)

		Post vaccination up to Day 60									
		HBsAg1 Group					HBsAg2 Group				
		HBsAg3 Group									

Laboratory parameter	Baseline Assessment (Day 0)	N	Normal		Abnormal		N	Normal		Abnormal		N	Normal		Abnormal	
			n	%	n	%		n	%	n	%		n	%	n	%
WHITE BLOOD CELLS	Normal	61	54	88.5	7	11.5	57	50	87.7	7	12.3	56	49	87.5	7	12.5
	Abnormal	7	2	28.6	5	71.4	10	3	30.0	7	70.0	9	4	44.4	5	55.6
NEUTROPHILS	Normal	63	54	85.7	9	14.3	58	46	79.3	12	20.7	59	42	71.2	17	28.8
	Abnormal	5	2	40.0	3	60.0	8	4	50.0	4	50.0	6	3	50.0	3	50.0
LYMPHOCYTES	Normal	60	50	83.3	10	16.7	56	46	82.1	10	17.9	58	45	77.6	13	22.4
	Abnormal	8	3	37.5	5	62.5	10	6	60.0	4	40.0	7	1	14.3	6	85.7
MONOCYTES	Normal	64	56	87.5	8	12.5	63	54	85.7	9	14.3	62	53	85.5	9	14.5
	Abnormal	4	4	100	0	0.0	3	1	33.3	2	66.7	3	0	0.0	3	100
EOSINOPHILS	Normal	59	51	86.4	8	13.6	57	49	86.0	8	14.0	60	52	86.7	8	13.3
	Abnormal	9	1	11.1	8	88.9	9	3	33.3	6	66.7	5	0	0.0	5	100
BASOPHILS	Normal	64	59	92.2	5	7.8	62	56	90.3	6	9.7	63	60	95.2	3	4.8
	Abnormal	4	3	75.0	1	25.0	4	0	0.0	4	100	2	1	50.0	1	50.0
CRP	Normal	57	51	89.5	6	10.5	51	42	82.4	9	17.6	54	45	83.3	9	16.7
	Abnormal	8	3	37.5	5	62.5	12	1	8.3	11	91.7	9	1	11.1	8	88.9
CPK	Normal	56	42	75.0	14	25.0	60	51	85.0	9	15.0	47	38	80.9	9	19.1
	Abnormal	12	2	16.7	10	83.3	7	1	14.3	6	85.7	18	6	33.3	12	66.7

Post vaccination up to Day 60

		HBsAg4 Group					HBsAg5 Group				
		N	Normal		Abnormal		N	Normal		Abnormal	
Laboratory parameter	Baseline Assessment (Day 0)		n	%	n	%		n	%	n	%
WHITE BLOOD CELLS	Normal	58	48	82.8	10	17.2	57	51	89.5	6	10.5
	Abnormal	12	1	8.3	11	91.7	9	1	11.1	8	88.9
NEUTROPHILS	Normal	64	51	79.7	13	20.3	58	53	91.4	5	8.6
	Abnormal	6	3	50.0	3	50.0	8	3	37.5	5	62.5
LYMPHOCYTES	Normal	56	50	89.3	6	10.7	55	43	78.2	12	21.8
	Abnormal	14	5	35.7	9	64.3	11	4	36.4	7	63.6
MONOCYTES	Normal	66	62	93.9	4	6.1	63	57	90.5	6	9.5
	Abnormal	4	2	50.0	2	50.0	3	1	33.3	2	66.7
EOSINOPHILS	Normal	64	50	78.1	14	21.9	59	51	86.4	8	13.6
	Abnormal	6	2	33.3	4	66.7	7	2	28.6	5	71.4
BASOPHILS	Normal	64	58	90.6	6	9.4	63	60	95.2	3	4.8
	Abnormal	6	3	50.0	3	50.0	3	2	66.7	1	33.3
CRP	Normal	62	58	93.5	4	6.5	56	50	89.3	6	10.7
	Abnormal	5	1	20.0	4	80.0	8	3	37.5	5	62.5
CPK	Normal	57	45	78.9	12	21.1	49	37	75.5	12	24.5
	Abnormal	13	5	38.5	8	61.5	17	6	35.3	11	64.7

% = Percentage of subjects based on N

N = Number of subjects with the administered dose for whom data is available

n = Number of subjects in the appropriate category

Secondary Outcome Variable(s): Frequency distribution of red blood cells and platelets counts, haemoglobin, ALT, AST, Serum creatinine, Urea and LDH with respect to normal ranges at baseline (Day 0) versus post vaccination up to Day 60 (Total Vaccinated cohort, all subjects)

		Post vaccination up to Day 60														
		HBsAg1 Group					HBsAg2 Group					HBsAg3 Group				
			Normal		Abnormal			Normal		Abnormal			Normal		Abnormal	
Laboratory parameter	Baseline Assessment (Day 0)	N	n	%	n	%	N	n	%	n	%	N	n	%	n	%
RED BLOOD	Normal	134	127	94.8	7	5.2	128	116	90.6	12	9.4	130	113	86.9	17	13.1

CELLS	Abnormal	7	2	28.6	5	71.4	13	4	30.8	9	69.2	8	6	75.0	2	25.0
PLATELETS	Normal	131	122	93.1	9	6.9	133	122	91.7	11	8.3	132	122	92.4	10	7.6
	Abnormal	10	1	10.0	9	90.0	8	0	0.0	8	100	6	0	0.0	6	100
HAEMOGLOBIN	Normal	122	112	91.8	10	8.2	126	113	89.7	13	10.3	126	115	91.3	11	8.7
	Abnormal	19	4	21.1	15	78.9	15	6	40.0	9	60.0	12	4	33.3	8	66.7
ALT	Normal	125	113	90.4	12	9.6	127	122	96.1	5	3.9	125	115	92.0	10	8.0
	Abnormal	16	1	6.3	15	93.8	14	4	28.6	10	71.4	13	4	30.8	9	69.2
AST	Normal	137	125	91.2	12	8.8	137	136	99.3	1	0.7	135	128	94.8	7	5.2
	Abnormal	4	0	0.0	4	100	4	1	25.0	3	75.0	3	2	66.7	1	33.3
SERUM CREATININE	Normal	136	128	94.1	8	5.9	135	127	94.1	8	5.9	131	124	94.7	7	5.3
	Abnormal	5	1	20.0	4	80.0	6	3	50.0	3	50.0	7	3	42.9	4	57.1
UREA	Normal	135	117	86.7	18	13.3	138	127	92.0	11	8.0	129	113	87.6	16	12.4
	Abnormal	6	4	66.7	2	33.3	3	1	33.3	2	66.7	9	5	55.6	4	44.4
LDH	Normal	130	119	91.5	11	8.5	132	123	93.2	9	6.8	132	126	95.5	6	4.5
	Abnormal	11	1	9.1	10	90.9	8	1	12.5	7	87.5	6	1	16.7	5	83.3

Laboratory parameter		Post vaccination up to Day 60														
		HBsAg4 Group						HBsAg5 Group								
		Normal			Abnormal			Normal			Abnormal					
		N	n	%	n	%	N	n	%	n	%	N	n	%	n	%
RED BLOOD CELLS	Baseline Assessment (Day 0)															
	Normal	135	121	89.6	14	10.4	130	124	95.4	6	4.6					
PLATELETS	Abnormal	6	4	66.7	2	33.3	9	5	55.6	4	44.4					
	Normal	130	122	93.8	8	6.2	131	126	96.2	5	3.8					
HAEMOGLOBIN	Abnormal	11	3	27.3	8	72.7	8	1	12.5	7	87.5					
	Normal	128	119	93.0	9	7.0	126	110	87.3	16	12.7					
ALT	Abnormal	13	2	15.4	11	84.6	13	4	30.8	9	69.2					
	Normal	128	120	93.8	8	6.3	122	113	92.6	9	7.4					
AST	Abnormal	13	7	53.8	6	46.2	17	5	29.4	12	70.6					
	Normal	137	129	94.2	8	5.8	134	128	95.5	6	4.5					
SERUM CREATININE	Abnormal	4	3	75.0	1	25.0	5	2	40.0	3	60.0					
	Normal	134	122	91.0	12	9.0	124	119	96.0	5	4.0					
UREA	Abnormal	7	1	14.3	6	85.7	15	3	20.0	12	80.0					
	Normal	130	116	89.2	14	10.8	133	125	94.0	8	6.0					
LDH	Abnormal	11	3	27.3	8	72.7	6	3	50.0	3	50.0					
	Normal	133	124	93.2	9	6.8	130	121	93.1	9	6.9					
	Abnormal	8	6	75.0	2	25.0	9	1	11.1	8	88.9					

N = Number of subjects with the administered dose for whom data is available

% = Percentage of subjects based on N

n = Number of subjects in the appropriate category

ALT = Alanine aminotransferase

AST= Aspartate aminotransferase

LDH = Lactate dehydrogenase

Secondary Outcome Variable(s): Frequency distribution of White blood cells, differential counts and CPK with respect to normal ranges at post vaccination Day 180 and Day 360 (Total Vaccinated cohort)

Post vaccination – Day 180 or Day 360															
Laboratory parameter	HBsAg 1 Group					HBsAg 2 Group					HBsAg 3 Group				
	N	Normal		Abnormal		N	Normal		Abnormal		N	Normal		Abnormal	
		n	%	n	%		n	%	n	%		n	%	n	%
WHITE BLOOD CELLS	138	118	85.5	20	14.5	140	122	87.1	18	12.9	131	106	80.9	25	19.1
NEUTROPHILS	138	124	89.9	14	10.1	140	122	87.1	18	12.9	131	107	81.7	24	18.3
LYMPHOCYTES	138	119	86.2	19	13.8	140	118	84.3	22	15.7	131	112	85.5	19	14.5
MONOCYTES	138	126	91.3	12	8.7	140	130	92.9	10	7.1	131	118	90.1	13	9.9
EOSINOPHILS	138	125	90.6	13	9.4	140	120	85.7	20	14.3	131	111	84.7	20	15.3
BASOPHILS	138	126	91.3	12	8.7	140	127	90.7	13	9.3	131	118	90.1	13	9.9
CPK	138	103	74.6	35	25.4	140	115	82.1	25	17.9	131	95	72.5	36	27.5

Post vaccination – Day 180 or Day 360										
Laboratory parameter	HBsAg 4 Group					HBsAg 5 Group				
	N	Normal		Abnormal		N	Normal		Abnormal	
		n	%	n	%		n	%	n	%
WHITE BLOOD CELLS	133	119	89.5	14	10.5	135	115	85.2	20	14.8
NEUTROPHILS	133	117	88.0	16	12.0	135	120	88.9	15	11.1
LYMPHOCYTES	133	111	83.5	22	16.5	135	110	81.5	25	18.5
MONOCYTES	133	119	89.5	14	10.5	135	126	93.3	9	6.7
EOSINOPHILS	133	114	85.7	19	14.3	135	125	92.6	10	7.4
BASOPHILS	133	122	91.7	11	8.3	135	123	91.1	12	8.9
CPK	133	95	71.4	38	28.6	135	98	72.6	37	27.4

% = Percentage of subjects based on N

N = Number of subjects with the administered dose for whom data is available

n = Number of subjects in the appropriate category

Secondary Outcome Variable(s): Frequency distribution of Red blood cells and Platelets counts, Haemoglobin, Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Serum creatinine, Urea and Lactate dehydrogenase (LDH) with respect to normal ranges at post vaccination Day 180 or Day 360 (Total Vaccinated cohort)

Post vaccination – Day 180 or Day 360															
Laboratory parameter	HBsAg 1 Group					HBsAg 2 Group					HBsAg 3 Group				
	N	Normal		Abnormal			Normal		Abnormal		N	Normal		Abnormal	
		n	%	n	%	N	n	%	n	%		n	%	n	%
RED BLOOD CELLS	138	123	89.1	15	10.9	140	120	85.7	20	14.3	131	115	87.8	16	12.2
PLATELETS	138	127	92.0	11	8.0	140	131	93.6	9	6.4	131	124	94.7	7	5.3
HAEMOGLOBIN	138	114	82.6	24	17.4	140	127	90.7	13	9.3	131	119	90.8	12	9.2
ALT	138	112	81.2	26	18.8	140	123	87.9	17	12.1	131	113	86.3	18	13.7
AST	138	127	92.0	11	8.0	140	135	96.4	5	3.6	131	122	93.1	9	6.9
SERUM CREATININE	138	127	92.0	11	8.0	140	129	92.1	11	7.9	131	119	90.8	12	9.2
UREA	138	127	92.0	11	8.0	140	126	90.0	14	10.0	131	112	85.5	19	14.5
LDH	138	128	92.8	10	7.2	140	126	90.0	14	10.0	131	121	92.4	10	7.6

Post vaccination – Day 180 or Day 360										
Laboratory parameter	HBsAg 4 Group					HBsAg 5 Group				
	N	Normal		Abnormal		N	Normal		Abnormal	
		n	%	n	%		n	%	n	%
RED BLOOD CELLS	133	126	94.7	7	5.3	135	123	91.1	12	8.9
PLATELETS	133	120	90.2	13	9.8	135	125	92.6	10	7.4
HAEMOGLOBIN	133	116	87.2	17	12.8	135	120	88.9	15	11.1
ALT	133	110	82.7	23	17.3	135	118	87.4	17	12.6
AST	133	128	96.2	5	3.8	135	126	93.3	9	6.7
SERUM CREATININE	133	124	93.2	9	6.8	135	117	86.7	18	13.3
UREA	133	116	87.2	17	12.8	135	127	94.1	8	5.9
LDH	133	129	97.0	4	3.0	135	124	91.9	11	8.1

% = Percentage of subjects based on N

N = Number of subjects with at least one administered dose for whom data is available

n = Number of subjects in the appropriate category

ALT = Alanine aminotransferase

AST= Aspartate aminotransferase

LDH = Lactate dehydrogenase

Secondary Outcome Variable(s): Frequency distribution of White blood cells, differential counts and CPK with respect to normal ranges at pre booster (Day 360) versus post booster (Day 390) (Booster Total Vaccinated cohort; Subjects in Subsets 1 and 2)

Laboratory parameter	Pre-booster Assessment (Day 360)	Post booster – Day 390															
		HBsAg 1 Group						HBsAg 2 Group					HBsAg 3 Group				
		N	Normal		Abnormal		N	Normal		Abnormal		N	Normal		Abnormal		
			n	%	n	%		n	%	n	%		n	%	n	%	
WHITE BLOOD CELLS	Normal	50	44	88.0	6	12.0	53	51	96.2	2	3.8	48	46	95.8	2	4.2	
	Abnormal	9	6	66.7	3	33.3	3	2	66.7	1	33.3	8	4	50.0	4	50.0	

NEUTROPHILS	Normal	51	47	92.2	4	7.8	52	50	96.2	2	3.8	51	51	100	0	0.0
	Abnormal	8	4	50.0	4	50.0	4	4	100	0	0.0	5	3	60.0	2	40.0
LYMPHOCYTES	Normal	50	47	94.0	3	6.0	51	48	94.1	3	5.9	48	47	97.9	1	2.1
	Abnormal	9	4	44.4	5	55.6	5	3	60.0	2	40.0	8	3	37.5	5	62.5
MONOCYTES	Normal	58	56	96.6	2	3.4	55	54	98.2	1	1.8	53	52	98.1	1	1.9
	Abnormal	1	1	100	0	0.0	1	0	0.0	1	100	3	2	66.7	1	33.3
EOSINOPHILS	Normal	57	56	98.2	1	1.8	54	51	94.4	3	5.6	54	53	98.1	1	1.9
	Abnormal	2	2	100	0	0.0	2	1	50.0	1	50.0	2	1	50.0	1	50.0
BASOPHILS	Normal	56	55	98.2	1	1.8	52	51	98.1	1	1.9	54	50	92.6	4	7.4
	Abnormal	3	1	33.3	2	66.7	4	3	75.0	1	25.0	2	2	100	0	0.0
CPK	Normal	44	39	88.6	5	11.4	52	50	96.2	2	3.8	45	38	84.4	7	15.6
	Abnormal	15	5	33.3	10	66.7	4	4	100	0	0.0	11	7	63.6	4	36.4

Laboratory parameter	Pre-booster Assessment (Day 360)	Post booster – Day 390									
		HBsAg 4 Group					HBsAg 5 Group				
		N	Normal		Abnormal		N	Normal		Abnormal	
			n	%	n	%		n	%	n	%
WHITE BLOOD CELLS	Normal	52	50	96.2	2	3.8	49	47	95.9	2	4.1
	Abnormal	2	1	50.0	1	50.0	5	3	60.0	2	40.0
NEUTRO-PHILS	Normal	50	47	94.0	3	6.0	51	49	96.1	2	3.9
	Abnormal	4	2	50.0	2	50.0	3	3	100	0	0.0
LYMPHO-CYTES	Normal	50	47	94.0	3	6.0	47	46	97.9	1	2.1
	Abnormal	4	0	0.0	4	100	7	2	28.6	5	71.4
MONOCYTES	Normal	51	49	96.1	2	3.9	53	53	100	0	0.0
	Abnormal	3	1	33.3	2	66.7	1	1	100	0	0.0
EOSINO-PHILS	Normal	50	50	100	0	0.0	54	53	98.1	1	1.9
	Abnormal	4	1	25.0	3	75.0	0	-	-	-	-
BASOPHILS	Normal	53	52	98.1	1	1.9	52	50	96.2	2	3.8
	Abnormal	1	1	100	0	0.0	2	1	50.0	1	50.0
CPK	Normal	49	39	79.6	10	20.4	47	46	97.9	1	2.1
	Abnormal	6	3	50.0	3	50.0	6	1	16.7	5	83.3

% = Percentage of subjects based on N

N = Number of subjects with the administered dose for whom data is available

n = Number of subjects in the appropriate category

Secondary Outcome Variable(s): Frequency distribution of Red blood cells and Platelets counts, Haemoglobin, ALT, AST, Serum creatinine, Urea and LDH with respect to normal ranges at pre booster (Day 360) versus post booster (Day 390) (Booster Total Vaccinated cohort; Subjects in subsets 1 and 2)

Laboratory parameter	Pre-booster Assessment (Day 360)	Post booster – Day 390														
		HBsAg 1 Group					HBsAg 2 Group					HBsAg 3 Group				
		N	Normal		Abnormal		N	Normal		Abnormal		N	Normal		Abnormal	
			n	%	n	%		n	%	n	%		n	%	n	%
RED BLOOD CELLS	Normal	57	55	96.5	2	3.5	52	51	98.1	1	1.9	53	50	94.3	3	5.7
	Abnormal	2	1	50.0	1	50.0	4	2	50.0	2	50.0	3	2	66.7	1	33.3
PLATELETS	Normal	55	52	94.5	3	5.5	55	55	100	0	0.0	54	53	98.1	1	1.9
	Abnormal	4	1	25.0	3	75.0	1	1	100	0	0.0	2	2	100	0	0.0
HAEMOGL.	Normal	55	53	96.4	2	3.6	53	53	100	0	0.0	54	53	98.1	1	1.9
	Abnormal	4	2	50.0	2	50.0	3	1	33.3	2	66.7	2	0	0.0	2	100
ALT	Normal	52	51	98.1	1	1.9	53	51	96.2	2	3.8	46	46	100	0	0.0
	Abnormal	7	3	42.9	4	57.1	3	1	33.3	2	66.7	10	4	40.0	6	60.0
AST	Normal	55	52	94.5	3	5.5	56	54	96.4	2	3.6	52	51	98.1	1	1.9
	Abnormal	4	2	50.0	2	50.0	0	4	3	75.0	1	25.0
SERUM CREATININE	Normal	59	58	98.3	1	1.7	56	56	100	0	0.0	53	53	100	0	0.0
	Abnormal	0	0	3	1	33.3	2	66.7
UREA	Normal	56	55	98.2	1	1.8	52	48	92.3	4	7.7	49	47	95.9	2	4.1
	Abnormal	3	1	33.3	2	66.7	4	4	100	0	0.0	7	5	71.4	2	28.6

LDH	Normal	55	54	98.2	1	1.8	55	55	100	0	0.0	53	51	96.2	2	3.8
	Abnormal	4	2	50.0	2	50.0	1	0	0.0	1	100	3	3	100	0	0.0
		Post booster – Day 390														
		HBsAg 4 Group							HBsAg 5 Group							
		N	Normal		Abnormal		N	Normal		Abnormal						
			n	%	n	%		n	%	n	%					
RED BLOOD CELLS	Normal	51	48	94.1	3	5.9	50	50	100	0	0.0					
	Abnormal	3	2	66.7	1	33.3	4	0	0.0	4	100					
PLATELETS	Normal	49	48	98.0	1	2.0	50	50	100	0	0.0					
	Abnormal	5	2	40.0	3	60.0	4	0	0.0	4	100					
HAEMOGL.	Normal	50	48	96.0	2	4.0	49	47	95.9	2	4.1					
	Abnormal	4	1	25.0	3	75.0	5	1	20.0	4	80.0					
ALT	Normal	50	45	90.0	5	10.0	49	49	100	0	0.0					
	Abnormal	5	2	40.0	3	60.0	4	1	25.0	3	75.0					
AST	Normal	55	51	92.7	4	7.3	52	51	98.1	1	1.9					
	Abnormal	0	-	-	-	-	1	1	100	0	0.0					
SERUM CREATININE	Normal	53	50	94.3	3	5.7	49	47	95.9	2	4.1					
	Abnormal	2	1	50.0	1	50.0	4	1	25.0	3	75.0					
UREA	Normal	50	50	100	0	0.0	49	48	98.0	1	2.0					
	Abnormal	5	4	80.0	1	20.0	4	3	75.0	1	25.0					
LDH	Normal	55	52	94.5	3	5.5	51	51	100	0	0.0					
	Abnormal	0	-	-	-	-	2	1	50.0	1	50.0					

N = Number of subjects with the administered dose for whom data is available

% = Percentage of subjects based on N

n = Number of subjects in the appropriate category

ALT = Alanine aminotransferase

AST= Aspartate aminotransferase

LDH = Lactate dehydrogenase

Secondary Outcome Variable(s): Descriptive statistics of the mRNA levels (by qPCR) (ATP cohort for innate immunogenicity up to Day 60, subjects in subsets 1 and 2 from IH center)

Parameter	Group	Activity	N	Min	Median	Max
TNF.mRNA	HBsAg 1	PI(D0)	17	0.55	1.18	2.66
		PI(D1)	17	0.71	1.33	2.48
		PI(D14)	16	0.63	0.95	2.14
		PII(D30)	17	0.74	1.03	1.63
		PII(D31)	16	0.66	1.31	2.2
		PII(D33)	17	0.44	0.99	2.47
		PII(D37)	17	0.36	0.82	1.56
	HBsAg 2	PI(D0)	23	0.78	1.09	1.75
		PI(D1)	23	0.44	1.08	3.01
		PI(D14)	23	0.57	1.07	1.8
		PII(D30)	22	0.55	1.21	2.56
		PII(D31)	22	0.58	1.26	2.13
		PII(D33)	21	0.67	1.04	2.1
		PII(D37)	21	0.32	1.04	1.69
	HBsAg 3	PI(D0)	28	0.84	1.24	2.64
		PI(D1)	27	0.4	1.1	2.58
		PI(D14)	27	0.63	1	2.96
		PII(D30)	28	0.58	1.25	2.89
		PII(D31)	28	0.5	1.41	3.42
		PII(D33)	28	0.54	1.12	2.99
		PII(D37)	28	0.39	1	2.39
	HBsAg 4	PI(D0)	21	0.78	1.18	3.18
		PI(D1)	21	0.56	1	2.39
		PI(D14)	21	0.62	1.03	1.58
		PII(D30)	19	0.64	1.19	2

TNFRSF9.mRNA	HBsAg 5	PII(D31)	19	0.46	1.15	2.59
		PII(D33)	19	0.47	1.18	2.27
		PII(D37)	17	0.42	1.07	1.99
		PI(D0)	21	0.76	1.18	2.89
		PI(D1)	21	0.63	1.06	2.09
		PI(D14)	21	0.52	1.13	1.67
		PII(D30)	21	0.48	1.09	2.97
		PII(D31)	21	0.49	1.1	2.24
		PII(D33)	21	0.57	0.97	2.48
		PII(D37)	21	0.38	1.06	3.39
	HBsAg 1	PI(D0)	17	0.81	1.04	2.17
		PI(D1)	18	0.74	1.14	1.67
		PI(D14)	18	0.52	0.98	1.74
		PII(D30)	18	0.67	1.06	1.51
		PII(D31)	18	0.8	1.14	1.98
		PII(D33)	18	0.46	0.67	2.76
		PII(D37)	18	0.41	0.77	3.06
	HBsAg 2	PI(D0)	23	0.74	1.11	1.52
		PI(D1)	23	0.59	1.14	2.5
		PI(D14)	23	0.52	1.02	1.97
		PII(D30)	23	0.73	1.02	1.61
		PII(D31)	23	0.55	1.09	1.49
		PII(D33)	22	0.32	0.7	1.45
		PII(D37)	22	0.6	1.01	1.61
	HBsAg 3	PI(D0)	28	0.7	1.14	2.64
		PI(D1)	27	0.72	1.24	2.13
		PI(D14)	28	0.63	1.19	3.31
		PII(D30)	28	0.78	1.08	1.89
		PII(D31)	28	0.57	1	1.8
		PII(D33)	28	0.49	0.73	1.7
		PII(D37)	28	0.55	0.91	3.2
	HBsAg 4	PI(D0)	22	0.86	1.14	2.11
		PI(D1)	22	0.73	1.24	3.19
		PI(D14)	21	0.59	1.15	2.13
		PII(D30)	19	0.72	1.03	1.42
		PII(D31)	19	0.73	0.97	2.01
		PII(D33)	19	0.84	1.12	1.95
		PII(D37)	17	0.59	1.01	1.78
	HBsAg 5	PI(D0)	21	0.8	1.11	1.98
		PI(D1)	21	0.55	1.01	1.53
		PI(D14)	21	0.46	1.02	1.69
		PII(D30)	21	0.66	1.14	1.65
		PII(D31)	20	0.68	1.07	1.75
		PII(D33)	20	0.67	1.07	1.86
		PII(D37)	21	0.55	1.14	2.01
FAF1.mRNA	HBsAg 1	PI(D0)	18	0.66	1.08	1.54
		PI(D1)	18	0.66	0.83	1.04
		PI(D14)	18	0.69	1.05	1.32
		PII(D30)	18	0.73	0.93	1.29
		PII(D31)	18	0.46	0.6	1.09
		PII(D33)	18	0.65	0.85	1.37
		PII(D37)	18	0.63	0.93	1.38
	HBsAg 2	PI(D0)	23	0.74	1.02	1.34
		PI(D1)	23	0.62	0.88	1.63
		PI(D14)	23	0.7	1.06	1.68
		PII(D30)	23	0.77	1.03	1.79

STAT1.mRNA	HBsAg 3	PII(D31)	23	0.49	0.67	1.35
		PII(D33)	22	0.72	0.95	1.23
		PII(D37)	22	0.79	0.97	1.73
		PI(D0)	28	0.72	1.06	1.39
		PI(D1)	27	0.57	0.89	1.28
		PI(D14)	28	0.7	0.97	1.48
		PII(D30)	28	0.77	1.03	1.58
		PII(D31)	28	0.4	0.83	1.43
		PII(D33)	28	0.71	0.94	1.38
		PII(D37)	28	0.77	0.97	1.65
	HBsAg 4	PI(D0)	22	0.68	1.06	1.61
		PI(D1)	22	0.71	0.93	1.29
		PI(D14)	22	0.65	1	1.26
		PII(D30)	19	0.8	0.99	1.25
		PII(D31)	19	0.66	0.9	1.46
		PII(D33)	19	0.7	1.01	1.34
		PII(D37)	17	0.73	0.97	1.54
		PI(D0)	21	0.85	1.07	1.39
	HBsAg 5	PI(D1)	21	0.72	1.08	1.44
		PI(D14)	21	0.75	1.01	1.3
		PII(D30)	21	0.7	1.02	1.54
		PII(D31)	21	0.79	1.02	1.72
		PII(D33)	21	0.54	0.98	1.89
		PII(D37)	21	0.71	1.07	1.95
	HBsAg 1	PI(D0)	18	0.7	0.92	1.21
		PI(D1)	18	0.71	2.31	5.23
		PI(D14)	18	0.15	1.02	2.84
		PII(D30)	18	0.63	0.96	1.2
		PII(D31)	18	1.5	4.95	7.8
		PII(D33)	18	0.82	2.03	4.86
		PII(D37)	18	0.63	0.87	1.45
	HBsAg 2	PI(D0)	23	0.79	0.99	1.3
		PI(D1)	23	0.24	2.88	6.32
		PI(D14)	23	0.18	0.96	1.93
		PII(D30)	23	0.6	0.88	1.17
		PII(D31)	23	1.61	3.83	7.2
		PII(D33)	22	0.49	1.25	4.19
		PII(D37)	22	0.35	0.89	1.45
	HBsAg 3	PI(D0)	28	0.77	0.97	1.41
		PI(D1)	27	0.54	1.31	6.66
		PI(D14)	28	0.2	0.98	2.41
		PII(D30)	28	0.73	0.96	1.45
		PII(D31)	28	1.06	3.13	7.93
		PII(D33)	28	0.42	1.12	2.95
		PII(D37)	28	0.23	0.86	1.37
	HBsAg 4	PI(D0)	22	0.6	0.96	1.25
		PI(D1)	22	0.66	0.92	1.36
		PI(D14)	22	0.74	1.04	5.74
		PII(D30)	19	0.6	0.89	1.22
		PII(D31)	19	0.26	0.88	1.29
		PII(D33)	19	0.21	1.01	1.55
		PII(D37)	17	0.16	0.95	1.43
	HBsAg 5	PI(D0)	21	0.8	0.95	1.19
		PI(D1)	21	0.56	0.95	1.97
		PI(D14)	21	0.42	0.96	2.44
		PII(D30)	21	0.71	0.96	1.21

IRF1.mRNA		P1I(D31)	21	0.19	0.96	1.25
		P1I(D33)	21	0.25	1	1.54
		P1I(D37)	21	0.19	1.02	1.81
	HBsAg 1	PI(D0)	18	0.61	0.96	1.53
		PI(D1)	18	0.8	1.51	2.98
		PI(D14)	18	0.25	1.02	1.79
		P1I(D30)	18	0.59	1	1.82
		P1I(D31)	18	1.12	3.14	8.06
		P1I(D33)	18	0.78	1.33	2.63
		P1I(D37)	18	0.42	0.99	2.24
	HBsAg 2	PI(D0)	23	0.65	0.99	1.83
		PI(D1)	23	0.44	1.59	3.23
		PI(D14)	23	0.49	1.01	1.93
		P1I(D30)	23	0.69	0.93	1.62
		P1I(D31)	23	1.32	2.63	3.95
		P1I(D33)	22	0.62	1.03	1.72
		P1I(D37)	22	0.59	0.93	1.3
	HBsAg 3	PI(D0)	28	0.65	0.95	1.42
		PI(D1)	27	0.54	1.24	2.81
		PI(D14)	28	0.4	1.02	1.87
		P1I(D30)	28	0.71	0.92	1.45
		P1I(D31)	28	0.8	1.73	5.63
		P1I(D33)	28	0.54	0.9	1.6
		P1I(D37)	28	0.35	0.9	1.63
	HBsAg 4	PI(D0)	22	0.84	1.03	1.69
		PI(D1)	22	0.76	1.08	1.45
		PI(D14)	21	0.82	1.14	4.12
		P1I(D30)	19	0.71	0.96	1.2
		P1I(D31)	19	0.35	1.05	1.5
		P1I(D33)	19	0.43	1.11	1.59
		P1I(D37)	17	0.27	0.97	1.38
	HBsAg 5	PI(D0)	21	0.87	1	1.25
		PI(D1)	20	0.7	0.95	1.34
		PI(D14)	21	0.6	0.97	2
		P1I(D30)	21	0.65	0.99	1.67
		P1I(D31)	21	0.45	0.99	1.47
		P1I(D33)	21	0.52	1.05	1.62
		P1I(D37)	21	0.54	1	1.78
MX1.mRNA	HBsAg 1	PI(D0)	18	0.77	1	1.21
		PI(D1)	18	0.96	1.61	3.42
		PI(D14)	18	0.05	0.95	8.35
		P1I(D30)	18	0.41	0.96	1.46
		P1I(D31)	18	0.69	3.06	6.38
		P1I(D33)	18	0.6	2.92	8.49
		P1I(D37)	18	0.63	0.93	5.86
	HBsAg 2	PI(D0)	23	0.77	1.01	1.38
		PI(D1)	23	0.14	1.59	3.29
		PI(D14)	23	0.08	1.03	4.12
		P1I(D30)	23	0.74	0.92	2.02
		P1I(D31)	23	1.18	2.19	9.95
		P1I(D33)	22	0.32	1.83	7.39
		P1I(D37)	22	0.19	0.9	1.75
	HBsAg 3	PI(D0)	28	0.7	0.98	1.32
		PI(D1)	27	0.45	1.18	4.98
		PI(D14)	28	0.06	0.91	5.32
		P1I(D30)	28	0.69	0.92	1.51

IL-12A.mRNA	HBsAg 4	PII(D31)	28	0.84	2.06	6.64
		PII(D33)	27	0.38	1.87	5.45
		PII(D37)	28	0.1	0.86	1.74
		PI(D0)	22	0.82	1.01	2.02
		PI(D1)	22	0.48	1.01	1.4
		PI(D14)	22	0.4	1.11	9.7
		PII(D30)	19	0.55	0.96	1.26
		PII(D31)	19	0.28	0.96	1.22
		PII(D33)	19	0.16	1.07	1.35
		PII(D37)	17	0.06	1.07	2.17
	HBsAg 5	PI(D0)	21	0.66	0.98	1.29
		PI(D1)	21	0.58	0.9	1.35
		PI(D14)	21	0.26	1.08	3.54
		PII(D30)	21	0.58	0.94	1.5
		PII(D31)	21	0.17	0.92	1.69
		PII(D33)	21	0.12	0.98	1.54
		PII(D37)	21	0.08	1.08	4.66
	HBsAg 1	PI(D0)	18	0.53	1.01	2.3
		PI(D1)	18	0.5	1.04	2.68
		PI(D14)	18	0.6	0.97	1.73
		PII(D30)	18	0.5	1.01	1.61
		PII(D31)	16	0.68	1.32	3.55
		PII(D33)	18	0.61	0.94	2.92
		PII(D37)	18	0.56	1.14	1.73
	HBsAg 2	PI(D0)	23	0.54	0.97	1.36
		PI(D1)	23	0.56	1.01	2.97
		PI(D14)	23	0.42	0.97	2.64
		PII(D30)	23	0.44	1	5.85
		PII(D31)	22	0.61	1.2	2.61
		PII(D33)	21	0.44	0.85	1.64
		PII(D37)	22	0.42	1.08	2.75
	HBsAg 3	PI(D0)	28	0.53	0.95	1.88
		PI(D1)	27	0.45	1.04	2.23
		PI(D14)	28	0.36	1.09	2.06
		PII(D30)	28	0.46	0.87	1.8
		PII(D31)	28	0.47	1.04	2.35
		PII(D33)	28	0.41	0.86	1.78
		PII(D37)	27	0.47	0.95	2.45
	HBsAg 4	PI(D0)	21	0.31	0.9	1.73
		PI(D1)	21	0.39	0.94	1.71
		PI(D14)	21	0.57	0.77	1.72
		PII(D30)	18	0.39	1.1	2.52
		PII(D31)	19	0.36	0.9	1.41
		PII(D33)	19	0.46	0.89	1.52
		PII(D37)	17	0.33	1.09	3.13
	HBsAg 5	PI(D0)	21	0.55	1.07	1.69
		PI(D1)	21	0.44	1.06	2.56
		PI(D14)	21	0.5	0.96	2.1
		PII(D30)	21	0.38	1.03	1.76
		PII(D31)	21	0.43	1.01	2.22
		PII(D33)	21	0.37	1.05	2.72
		PII(D37)	21	0.61	1.22	1.78
MKI67.mRNA	HBsAg 1	PI(D0)	18	0.23	0.91	1.63
		PI(D1)	18	0.33	0.89	1.7
		PI(D14)	18	0.57	1.06	2.83
		PII(D30)	18	0.56	1	1.61

			PII(D31)	18	0.45	0.84	1.57
			PII(D33)	18	0.44	0.96	2.13
			PII(D37)	18	0.38	1.52	3.28
		HBsAg 2	PI(D0)	23	0.45	0.89	2.72
			PI(D1)	23	0.46	0.9	2.63
			PI(D14)	22	0.39	1.14	3.17
			PII(D30)	23	0.68	0.92	1.56
			PII(D31)	23	0.5	0.83	1.87
			PII(D33)	22	0.5	1.02	2.72
			PII(D37)	22	0.58	1.56	4.01
		HBsAg 3	PI(D0)	28	0.45	0.98	1.74
			PI(D1)	27	0.55	0.99	1.48
			PI(D14)	27	0.32	1.18	2.74
			PII(D30)	27	0.48	1.1	1.77
			PII(D31)	28	0.42	0.97	2.44
			PII(D33)	28	0.38	1.14	2.52
			PII(D37)	28	0.37	1.38	3.94
		HBsAg 4	PI(D0)	22	0.51	0.83	2.12
			PI(D1)	22	0.37	0.94	1.85
			PI(D14)	21	0.6	0.99	2.75
			PII(D30)	19	0.42	0.98	1.8
			PII(D31)	19	0.3	0.95	1.52
			PII(D33)	18	0.28	0.89	1.42
			PII(D37)	17	0.58	1.06	2.01
		HBsAg 5	PI(D0)	20	0.61	1.03	2.51
			PI(D1)	21	0.48	1.03	1.79
			PI(D14)	20	0.4	1.07	3.71
			PII(D30)	21	0.5	0.97	1.7
			PII(D31)	21	0.52	1.12	4.01
			PII(D33)	21	0.55	1.03	8.12
			PII(D37)	21	0.35	1.08	1.76
	CXCL10.mRNA	HBsAg 1	PI(D0)	17	0.55	0.92	1.36
			PI(D1)	18	0.28	0.96	4.43
			PI(D14)	18	0.16	0.88	1.99
			PII(D30)	18	0.64	1.08	2.04
			PII(D31)	18	0.68	6.25	32.91
			PII(D33)	18	0.61	1.35	5.9
			PII(D37)	18	0.51	0.91	5.33
		HBsAg 2	PI(D0)	23	0.52	0.97	1.79
			PI(D1)	23	0.27	1.14	9.62
			PI(D14)	23	0.13	0.95	2.64
			PII(D30)	23	0.61	1.03	5.85
			PII(D31)	23	0.75	2.93	16.09
			PII(D33)	22	0.6	1.06	2.73
			PII(D37)	22	0.53	1.02	2.75
		HBsAg 3	PI(D0)	28	0.37	0.92	1.97
			PI(D1)	27	0.12	1.06	12.97
			PI(D14)	28	0.06	1.06	2.92
			PII(D30)	28	0.46	0.88	2.62
			PII(D31)	28	0.47	1.59	16.85
			PII(D33)	28	0.38	0.86	2.6
			PII(D37)	28	0.35	0.94	2.45
		HBsAg 4	PI(D0)	22	0.31	0.97	1.73
			PI(D1)	22	0.39	0.97	1.91
			PI(D14)	22	0.39	0.9	48.74
			PII(D30)	19	0.33	1.1	1.81

IL-1B.mRNA	HBsAg 5	PII(D31)	19	0.04	0.95	1.44
		PII(D33)	19	0.02	1.13	1.94
		PII(D37)	17	0.02	1.03	2.06
		PI(D0)	21	0.55	1.07	1.99
		PI(D1)	21	0.44	0.96	2.56
		PI(D14)	21	0.6	0.97	3.39
		PII(D30)	21	0.43	0.92	1.76
		PII(D31)	21	0.29	1.18	1.54
		PII(D33)	21	0.31	1.05	2.48
		PII(D37)	21	0.51	1.09	2.37
	HBsAg 1	PI(D0)	18	0.41	1.04	1.54
		PI(D1)	18	0.56	1.56	2.8
		PI(D14)	18	0.24	0.94	1.95
		PII(D30)	18	0.43	1.2	2.08
		PII(D31)	18	1.38	2.02	5.6
		PII(D33)	18	0.81	1.31	6.05
		PII(D37)	18	0.38	0.97	2.6
	HBsAg 2	PI(D0)	23	0.6	1.12	2.33
		PI(D1)	23	0.67	1.31	2.1
		PI(D14)	23	0.43	0.93	3.61
		PII(D30)	23	0.55	0.98	1.51
		PII(D31)	23	0.78	1.47	2.2
		PII(D33)	22	0.54	1.07	1.76
		PII(D37)	22	0.36	0.87	1.83
	HBsAg 3	PI(D0)	28	0.51	1.02	2.24
		PI(D1)	27	0.55	1.21	2.58
		PI(D14)	28	0.34	0.97	2.24
		PII(D30)	28	0.68	1.04	1.51
		PII(D31)	28	0.64	1.23	2.87
		PII(D33)	28	0.58	0.93	1.59
		PII(D37)	28	0.29	0.85	1.8
	HBsAg 4	PI(D0)	22	0.59	1.04	2.21
		PI(D1)	22	0.82	1.24	2.68
		PI(D14)	22	0.72	1.23	3.1
		PII(D30)	19	0.58	0.94	1.48
		PII(D31)	19	0.47	1.14	1.92
		PII(D33)	19	0.72	1.02	1.95
		PII(D37)	17	0.35	0.83	1.52
	HBsAg 5	PI(D0)	21	0.53	0.96	1.35
		PI(D1)	21	0.4	0.92	1.48
		PI(D14)	21	0.52	1	1.78
		PII(D30)	21	0.57	1.05	1.86
		PII(D31)	21	0.44	1.06	1.54
		PII(D33)	21	0.49	1.01	2.16
		PII(D37)	21	0.45	1.01	2.01
PTGS2.mRNA	HBsAg 1	PI(D0)	18	0.63	1.06	1.59
		PI(D1)	18	0.74	1.25	1.74
		PI(D14)	18	0.65	1.07	1.69
		PII(D30)	18	0.58	1.14	1.5
		PII(D31)	18	1.17	1.66	2.83
		PII(D33)	18	0.66	0.97	3.53
		PII(D37)	18	0.33	0.87	3.76
	HBsAg 2	PI(D0)	23	0.67	1.01	1.66
		PI(D1)	23	0.69	1.15	2.55
		PI(D14)	23	0.7	0.92	1.66
		PII(D30)	23	0.67	0.94	1.38

	HBsAg 3	PII(D31)	23	0.97	1.33	2.4	
		PII(D33)	22	0.52	0.85	1.22	
		PII(D37)	22	0.59	0.94	1.65	
		PI(D0)	28	0.64	1.07	1.73	
		PI(D1)	27	0.77	1.16	2.13	
		PI(D14)	28	0.4	1.01	2.08	
		PII(D30)	28	0.69	1.02	1.51	
		PII(D31)	28	0.74	1.11	1.99	
		PII(D33)	28	0.57	0.82	1.64	
		PII(D37)	28	0.57	0.91	2.15	
	HBsAg 4	PI(D0)	22	0.77	1.06	1.76	
		PI(D1)	22	0.73	1.05	1.47	
		PI(D14)	22	0.67	1.06	2.4	
		PII(D30)	19	0.58	0.98	1.22	
		PII(D31)	19	0.72	1.08	1.63	
		PII(D33)	19	0.77	1.07	2.73	
		PII(D37)	17	0.62	0.96	1.35	
		HBsAg 5	PI(D0)	21	0.63	1.04	1.28
	PI(D1)		21	0.71	0.95	1.32	
	PI(D14)		21	0.49	1.13	1.29	
	PII(D30)		21	0.67	1.09	1.56	
	PII(D31)		21	0.63	1.04	1.43	
	PII(D33)		21	0.6	1.01	2.03	
	PII(D37)		21	0.55	1.15	1.68	
	DUSP1.mRNA	HBsAg 1	PI(D0)	18	0.45	0.84	1.52
			PI(D1)	18	0.67	1.09	1.95
			PI(D14)	18	0.6	0.95	1.81
			PII(D30)	18	0.44	1.03	2.14
			PII(D31)	18	0.8	1.34	3.56
			PII(D33)	18	0.58	0.97	5.29
PII(D37)			18	0.27	0.91	4.05	
HBsAg 2			PI(D0)	23	0.52	0.96	1.8
		PI(D1)	23	0.52	1.1	2.03	
		PI(D14)	23	0.63	0.85	1.91	
		PII(D30)	23	0.48	0.81	1.46	
		PII(D31)	23	0.64	1.3	1.95	
		PII(D33)	22	0.43	0.84	1.42	
		PII(D37)	22	0.34	0.94	1.57	
		HBsAg 3	PI(D0)	28	0.58	1.02	2.27
PI(D1)			27	0.68	1.12	2.46	
PI(D14)			28	0.32	1.2	2.45	
PII(D30)			28	0.55	0.92	2.04	
PII(D31)			28	0.63	1.05	1.67	
PII(D33)			28	0.52	0.81	1.56	
PII(D37)			28	0.51	0.95	1.61	
HBsAg 4			PI(D0)	22	0.55	0.89	1.96
		PI(D1)	22	0.6	1.14	1.99	
		PI(D14)	22	0.81	1.07	1.86	
		PII(D30)	19	0.63	0.86	1.28	
		PII(D31)	19	0.76	1.31	1.97	
		PII(D33)	19	0.78	1.18	2.69	
		PII(D37)	17	0.68	0.94	1.53	
HBsAg 5		PI(D0)	21	0.5	0.9	1.27	
		PI(D1)	21	0.53	0.85	1.81	
	PI(D14)	21	0.45	1	1.55		
	PII(D30)	21	0.53	0.96	1.8		

NFATC2.mRNA		PII(D31)	21	0.57	0.94	1.85
		PII(D33)	21	0.42	0.99	1.91
		PII(D37)	21	0.45	1	2.3
	HBsAg 1	PI(D0)	18	0.52	0.98	1.25
		PI(D1)	18	0.48	0.66	1.06
		PI(D14)	18	0.48	1	1.69
		PII(D30)	18	0.7	0.92	1.64
		PII(D31)	18	0.32	0.46	1.06
		PII(D33)	18	0.59	0.79	1.36
		PII(D37)	18	0.74	1.03	1.22
	HBsAg 2	PI(D0)	23	0.64	0.94	1.64
		PI(D1)	23	0.43	0.73	2.55
		PI(D14)	23	0.42	0.98	2.12
		PII(D30)	23	0.72	0.99	1.37
		PII(D31)	23	0.34	0.58	1.15
		PII(D33)	22	0.56	0.9	1.79
		PII(D37)	22	0.66	1.03	1.59
	HBsAg 3	PI(D0)	28	0.74	1.03	1.91
		PI(D1)	27	0.47	0.83	1.56
		PI(D14)	28	0.61	1.09	1.78
		PII(D30)	28	0.78	1	1.57
		PII(D31)	28	0.33	0.78	1.46
		PII(D33)	28	0.63	0.87	1.55
		PII(D37)	28	0.72	0.98	1.99
	HBsAg 4	PI(D0)	22	0.51	0.93	1.56
		PI(D1)	22	0.6	0.83	1.23
		PI(D14)	22	0.53	0.89	1.39
		PII(D30)	19	0.82	1.05	1.5
		PII(D31)	19	0.69	0.87	1.78
		PII(D33)	19	0.63	1.05	1.43
		PII(D37)	17	0.83	1.16	1.56
	HBsAg 5	PI(D0)	21	0.64	1.11	1.5
		PI(D1)	21	0.73	1.04	1.57
		PI(D14)	21	0.64	1.1	1.59
		PII(D30)	21	0.79	1.08	1.44
		PII(D31)	21	0.83	1.1	1.33
		PII(D33)	21	0.75	1.05	1.62
		PII(D37)	21	0.69	1.11	1.91
IFN- γ .mRNA	HBsAg 1	PI(D0)	18	0.55	0.97	1.36
		PI(D1)	18	0.5	0.89	1.74
		PI(D14)	18	0.55	0.88	1.99
		PII(D30)	18	0.64	1.08	2.04
		PII(D31)	18	0.61	0.91	2.46
		PII(D33)	18	0.61	0.9	4.25
		PII(D37)	18	0.51	0.89	5.33
	HBsAg 2	PI(D0)	23	0.54	0.97	1.79
		PI(D1)	23	0.6	1.01	2.97
		PI(D14)	23	0.44	0.97	2.64
		PII(D30)	23	0.61	1.03	5.85
		PII(D31)	23	0.44	0.86	2.61
		PII(D33)	22	0.6	0.92	2.04
		PII(D37)	22	0.53	1.02	2.75
	HBsAg 3	PI(D0)	28	0.59	0.94	1.97
		PI(D1)	27	0.45	1.03	1.94
		PI(D14)	28	0.48	1.11	2.08
		PII(D30)	28	0.46	0.88	3.19

Pain	Any	143	122	85.3	78.4	90.7	139	57	41.0	32.7	49.7					
	Grade 3	143	5	3.5	1.1	8.0	139	0	0.0	0.0	2.6					
Redness	Any	143	43	30.1	22.7	38.3	139	18	12.9	7.9	19.7					
	> 50 mm	143	0	0.0	0.0	2.5	139	0	0.0	0.0	2.6					
Swelling	Any	143	31	21.7	15.2	29.3	139	11	7.9	4.0	13.7					
	> 50 mm	143	1	0.7	0.0	3.8	139	0	0.0	0.0	2.6					
Dose 2																
Pain	Any	125	105	84.0	76.4	89.9	121	38	31.4	23.3	40.5					
	Grade 3	125	2	1.6	0.2	5.7	121	0	0.0	0.0	3.0					
Redness	Any	125	38	30.4	22.5	39.3	121	14	11.6	6.5	18.7					
	> 50 mm	125	0	0.0	0.0	2.9	121	0	0.0	0.0	3.0					
Swelling	Any	125	33	26.4	18.9	35.0	121	8	6.6	2.9	12.6					
	> 50 mm	125	1	0.8	0.0	4.4	121	0	0.0	0.0	3.0					
Across doses																
Pain	Any	143	128	89.5	83.3	94.0	139	70	50.4	41.8	58.9					
	Grade 3	143	6	4.2	1.6	8.9	139	0	0.0	0.0	2.6					
Redness	Any	143	53	37.1	29.1	45.5	139	23	16.5	10.8	23.8					
	> 50 mm	143	0	0.0	0.0	2.5	139	0	0.0	0.0	2.6					
Swelling	Any	143	43	30.1	22.7	38.3	139	16	11.5	6.7	18.0					
	> 50 mm	143	2	1.4	0.2	5.0	139	0	0.0	0.0	2.6					
N= number of subjects with at least one documented dose n (%)= number/percentage of subjects reporting the symptom at least once 95%CI= exact 95% confidence interval; LL = lower limit; UL = upper limit Any = incidence of a particular symptom regardless of intensity grade Grade 3 pain = pain that prevented normal activity																
Secondary Outcome Variable(s): Number (%) of subjects with solicited general symptoms reported during the 14-day (Days 0-13) post- primary vaccination period following each dose and across doses (Total Vaccinated cohort)																
Symptom	Intensity/ Relationship	HBsAg 1 Group				HBsAg 2 Group				HBsAg 3 Group						
		N	n	%	95 % CI		N	n	%	95 % CI		N	n	%	95 % CI	
					LL	UL				LL	UL				LL	UL
Dose 1																
Fatigue	Any	142	67	47.2	38.8	55.7	140	52	37.1	29.1	45.7	138	51	37.0	28.9	45.6
	Grade 3	142	0	0.0	0.0	2.6	140	4	2.9	0.8	7.2	138	3	2.2	0.5	6.2
	Related	142	54	38.0	30.0	46.5	140	40	28.6	21.3	36.8	138	39	28.3	20.9	36.5
Fever (Orally)	≥37.5°C	142	21	14.8	9.4	21.7	140	11	7.9	4.0	13.6	138	10	7.2	3.5	12.9
	>39.5 °C	142	1	0.7	0.0	3.9	140	0	0.0	0.0	2.6	138	0	0.0	0.0	2.6
	Related	142	18	12.7	7.7	19.3	140	6	4.3	1.6	9.1	138	6	4.3	1.6	9.2
Gastro- intestinal	Any	142	25	17.6	11.7	24.9	140	18	12.9	7.8	19.6	138	21	15.2	9.7	22.3
	Grade 3	142	1	0.7	0.0	3.9	140	3	2.1	0.4	6.1	138	3	2.2	0.5	6.2
	Related	142	17	12.0	7.1	18.5	140	7	5.0	2.0	10.0	138	12	8.7	4.6	14.7
Headache	Any	142	64	45.1	36.7	53.6	140	42	30.0	22.6	38.3	138	48	34.8	26.9	43.4
	Grade 3	142	2	1.4	0.2	5.0	140	2	1.4	0.2	5.1	138	7	5.1	2.1	10.2
	Related	142	49	34.5	26.7	42.9	140	26	18.6	12.5	26.0	138	33	23.9	17.1	31.9
Malaise	Any	142	38	26.8	19.7	34.8	140	25	17.9	11.9	25.2	138	23	16.7	10.9	24.0
	Grade 3	142	1	0.7	0.0	3.9	140	3	2.1	0.4	6.1	138	3	2.2	0.5	6.2
	Related	142	33	23.2	16.6	31.1	140	18	12.9	7.8	19.6	138	13	9.4	5.1	15.6
Myalgia	Any	142	61	43.0	34.7	51.5	140	38	27.1	20.0	35.3	138	42	30.4	22.9	38.8
	Grade 3	142	2	1.4	0.2	5.0	140	2	1.4	0.2	5.1	138	1	0.7	0.0	4.0
	Related	142	56	39.4	31.3	48.0	140	31	22.1	15.6	29.9	138	32	23.2	16.4	31.1
Dose 2																
Fatigue	Any	125	67	53.6	44.5	62.6	123	54	43.9	35.0	53.1	118	50	42.4	33.3	51.8
	Grade 3	125	5	4.0	1.3	9.1	123	1	0.8	0.0	4.4	118	2	1.7	0.2	6.0
	Related	125	63	50.4	41.3	59.5	123	47	38.2	29.6	47.4	118	40	33.9	25.4	43.2
Fever (Orally)	≥37.5 °C	125	33	26.4	18.9	35.0	123	14	11.4	6.4	18.4	118	15	12.7	7.3	20.1
	>39.5 °C	125	0	0.0	0.0	2.9	123	0	0.0	0.0	3.0	118	1	0.8	0.0	4.6

	Related	125	31	24.8	17.5	33.3	123	12	9.8	5.1	16.4	118	11	9.3	4.7	16.1
Gastro-intestinal	Any	125	16	12.8	7.5	20.0	123	11	8.9	4.5	15.4	118	12	10.2	5.4	17.1
	Grade 3	125	1	0.8	0.0	4.4	123	2	1.6	0.2	5.8	118	1	0.8	0.0	4.6
	Related	125	10	8.0	3.9	14.2	123	6	4.9	1.8	10.3	118	9	7.6	3.5	14.0
Headache	Any	125	68	54.4	45.3	63.3	123	47	38.2	29.6	47.4	118	37	31.4	23.1	40.5
	Grade 3	125	7	5.6	2.3	11.2	123	5	4.1	1.3	9.2	118	1	0.8	0.0	4.6
	Related	125	56	44.8	35.9	54.0	123	37	30.1	22.1	39.0	118	24	20.3	13.5	28.7
Malaise	Any	125	50	40.0	31.3	49.1	123	31	25.2	17.8	33.8	118	25	21.2	14.2	29.7
	Grade 3	125	8	6.4	2.8	12.2	123	2	1.6	0.2	5.8	118	2	1.7	0.2	6.0
	Related	125	43	34.4	26.1	43.4	123	27	22.0	15.0	30.3	118	21	17.8	11.4	25.9
Myalgia	Any	125	65	52.0	42.9	61.0	123	41	33.3	25.1	42.4	118	34	28.8	20.8	37.9
	Grade 3	125	9	7.2	3.3	13.2	123	2	1.6	0.2	5.8	118	2	1.7	0.2	6.0
	Related	125	60	48.0	39.0	57.1	123	36	29.3	21.4	38.1	118	29	24.6	17.1	33.4

Across doses

Fatigue	Any	142	91	64.1	55.6	72.0	140	76	54.3	45.7	62.7	138	67	48.6	40.0	57.2
	Grade 3	142	5	3.5	1.2	8.0	140	5	3.6	1.2	8.1	138	5	3.6	1.2	8.3
	Related	142	83	58.5	49.9	66.7	140	67	47.9	39.3	56.5	138	57	41.3	33.0	50.0
Fever (Orally)	≥37.5 °C	142	45	31.7	24.1	40.0	140	23	16.4	10.7	23.6	138	24	17.4	11.5	24.8
	>39.5 °C	142	1	0.7	0.0	3.9	140	0	0.0	0.0	2.6	138	1	0.7	0.0	4.0
	Related	142	42	29.6	22.2	37.8	140	17	12.1	7.2	18.7	138	17	12.3	7.3	19.0
Gastro-intestinal	Any	142	30	21.1	14.7	28.8	140	27	19.3	13.1	26.8	138	29	21.0	14.5	28.8
	Grade 3	142	2	1.4	0.2	5.0	140	5	3.6	1.2	8.1	138	4	2.9	0.8	7.3
	Related	142	21	14.8	9.4	21.7	140	13	9.3	5.0	15.4	138	19	13.8	8.5	20.7
Headache	Any	142	90	63.4	54.9	71.3	140	67	47.9	39.3	56.5	138	66	47.8	39.3	56.5
	Grade 3	142	8	5.6	2.5	10.8	140	6	4.3	1.6	9.1	138	8	5.8	2.5	11.1
	Related	142	74	52.1	43.6	60.6	140	52	37.1	29.1	45.7	138	46	33.3	25.5	41.9
Malaise	Any	142	60	42.3	34.0	50.8	140	44	31.4	23.9	39.8	138	39	28.3	20.9	36.5
	Grade 3	142	9	6.3	2.9	11.7	140	5	3.6	1.2	8.1	138	4	2.9	0.8	7.3
	Related	142	53	37.3	29.4	45.8	140	36	25.7	18.7	33.8	138	30	21.7	15.2	29.6
Myalgia	Any	142	85	59.9	51.3	68.0	140	57	40.7	32.5	49.3	138	55	39.9	31.6	48.5
	Grade 3	142	10	7.0	3.4	12.6	140	4	2.9	0.8	7.2	138	3	2.2	0.5	6.2
	Related	142	79	55.6	47.1	64.0	140	49	35.0	27.1	43.5	138	47	34.1	26.2	42.6

Symptom	Intensity/ Relationship	HBsAg 4 Group					HBsAg 5 Group				
		N	n	%	95 % CI		N	n	%	95 % CI	
					LL	UL				LL	UL
Dose 1											
Fatigue	Any	144	56	38.9	30.9	47.4	139	50	36.0	28.0	44.5
	Grade 3	144	2	1.4	0.2	4.9	139	2	1.4	0.2	5.1
	Related	144	36	25.0	18.2	32.9	139	34	24.5	17.6	32.5
Fever (Orally)	≥37.5 °C	144	8	5.6	2.4	10.7	139	13	9.4	5.1	15.5
	>39.5 °C	144	0	0.0	0.0	2.5	139	1	0.7	0.0	3.9
	Related	144	3	2.1	0.4	6.0	139	4	2.9	0.8	7.2
Gastro- intestinal	Any	144	30	20.8	14.5	28.4	139	26	18.7	12.6	26.2
	Grade 3	144	2	1.4	0.2	4.9	139	5	3.6	1.2	8.2
	Related	144	16	11.1	6.5	17.4	139	15	10.8	6.2	17.2
Headache	Any	144	51	35.4	27.6	43.8	139	49	35.3	27.3	43.8
	Grade 3	144	2	1.4	0.2	4.9	139	4	2.9	0.8	7.2
	Related	144	29	20.1	13.9	27.6	139	29	20.9	14.4	28.6
Malaise	Any	144	30	20.8	14.5	28.4	139	19	13.7	8.4	20.5
	Grade 3	144	3	2.1	0.4	6.0	139	1	0.7	0.0	3.9
	Related	144	19	13.2	8.1	19.8	139	11	7.9	4.0	13.7
Myalgia	Any	144	46	31.9	24.4	40.2	139	23	16.5	10.8	23.8
	Grade 3	144	2	1.4	0.2	4.9	139	2	1.4	0.2	5.1
	Related	144	36	25.0	18.2	32.9	139	13	9.4	5.1	15.5

Dose 2											
Fatigue	Any	125	43	34.4	26.1	43.4	121	29	24.0	16.7	32.6
	Grade 3	125	2	1.6	0.2	5.7	121	1	0.8	0.0	4.5
	Related	125	35	28.0	20.3	36.7	121	20	16.5	10.4	24.4
Fever (Orally)	≥37.5 °C	125	6	4.8	1.8	10.2	121	5	4.1	1.4	9.4
	>39.5 °C	125	0	0.0	0.0	2.9	121	0	0.0	0.0	3.0
	Related	125	3	2.4	0.5	6.9	121	1	0.8	0.0	4.5
Gastro-intestinal	Any	125	17	13.6	8.1	20.9	121	15	12.4	7.1	19.6
	Grade 3	125	2	1.6	0.2	5.7	121	2	1.7	0.2	5.8
	Related	125	7	5.6	2.3	11.2	121	9	7.4	3.5	13.7
Headache	Any	125	30	24.0	16.8	32.5	121	24	19.8	13.1	28.1
	Grade 3	125	2	1.6	0.2	5.7	121	1	0.8	0.0	4.5
	Related	125	18	14.4	8.8	21.8	121	12	9.9	5.2	16.7
Malaise	Any	125	16	12.8	7.5	20.0	121	11	9.1	4.6	15.7
	Grade 3	125	2	1.6	0.2	5.7	121	1	0.8	0.0	4.5
	Related	125	13	10.4	5.7	17.1	121	6	5.0	1.8	10.5
Myalgia	Any	125	38	30.4	22.5	39.3	121	17	14.0	8.4	21.5
	Grade 3	125	0	0.0	0.0	2.9	121	0	0.0	0.0	3.0
	Related	125	35	28.0	20.3	36.7	121	12	9.9	5.2	16.7

Across doses											
Fatigue	Any	144	70	48.6	40.2	57.1	139	62	44.6	36.2	53.3
	Grade 3	144	4	2.8	0.8	7.0	139	3	2.2	0.4	6.2
	Related	144	55	38.2	30.2	46.7	139	42	30.2	22.7	38.6
Fever (Orally)	≥37.5 °C	144	12	8.3	4.4	14.1	139	17	12.2	7.3	18.9
	>39.5 °C	144	0	0.0	0.0	2.5	139	1	0.7	0.0	3.9
	Related	144	6	4.2	1.5	8.8	139	5	3.6	1.2	8.2
Gastro-intestinal	Any	144	36	25.0	18.2	32.9	139	35	25.2	18.2	33.2
	Grade 3	144	4	2.8	0.8	7.0	139	7	5.0	2.0	10.1
	Related	144	20	13.9	8.7	20.6	139	19	13.7	8.4	20.5
Headache	Any	144	62	43.1	34.8	51.6	139	59	42.4	34.1	51.1
	Grade 3	144	3	2.1	0.4	6.0	139	5	3.6	1.2	8.2
	Related	144	41	28.5	21.3	36.6	139	35	25.2	18.2	33.2
Malaise	Any	144	35	24.3	17.6	32.1	139	28	20.1	13.8	27.8
	Grade 3	144	4	2.8	0.8	7.0	139	2	1.4	0.2	5.1
	Related	144	27	18.8	12.7	26.1	139	16	11.5	6.7	18.0
Myalgia	Any	144	58	40.3	32.2	48.8	139	34	24.5	17.6	32.5
	Grade 3	144	2	1.4	0.2	4.9	139	2	1.4	0.2	5.1
	Related	144	50	34.7	27.0	43.1	139	22	15.8	10.2	23.0

N= number of subjects with at least one documented dose

n/%= number/percentage of subjects reporting the symptom at least once

95%CI= exact 95% confidence interval; LL = lower limit; UL = upper limit

Gastrointestinal symptoms included nausea, vomiting, diarrhea and/ or abdominal pain.

Any = incidence of a particular symptom regardless of intensity grade and relationship to vaccination

Grade 3 symptoms = general symptoms that prevented normal activity

Related = symptom assessed by the investigator as causally related to the vaccination

Secondary Outcome Variable(s): Number (%) of subjects with solicited local symptoms reported during the 7-day (Days 0-6) post-booster period (Booster Total Vaccinated cohort; Subjects in subsets 1 and 2)

Symptom	Intensity	HBsAg 1 Group					HBsAg 2 Group					HBsAg 3 Group				
		N	n	%	95 % CI		N	n	%	95 % CI		N	n	%	95 % CI	
					LL	UL				LL	UL				LL	UL
Pain	Any	59	19	32.2	20.6	45.6	56	19	33.9	21.8	47.8	56	13	23.2	13.0	36.4
	Grade 3	59	0	0.0	0.0	6.1	56	0	0.0	0.0	6.4	56	1	1.8	0.0	9.6
Redness	Any	59	6	10.2	3.8	20.8	56	3	5.4	1.1	14.9	56	8	14.3	6.4	26.2
	> 50 mm	59	1	1.7	0.0	9.1	56	0	0.0	0.0	6.4	56	0	0.0	0.0	6.4
Swelling	Any	59	3	5.1	1.1	14.1	56	4	7.1	2.0	17.3	56	2	3.6	0.4	12.3

		> 50 mm	59	1	1.7	0.0	9.1	56	0	0.0	0.0	6.4	56	0	0.0	0.0	6.4
			HBsAg 4 Group							HBsAg 5 Group							
			N		n	%	95 % CI		N		n	%	95 % CI				
						LL	UL					LL	UL				
Pain	Any	56	16	28.6	17.3	42.2	54	10	18.5	9.3	31.4						
	Grade 3	56	0	0.0	0.0	6.4	54	0	0.0	0.0	6.6						
Redness	Any	56	6	10.7	4.0	21.9	54	2	3.7	0.5	12.7						
	> 50 mm	56	0	0.0	0.0	6.4	54	0	0.0	0.0	6.6						
Swelling	Any	56	5	8.9	3.0	19.6	54	1	1.9	0.0	9.9						
	> 50 mm	56	0	0.0	0.0	6.4	54	0	0.0	0.0	6.6						
N= number of subjects with the documented dose n (%)= number/percentage of subjects reporting the symptom at least once 95%CI= exact 95% confidence interval; LL = lower limit; UL = upper limit Any = incidence of a particular symptom regardless of intensity grade Grade 3 pain = pain that prevented normal activity																	
Secondary Outcome Variable(s): Number (%) of subjects with solicited general symptoms reported during the 7-day (Days 0-6) post-booster period (Booster Total Vaccinated cohort; Subjects in subsets 1 and 2)																	
Symptom	Intensity/ Relationship	HBsAg 1 Group					HBsAg 2 Group					HBsAg 3 Group					
		N	n	%	95 % CI		N	n	%	95 % CI		N	n	%	95 % CI		
					LL	UL				LL	UL				LL	UL	
Fatigue	Any	59	15	25.4	15.0	38.4	56	14	25.0	14.4	38.4	56	7	12.5	5.2	24.1	
	Grade 3	59	0	0.0	0.0	6.1	56	0	0.0	0.0	6.4	56	0	0.0	0.0	6.4	
	Related	59	15	25.4	15.0	38.4	56	12	21.4	11.6	34.4	56	5	8.9	3.0	19.6	
Fever (Orally)	≥37.5 °C	59	3	5.1	1.1	14.1	56	1	1.8	0.0	9.6	56	0	0.0	0.0	6.4	
	>39.5 °C	59	0	0.0	0.0	6.1	56	0	0.0	0.0	6.4	56	0	0.0	0.0	6.4	
	Related	59	1	1.7	0.0	9.1	56	1	1.8	0.0	9.6	56	0	0.0	0.0	6.4	
Gastro-intestinal	Any	59	4	6.8	1.9	16.5	56	5	8.9	3.0	19.6	56	4	7.1	2.0	17.3	
	Grade 3	59	0	0.0	0.0	6.1	56	0	0.0	0.0	6.4	56	0	0.0	0.0	6.4	
	Related	59	4	6.8	1.9	16.5	56	5	8.9	3.0	19.6	56	2	3.6	0.4	12.3	
Headache	Any	59	15	25.4	15.0	38.4	56	7	12.5	5.2	24.1	56	7	12.5	5.2	24.1	
	Grade 3	59	0	0.0	0.0	6.1	56	0	0.0	0.0	6.4	56	0	0.0	0.0	6.4	
	Related	59	13	22.0	12.3	34.7	56	5	8.9	3.0	19.6	56	6	10.7	4.0	21.9	
Malaise	Any	59	6	10.2	3.8	20.8	56	5	8.9	3.0	19.6	56	2	3.6	0.4	12.3	
	Grade 3	59	0	0.0	0.0	6.1	56	0	0.0	0.0	6.4	56	0	0.0	0.0	6.4	
	Related	59	6	10.2	3.8	20.8	56	4	7.1	2.0	17.3	56	2	3.6	0.4	12.3	
Myalgia	Any	59	4	6.8	1.9	16.5	56	3	5.4	1.1	14.9	56	2	3.6	0.4	12.3	
	Grade 3	59	0	0.0	0.0	6.1	56	0	0.0	0.0	6.4	56	0	0.0	0.0	6.4	
	Related	59	4	6.8	1.9	16.5	56	2	3.6	0.4	12.3	56	2	3.6	0.4	12.3	
		HBsAg 4 Group							HBsAg 5 Group								
		N	n	%	95 % CI		N	n	%	95 % CI							
					LL	UL				LL	UL						
Fatigue	Any	56	15	26.8	15.8	40.3	54	12	22.2	12.0	35.6						
	Grade 3	56	0	0.0	0.0	6.4	54	1	1.9	0.0	9.9						
	Related	56	13	23.2	13.0	36.4	54	10	18.5	9.3	31.4						
Fever (Orally)	≥37.5 °C	56	3	5.4	1.1	14.9	54	1	1.9	0.0	9.9						
	>39.5 °C	56	0	0.0	0.0	6.4	54	0	0.0	0.0	6.6						
	Related	56	2	3.6	0.4	12.3	54	1	1.9	0.0	9.9						
Gastro-intestinal	Any	56	3	5.4	1.1	14.9	54	5	9.3	3.1	20.3						
	Grade 3	56	0	0.0	0.0	6.4	54	0	0.0	0.0	6.6						
	Related	56	2	3.6	0.4	12.3	54	3	5.6	1.2	15.4						
Headache	Any	56	8	14.3	6.4	26.2	54	14	25.9	15.0	39.7						
	Grade 3	56	1	1.8	0.0	9.6	54	0	0.0	0.0	6.6						
	Related	56	7	12.5	5.2	24.1	54	9	16.7	7.9	29.3						
Malaise	Any	56	4	7.1	2.0	17.3	54	4	7.4	2.1	17.9						
	Grade 3	56	0	0.0	0.0	6.4	54	0	0.0	0.0	6.6						

	Related	56	4	7.1	2.0	17.3	54	4	7.4	2.1	17.9
Myalgia	Any	56	5	8.9	3.0	19.6	54	1	1.9	0.0	9.9
	Grade 3	56	0	0.0	0.0	6.4	54	1	1.9	0.0	9.9
	Related	56	5	8.9	3.0	19.6	54	1	1.9	0.0	9.9

N= number of subjects with at least one documented dose

n/%= number/percentage of subjects reporting the symptom at least once

95%CI= exact 95% confidence interval; LL = lower limit; UL = upper limit

Gastrointestinal symptoms included nausea, vomiting, diarrhea and/ or abdominal pain.

Any = incidence of a particular symptom regardless of intensity grade and relationship to vaccination

Grade 3 symptoms = general symptoms that prevented normal activity

Related = symptom assessed by the investigator as causally related to the vaccination

Secondary Outcome Variable(s): Number (%) of subjects with AESI, including AID, up to Day 60 (Total Vaccinated cohort)

AESIs including AID	HBsAg 1 Group N = 143	HBsAg 2 Group N = 142	HBsAg 3 Group N = 141	HBsAg 4 Group N = 145	HBsAg 5 Group N = 142
Subjects with any AESI(s), n (%)	0 (0.0)	1 (0.7)	0 (0.0)	0 (0.0)	0 (0.0)
Palindromic rheumatism	-	1 (0.7)	-	-	-

- : Adverse event absent

Secondary Outcome Variable(s): Number (%) of subjects with AESI, including AID, during the entire study period – Days 0-390 (Total Vaccinated cohort)

AESIs including AID	HBsAg 1 Group N = 143	HBsAg 2 Group N = 142	HBsAg 3 Group N = 141	HBsAg 4 Group N = 145	HBsAg 5 Group N = 142
Subjects with any AESI(s), n (%)	0 (0.0)	1 (0.7)	0 (0.0)	0 (0.0)	0 (0.0)
Palindromic rheumatism	-	1 (0.7)	-	-	-

- : Adverse event absent

Safety Results: Number (%) of subjects with unsolicited AEs during the 31-day (Days 0-30) post-primary vaccination period (Total Vaccinated cohort)

Most frequent adverse events - On-Therapy (occurring within Days 0-30 following vaccination)	HBsAg 1 Group N = 143	HBsAg 2 Group N = 142	HBsAg 3 Group N = 141	HBsAg 4 Group N = 145	HBsAg 5 Group N = 142
Subjects with any AE(s), n (%)	80 (55.9)	73 (51.4)	76 (53.9)	67 (46.2)	71 (50.0)
Subjects with any grade 3 AE(s), n (%)	17 (11.9)	11 (7.7)	12 (8.5)	19 (13.1)	15 (10.6)
Subjects with related AE(s), n (%)	32 (22.4)	19 (13.4)	27 (19.1)	21 (14.5)	19 (13.4)
Subjects with Grade 3 and related AE(s), n (%)	7 (4.9)	1 (0.7)	2 (1.4)	1 (0.7)	2 (1.4)
Nasopharyngitis	11 (7.7)	8 (5.6)	7 (5.0)	4 (2.8)	7 (4.9)
Rhinitis	5 (3.5)	-	5 (3.5)	7 (4.8)	-
Oropharyngeal pain	6 (4.2)	-	5 (3.5)	-	5 (3.5)
Back pain	-	-	6 (4.3)	5 (3.4)	-
Influenza like illness	-	-	-	4 (2.8)	5 (3.5)
Headache	-	-	-	-	8 (5.6)
Pharyngitis	-	3 (2.1)	5 (3.5)	-	-
Upper respiratory tract infection	5 (3.5)	3 (2.1)	-	-	-
Toothache	-	-	-	-	7 (4.9)
Chills	5 (3.5)	-	-	-	-
Iron deficiency	-	5 (3.5)	-	-	-
Pain in extremity	-	-	-	5 (3.4)	-
Dizziness	-	3 (2.1)	-	-	-
Dysmenorrhoea	-	3 (2.1)	-	-	-
Sinusitis	-	3 (2.1)	-	-	-

Counting rule applied: As there were more than 30 subjects per treatment group and > 3 groups, only the 5 most frequent events in each treatment group are to be listed.

-: Implies that adverse event was not reported in the particular group or that the adverse event was reported in the particular group but did not fall within the pre-defined counting rule of 5 most frequent events for that group.

Grade 3 = Event that prevented normal activities

Related = Event assessed by the investigators as causally related to the study vaccination					
Safety Results: Number (%) of subjects with unsolicited adverse events during the 31-day (Days 0-30) post-booster period (Booster Total Vaccinated cohort; Subjects in subsets 1 and 2)					
Most frequent adverse events - On-Therapy (occurring within Days 0-30 following vaccination)	HBsAg 1 Group N = 59	HBsAg 2 Group N = 56	HBsAg 3 Group N = 56	HBsAg 4 Group N = 56	HBsAg 5 Group N = 54
Subjects with any AE(s), n (%)	12 (20.3)	8 (14.3)	9 (16.1)	14 (25.0)	10 (18.5)
Subjects with any grade 3 AE(s), n (%)	2 (3.4)	2 (3.6)	2 (3.6)	4 (7.1)	1 (1.9)
Subjects with related AE(s), n (%)	3 (5.1)	1 (1.8)	0 (0.0)	2 (3.6)	2 (3.7)
Subjects with grade 3 and related AE(s), n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Gastroenteritis	1 (1.7)	-	1 (1.8)	2 (3.6)	-
Nasopharyngitis	3 (5.1)	-	1 (1.8)	-	-
Influenza like illness	2 (3.4)	-	-	1 (1.8)	-
Oropharyngeal pain	1 (1.7)	-	-	1 (1.8)	1 (1.9)
Toothache	-	1 (1.8)	1 (1.8)	1 (1.8)	-
Back pain	-	-	-	1 (1.8)	1 (1.9)
Injection site haemorrhage	1 (1.7)	-	-	-	1 (1.9)
Rhinitis	-	-	1 (1.8)	-	1 (1.9)
Sinusitis	1 (1.7)	-	-	1 (1.8)	-
Syncope	1 (1.7)	1 (1.8)	-	-	-
Tinnitus	-	1 (1.8)	-	1 (1.8)	-
Arthralgia	1 (1.7)	-	-	-	-
Bronchitis	1 (1.7)	-	-	-	-
Chest pain	-	-	1 (1.8)	-	-
Conjunctivitis	-	-	-	1 (1.8)	-
Conjunctivitis allergic	-	-	-	1 (1.8)	-
Contusion	-	-	-	-	1 (1.9)
Depression	-	1 (1.8)	-	-	-
Diarrhoea	-	-	1 (1.8)	-	-
Dizziness	-	-	1 (1.8)	-	-
Dry mouth	-	1 (1.8)	-	-	-
Eosinophilia	-	1 (1.8)	-	-	-
Euphoric mood	-	-	-	1 (1.8)	-
Eye injury	-	1 (1.8)	-	-	-
Fatigue	-	-	1 (1.8)	-	-
Gastroenteritis viral	1 (1.7)	-	-	-	-
Haemoglobin decreased	-	-	-	1 (1.8)	-
Headache	-	-	-	-	1 (1.9)
Hypotension	-	-	-	1 (1.8)	-
Influenza	-	-	-	-	1 (1.9)
Injection site reaction	-	-	-	1 (1.8)	-
Laryngitis	-	-	1 (1.8)	-	-
Lymphadenopathy	1 (1.7)	-	-	-	-
Menstrual disorder	-	-	-	-	1 (1.9)
Myalgia	1 (1.7)	-	-	-	-
Nausea	-	-	-	1 (1.8)	-
Otitis externa	-	-	-	1 (1.8)	-
Painful respiration	-	1 (1.8)	-	-	-
Pharyngitis	-	1 (1.8)	-	-	-
Rhinitis allergic	-	-	-	1 (1.8)	-
Skeletal injury	-	-	-	-	1 (1.9)
Tendonitis	-	-	1 (1.8)	-	-
Tooth extraction	-	-	-	-	1 (1.9)

Tooth fracture	-	-	1 (1.8)	-	-
Upper respiratory tract infection	-	-	-	1 (1.8)	-
- : Adverse event absent					
Grade 3 = Event that prevented normal activities					
Related = Event assessed by the investigators as causally related to the study vaccination					
Safety Results: Number (%) of subjects with serious adverse events reported up to Day 60 (Total Vaccinated cohort)					
Serious adverse event, n (%) [n considered by the investigator to be related to study medication]					
All SAEs	HBsAg 1 Group N = 143	HBsAg 2 Group N = 142	HBsAg 3 Group N = 141	HBsAg 4 Group N = 145	HBsAg 5 Group N = 142
Subjects with any SAE(s), n (%) [n assessed by the investigator as related]	1 (0.7) [0]	2 (1.4) [0]	3 (2.1) [0]	2 (1.4) [0]	3 (2.1) [0]
Depression	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]	1 (0.7) [0]
Abdominal injury	0 (0.0) [0]	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Acute stress disorder	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]
Anxiety disorder	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]
Appendicitis	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Diverticulitis	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]
Fibula fracture	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]
Glioblastoma	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]
Ligament rupture	0 (0.0) [0]	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Post-traumatic stress disorder	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]	0 (0.0) [0]
Rib fracture	0 (0.0) [0]	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Somatisation disorder	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]
Tibia fracture	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]
Fatal SAEs	HBsAg 1 Group N = 143	HBsAg 2 Group N = 142	HBsAg 3 Group N = 141	HBsAg 4 Group N = 145	HBsAg 5 Group N = 142
Subjects with fatal SAE(s), n (%) [n assessed by the investigator as related]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Safety Results: Number (%) of subjects with serious adverse events during the entire study period – Days 0-360/390 (Total Vaccinated cohort)					
Serious adverse event, n (%) [n considered by the investigator to be related to study medication]					
All SAEs	HBsAg 1 Group N = 143	HBsAg 2 Group N = 142	HBsAg 3 Group N = 141	HBsAg 4 Group N = 145	HBsAg 5 Group N = 142
Subjects with any SAE(s), n (%) [n assessed by the investigator as related]	7 (4.9) [0]	4 (2.8) [0]	10 (7.1) [0]	7 (4.8) [0]	7 (4.9) [0]
Depression	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	2 (1.4) [0]	1 (0.7) [0]
Appendicitis	1 (0.7) [0]	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Intervertebral disc protrusion	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]	1 (0.7) [0]	0 (0.0) [0]
Musculoskeletal pain	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]	0 (0.0) [0]
Tonsillar hypertrophy	1 (0.7) [0]	0 (0.0) [0]	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]
Abdominal injury	0 (0.0) [0]	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Acute stress disorder	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]
Anxiety disorder	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]
Asthma	0 (0.0) [0]	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Cervical dysplasia	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]
Chondropathy	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Cluster headache	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Colitis	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]	0 (0.0) [0]
Constipation	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]
Diarrhoea	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]	0 (0.0) [0]
Diverticulitis	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]
Dyslipidaemia	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]
Epicondylitis	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]

Fibula fracture	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]
Foot deformity	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Glioblastoma	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]
Hypertension	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]
Inguinal hernia	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Joint effusion	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]
Laceration	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Ligament rupture	0 (0.0) [0]	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Ovarian cyst torsion	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Paranasal cyst	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]	0 (0.0) [0]
Pharyngitis	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]
Post-traumatic stress disorder	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]	0 (0.0) [0]
Pyelonephritis	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]
Rib fracture	0 (0.0) [0]	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Rotator cuff syndrome	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]
Somatisation disorder	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]
Tibia fracture	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]
Tonsillitis	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]
Type 2 diabetes mellitus	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]
Varicocele	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]
Weight decreased	0 (0.0) [0]	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Fatal SAEs	HBsAg 1 Group N = 143	HBsAg 2 Group N = 142	HBsAg 3 Group N = 141	HBsAg 4 Group N = 145	HBsAg 5 Group N = 142
Subjects with fatal SAE(s), n (%) [n assessed by the investigator as related]	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]
Glioblastoma	0 (0.0) [0]	0 (0.0) [0]	1 (0.7) [0]	0 (0.0) [0]	0 (0.0) [0]

Conclusion:

The frequency of HBs-specific CD4⁺ T cells expressing at least two immune markers, 14 days post dose 2 (Day 44) was shown to be statistically higher in the HBsAg 1 group when compared to the HBsAg 3, the HBsAg 4 and the HBsAg 5 groups. No statistical difference in terms of CD4⁺ T-cell response at Day 44 between the HBsAg 1 group and the HBsAg 2 group was detected.

Within the 31-day post-vaccination period (i.e. following doses 1 and 2), at least one unsolicited AE was reported by 80 (55.9%), 73 (51.4%), 76 (53.9%), 67 (46.2%) and 71 (50.0%) subjects in the HBsAg 1, HBsAg 2, HBsAg 3, HBsAg 4 and HBsAg 5 groups, respectively.

Within the 31-day post-vaccination period post-booster period, at least one unsolicited AE was reported by 12 (20.3%), 8 (14.3%), 9 (16.1%), 14 (25.0%) 10 (18.5%) subjects in the HBsAg 1, HBsAg 2, HBsAg 3, HBsAg 4 and HBsAg 5 groups, respectively.

Up to Day 60 (i.e. 1 month post dose 2), at least one SAE was reported by 1 (0.7%), 2 (1.4%), 3 (2.1%), 2 (1.4%) and 3 (2.1%) subjects in the HBsAg 1, HBsAg 2, HBsAg 3, HBsAg 4 and HBsAg 5 groups, respectively. None of the SAEs were fatal; they were all assessed by the investigators as not related to the study vaccination.

Up to the end of the study period on Day 360/Day 390, at least one SAE was reported by 7 (4.9%), 4 (2.8%), 10 (7.1%), 7 (4.8%) and 7 (4.9%) subjects in the HBsAg 1, HBsAg 2, HBsAg 3, HBsAg 4 and HBsAg 5 groups, respectively. One of these SAEs (HBsAg 3 Group) was fatal; all SAEs were assessed by the investigators as not related to the study vaccination.

Date updated: 25-February-2016